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Chapter 1 
IMAGING GENETICS OF ALZHEIMER’S DISEASE AND DOWN SYNDROME: TWO 
AMYLOID BASED DISEASES 
The advancement of in vivo imaging modalities that detect the neuropathologies 
associated with both Down Syndrome and Alzheimer’s Disease present new 
opportunities to explore these diseases in living human subjects. Previously, these 
neuropathologies could not be detected until after autopsy or in a living patient, with a 
rarely taken brain biopsy. The use of quantitative traits derived from these imaging 
modalities offers increased power to detect associations with large-scale genetic data, 
and these studies fall under the category of imaging genetics. Imaging genetics studies 
can identify novel risk genes and elucidate gene function and novel mechanisms of 
disease pathology and etiology. Recent imaging genetics studies of the 
neuropathologies of Alzheimer’s Disease and Down Syndrome have attempted to obtain 
a more complete and in depth understanding of the underlying genetic etiology of their 
pathologies. Here, we will briefly overview both diseases, the neuropathologies 
associated with each, the imaging modalities used to detect these pathologies, and 
finally, the studies combining these imaging modalities with genetic data. 
Alzheimer’s Disease 
Alzheimer’s Disease (AD) is an irreversible, degenerative disease of the brain that 
accounts for an estimated 55-75% of dementia cases each year 1. This disorder results 
in a gradual loss of memory, judgment and cognitive function along with the massive 
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death of brain cells. While AD usually appears in individuals 65 years of age and older, 
less common forms do affect individuals earlier in adulthood. In 2000, there were 4.8 
million people in the United States with AD , and that number is expected to increase to 
13.2 million by 2050 2, prompting many researchers throughout the scientific community 
to eagerly research ways in which the disease can be detected and prevented, or 
slowed. 
Late onset Alzheimer’s disease (LOAD) accounts for about 96% of AD cases and 
develops in patients over the age of 65, with early-onset AD affecting subjects less than 
65 years of age and accounting for 4% of the AD population  3. Clinical diagnosis of 
LOAD is based on a patient’s symptoms and cognitive function assessed using a battery 
of neuropsychological tests 4. When an individual is in the early-stages of AD, 
characteristic symptoms include problems with thinking, memory and concentration that 
may be attributed to normal aging and stress. As the disease progresses into mild 
cognitive impairment (MCI) and various stages of dementia, cognitive functions continue 
to decline. Most noticeably, short term memory becomes highly impaired 5. In addition, 
language abilities, motor skills, perception and attention deteriorate eventually leaving 
many people unable to care for themselves and completely dependent on others 6. Even 
with neuropsychological testing of these features of disease, LOAD cannot be 
definitively diagnosed until autopsy, when the neuropathological hallmarks can be 
detected. These hallmarks include amyloid beta plaques that can be 
immunohistochemically analyzed in brain sections 4. Large amounts of amyloid beta 
peptide, a toxic protein fragment, are produced in the brain and as this peptide 
accumulates in the brain, extracellular senile amyloid beta plaques form 7. Although still 
debated, these plaques may lead to nerve cell death and the progressive symptoms of 
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this disorder 8. The brain of a patient with AD is marked by profound atrophy of the 
hippocampus and cerebral cortex 9.  
LOAD has a complex genetic etiology that has proven difficult to unravel, involving 
heterogeneity and gene-gene and gene-environment interactions 1. LOAD is not 
inherited in a Mendelian (dominant or recessive) manner, but the disease does cluster in 
families 1. The heritability estimates of LOAD are high, with h2 between 60 and 80%, but 
much of the genetic contribution to this condition remains unexplained 10,11.  
Early work investigating the genetic contributions to LOAD found associations between 
disease status and the gene encoding apolipoprotein-E (APOE) 12,13. Genetic studies in 
LOAD have continued with single marker genetic associations, or genome wide 
association studies (GWAS), in which disease status is the outcome variable. In these 
studies, 21 genes/genomic loci that have been confirmed to be associated with LOAD, 
but only APOE has a large effect size, with an odds ratio of about 3.7 for one copy of the 
high risk e4 allele 11,14. The remaining 20 loci  exhibit small effect sizes, with odds ratios 
hovering between 0.73 and 1.22 (these include: BIN1, CLU, ABCA7, CR1, PICALM, 
MS4A6A, CD33, MS4A4E, CD2AP, EPHA1, HLA-DRB5–HLA-DRB1, PTK2B, SORL1, 
SLC24A4-RIN3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2, and 
CASS4  11,14. In depth reviews discussing the genetics of LOAD have been published 
elsewhere 15–17. 
Down Syndrome 
Down syndrome (DS; trisomy 21) is a neurodevelopmental disorder that is caused by the 
presence of three copies of chromosome 21. It occurs in 1 in every 691 live births in the 
US 18 and is the most common genetic cause of intellectual disability 19,20. DS is typically 
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identified at birth or shortly thereafter and can be diagnosed prenatally using a 
combination of ultrasound, blood tests, amniocentesis, or chorionic villus sampling.  
Postnatally, the diagnosis of DS is initially based on common physical characteristics 
that can be observed in infancy, such as low muscle tone, a single crease across the 
palm of the hand, brachycephaly, and upward slanting palpebral fissures. Diagnosis can 
then be confirmed with karyotype analysis. The degree of cognitive impairment 
associated with DS ranges from mild to severe, with the mean IQ of 50 20. Individuals 
with DS exhibit deficits in language, verbal short term-memory, and explicit long-term 
memory; whereas visuospatial short-term memory, associative learning, and implicit 
memory are relatively preserved 21. Common medical comorbidities include heart 
defects, digestive malformations, cataracts, seizures, leukemia, and sleep apnea. 
Advances in the treatment of these medical comorbidities have resulted in dramatic 
improvements in lifespan in the U.S., rising from 9 years in the early-twentieth century 22 
to nearly 60 years in 2010 23. With this substantial increase in life expectancy for 
individuals with DS has come the need for an increased focus on health issues in aging 
people with DS. Most prominently, aging in individuals with DS is associated with an 
increased risk of developing AD, with up to 70 percent developing dementia by age 70 24. 
Adults with DS account for up to 60% of individuals with developmental disabilities who 
exhibit signs of AD 25. The clinical presentation of AD in individuals with DS can be 
complex and less straightforward due to pre-existing intellectual disability. Further 
complicating the diagnostic picture is that the most commonly used neuropsychological 
batteries for assessing dementia in the general population are not effective in measuring 
cognitive dysfunction in people with intellectual disabilities because these subjects tend 
to score at or near the bottom of the normative range, exhibiting floor effects. Therefore, 
AD in subjects with DS is clinically diagnosed through specially designed 
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neuropsychological tests like the Dementia in People with Learning Disabilities (DLD), 
formerly known as the Dementia Questionnaire for Persons with Mental Retardation 
(DMR), which is commonly used to assess dementia in individuals with DS 26,27. 
Generally, clinical signs of AD in persons with DS include a decline in long-term 
memory, learning ability, orientation, and increased dependence on caretakers 28. 
However, these are often accompanied or preceded by personality changes consistent 
with frontal lobe dysfunction 29,as well as behavioral changes such as excessive over-
activity or restlessness, sleep disturbance, an unwillingness to cooperate with 
caregivers, and auditory hallucinations 30. It has been reported that the rate of 
deterioration increases with age in individuals with DS 28 and that the level of pre-
existing cognitive function is associated with the rate of cognitive decline 31.  
Postmortem studies have revealed that, by 40 years of age, nearly all individuals with 
DS have lesions present in the brain that meet the pathological criteria for AD, including 
amyloid beta plaques 32. AD in DS may be linked to the presence of three copies of the 
APP gene, which resides on chromosome 21 and encodes the amyloid precursor 
protein. The extra copy of the APP gene leads to an increase in APP mRNA and protein 
expression in brains of individuals with DS 33. Mutations in APP cause a rare autosomal 
dominant form of early onset AD in non-DS populations 34. Individuals who inherit such 
mutations in the APP gene develop AD before age 65, often times as early as age 30. 
Isolated duplication of the APP locus on chromosome 21 (such that an individual would 
have 3 copies of APP) also results in an autosomal dominant, early-onset form of AD in 
non-DS populations 35. Further evidence for a role of APP overexpression in the 
development of AD pathology and dementia in DS is demonstrated in a case study of an 
elderly adult with DS who had a microdeletion of APP resulting in APP disomy and did 
not develop dementia or significant AD pathology 36.   
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In addition to APP triplication, APOE genotype also modulates risk for developing AD in 
the DS population. Several studies have shown an increased risk with the APOEε4 allele 
36,37 and a decreased risk with APOEε2 allele for individuals with DS  38, which mirrors 
what is observed in the general population.  
In addition to the lesions seen neuropathologically in these subjects, adults with DS have 
reduced brain volumes compared to typically-developing controls (TDs) 21. They exhibit 
a similar pattern of neurodegeneration to that seen in the early stages of AD in the 
general population 39 at an earlier age, and it has been suggested that this is indicative 
of accelerated brain aging in these patients 40. 
Imaging Phenotypes in Alzheimer’s Disease and Down Syndrome 
Researchers and clinicians have employed multiple in vivo neuroimaging strategies to 
uncover the underlying structural, functional and pathological effects of DS and AD. 
Here, we will focus on the modalities that can detect changes in regional brain volume 
and the quantity of amyloid beta protein deposition in the brain.  
Structural ImagingQuantified volumes of regions of interest in the brain can be derived 
from T1- or T2-weighted MRI scans and used as biomarkers of brain atrophy. 
Structurally, subjects with LOAD have significant deficits in volume compared to their 
normal aging counterparts, which can be detected by both CT and MRI sequences. AD 
is usually characterized by whole brain atrophy with extensive atrophy of the medial 
temporal lobe 41. Structures in the medial temporal lobe, like the hippocampus, have 
been the focus of many of these studies, and atrophy in these structures correlates well 
with neuropathology found at autopsy 41.   Cortical atrophy of the medial temporal lobes, 
as measured using MRI in both transgenic mouse models and in humans, is a valid and 
 7 
 
reliable biomarker for detection of preclinical LOAD 42–45. During early stages of the 
disease, in subjects with MCI and early AD, atrophy is seen primarily in the entorhinal 
cortex and hippocampus  and can reliably predict MCI conversion to AD 46,47. The lateral 
ventricles, also, have repeatedly shown a relationship to AD status and progression 48–51.  
The lateral ventricles normally dilate over time with age, as brain tissue volume 
decreases, but in patients with AD, the rate of ventricular dilation is much greater than in 
the normal aging population, indicative of underlying increased neuronal degeneration 52.  
Volumetric MRI studies in DS subjects have revealed that adults with DS have reduced 
whole brain weight; reduced prefrontal, parietal, and temporal  lobe volumes; and 
reduced amygdala, hippocampal , and cerebellar volumes compared to TD controls 21. 
Adults with DS have an increase in parahippocampal volume and relatively preserved 
lenticular nuclei, basal ganglia, and occipital and parietal lobe volumes 21. Non-
demented elderly individuals with DS (> 50 years of age) have reduced whole brain, 
prefrontal, posterior cingulate, hippocampal, parahippocampal, amygdalar, and 
cerebellar volumes, as well as degeneration of the locus coeruleus and nucleus basalis 
of Meynert compared to TD controls 21. Studies have shown that individuals with DS 
exhibit a similar pattern of neurodegeneration to that seen in the early stages of AD in 
the general population, where the earliest neuropathological changes present in the 
medial-temporal lobe (MTL) and progress to neocortex and subcortical regions 39. 
However, a hypothesis of accelerated brain aging occurring in individuals with DS has 
been proposed since these changes occur earlier in DS versus TD subjects 40. 
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Amyloid Imaging 
Positron emission tomography (PET) uses a radio-isotope tracer bound to a chemical 
with known physiological properties to produce images of functional or physiologic 
processes in the body. The isotope emits positrons which then annihilate and produce 
gamma ray photons that are detected by the PET scanner. Radio-labeled tracers have 
been developed that bind to amyloid beta plaques in living patients. Before these tracers 
were developed, the presence of amyloid beta plaques could only be confirmed at 
autopsy or through invasive brain biopsy. In AD, the tracers florbetapir (18F-AV-45 or AV-
45) and Pittsburgh Compound-B (PiB, N-methyl-[11C]2-(4′-methylaminophenyl)-6-
hydroxybenzothiazole)  selectively bind amyloid beta plaques in living patients, have 
been correlated with disease onset and progression, have been validated post-mortem, 
and more recently have been included as biomarkers for classifying patients with AD in 
research studies 53–56. In DS, florbetapir  and PiB PET images have been used to 
quantify amyloid load and have been validated post-mortem as well 57,58. 
Though PET has been approved for clinical detection of amyloid beta plaques, it is not 
ideal for routine screening or monitoring of patients, particularly before clinical symptoms 
are present, because it involves radiation exposure. The non-invasive imaging 
technique, T1ρ-weighted MRI (T1ρ) has been validated in a mouse model of AD to 
detect amyloid beta plaque in vivo 59 but has not yet been validated in humans. It is 
sensitive to chemical exchange rates, and provides a contrast that is distinct from 
conventional MR contrasts 60. It is thought to be of particular use for investigating low-
frequency interactions between macromolecules and water, like the interaction between 
amyloid beta plaques and surrounding water-based brain tissue 60. 
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Utilizing Imaging Modalities in Genetic Studies 
By leveraging quantitative traits derived from imaging modalities, researchers can take 
advantage of the increased power these traits provide genetic association studies 61. In 
order to do so, one must define the trait of interest first. To define phenotype, or disease 
status, in genetic studies, just as in the clinic, physicians and scientists traditionally 
depend on a patient’s clinical symptoms as measured through a battery of cognitive 
tests 4. There are strengths and weaknesses to using a solely clinical approach in 
defining outcome variable in genetic studies. This approach matches the diagnosis 
made in a clinical setting and these cognitive measures have been validated, 
normalized, and in use for decades, which allows data to be compiled across research 
centers. Despite these advantages, when compared to the neuropathological gold 
standard for diagnosis of AD at autopsy, the diagnostic accuracy of neurocognitive tests 
range from 65-96% and the specificity ranges between 23-88% 45. Therefore, using only 
clinical disease status, as diagnosed by cognitive and neuropsychological tests, in 
genetic association studies introduces potential error into the results. There are many 
effects of a genetic variant—from protein to cell function to system physiology—that are 
intermediate to final disease status. Measuring these intermediate effects can provide 
endophenotypes for a genetic association study, potentially increasing the power to 
detect a genetic effect that ultimately impacts disease status 62.  To quantify these 
intermediary effects, biomarkers like protein levels in cerebrospinal fluid (CSF) or 
quantitative neuroimaging modalities like MRI and PET, have been added to the 
research criteria for AD diagnosis 63 and have been used in genetic studies as explored 
below. For AD, DS, and other neurological disorders, brain structure or pathology 
derived from imaging modalities can be the source of relevant quantitative traits (QTs) to 
be used as endophenotypes. Endophenotypes can provide increased statistical power 
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(and therefore decreased sample size requirements) over dichotomous outcome 
variables 64 and since both brain structure 65 and PET-derived amyloid load 66 are highly 
heritable, both are suitable as endophenotypes in genetic studies.  
In recognition of this great opportunity and the need for large sample sizes for 
exploration of modest genetic effects, the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) was developed.  ADNI is as a joint venture between the National Institutes of 
Health (NIH) and private biotechnology and pharmaceutical companies with the goal of 
acquiring serial measurements of MRI, PET, neurocognitive testing and other biological 
markers, along with genetic data, in hundreds of older adults for the purpose of 
identifying biomarkers for early detection and monitoring of disease progression and 
response to treatment for AD. ADNI maintains a publicly available dataset that contains 
rich biomarker data on study participants with normal cognition and those diagnosed 
MCI or AD.  This is an extraordinary resource for AD researchers, especially those 
interested in imaging genetics research. The availability of ADNI and other similarly 
sized data sets has advanced the field of imaging genetics in LOAD, by enabling the use 
of quantitative structural data from MRI and quantitative amyloid load from PET as 
endophenotypes in genetic association studies. 
Imaging Genetics 
Imaging Genetics in LOAD  
Here we will focus on the progress made in imaging genetics of LOAD using PET and 
structural MRI modalities. As discussed above, structural MRI and quantified PET 
images are able to successfully quantify different aspects of brain pathology, and these 
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quantitative traits have been used in genetic association studies to confirm previous and 
identify novel genetic associations.  
APOE 
Although researchers have not yet found a specific gene that is determinative of the late 
onset form of AD, one genetic risk factor, APOE, does substantially increase a person’s 
risk of developing the disease. APOE is located on chromosome 19 and encodes the 
protein apolipoprotein E that combines with lipids to form lipoproteins. There are three 
variants of this gene, APOE e2, APOE e3, and APOE e4 (average frequency (in 
percentage) across 430 populations: 6.4, 78.3, 14.5, respectively67). APOE e3, is the 
most common allele and, therefore, risk attributed to the other two allelic variants is 
compared against this reference allele. APOE e2 may provide some protection against 
the disease in younger individuals 68. Risk for AD is highest in individuals who possess 
an APOE e4 allele. An individual’s risk for developing AD increases from 20% when no 
APOE e4 alleles are present to 90% when two copies of the allele are present 13.  It is 
important to note, however, that the increased risk conferred by APOE e4 is lower for 
African Americans and Hispanics than it is for Caucasians 69. 
Using AV-45 ligand PET images and genetic data collected by ADNI on 555 subjects, 
Ramanan, et.al., confirmed the association of APOE (rs429358) with amyloid load in 
Caucasian subjects 70. In fact, there is a gene dosage effect of the e4 risk allele on PET-
derived amyloid load that has been observed in cognitively normal people 71 as well as 
MCI subjects 72. The APOE e4 allele has also been associated with faster conversion 
rates from MCI to AD in PIB-positive MCI subjects 73.  
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In a genome wide association study (GWAS) using quantitative endophenotypes derived 
from MRI, APOE has also been associated with multiple measures of brain volume, grey 
matter density, and cortical thickness extracted from structural MRI through FreeSurfer 
and voxel-based morphometry 74. A variant in APOE (rs429358) was associated with 
volumetric measures of the left and right amygdalar and hippocampal regions, right 
middle temporal lobe, left and right inferior parietal lobe, and right cerebral white matter 
74. These associations were all significant at p < 10− 7.  
TOMM40 
TOMM40 is a gene adjacent to APOE and is reported to be a contributor to LOAD risk, 
though this is debated 70,75. It encodes a channel-forming subunit of the multisubunit 
translocase of the outer mitochondrial membrane (TOMM complex), which plays a role 
in the transport of cytoplasmic peptides and proteins into mitochondria. Given that 
mitochondrial dysfunction has been widely implicated in the etiology of LOAD, this 
association of TOMM40 with LOAD was logical. TOMM40 has been associated with 
measures of brain structure volume, grey matter density, and cortical thickness extracted 
from structural MRI: a variant in TOMM40 (rs2075650) was significantly associated with 
bilateral hippocampal volume and left amygdalar volume 74. In a PET imaging GWAS, 
variants in TOMM40 displayed significant association with Amyloid beta levels but, their 
association signals disappeared (P >0.05) when APOE ε4 status was included as a 
covariate, so the validity of the association of TOMM40 with LOAD and its 
endophenotypes is still contentious 70.  
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BCHE  
In addition to confirming the association of APOE with amyloid load in 555 ADNI 
subjects with AV-45 ligand PET scans, Ramanan, et.al., discovered the association of 
BCHE (rs509208) with amyloid load 70. BCHE, located on chromosome 3, encodes 
butyrylcholinesterase and has been associated with amyloid beta plaques and 
neurofibrillary tangles along with amyloid angiopathy in AD 76. Together, variants in 
BCHE and APOE explained 15% of the variance in amyloid load 70. The risk variant of 
BCHE has been associated with further risk of LOAD in APOE e4 carriers and with 
cognitive decline in the later stages of the illness 77. However, some studies have found 
that the risk variant of BCHE has an important role in the progression of AD in which 
subjects carrying the risk allele, or K-variant, exhibited a slower rate of cognitive decline 
78. These observations have potential implications for the treatment of AD with 
cholinesterase inhibitors that inhibit the production of butyrylcholinesterase as the 
disease progresses. 
GRIN2B 
GRIN2B,  located on chromosome 12, encodes the N-methyl-d-aspartate (NMDA) 
glutamate receptor NR2B subunit that has previously been associated with temporal 
lobe volume, excitotoxic cell death and is already a therapeutic target in Alzheimer's 
disease 79. In this study, a variant in GRIN2B (rs10845840) was associated with bilateral 
temporal lobe volume with p < 5 × 10−7 and the risk alleles for lower temporal lobe 
volume at this SNP were significantly over-represented in AD and MCI subjects versus 
controls 79.  
  
 14 
 
DHCR24 
An association with DHCR24, encoding 24-dehydrocholesterol reductase, which confers 
resistance to amyloid, was discovered in the ADNI dataset using PiB-PET imaging as a 
quantitative trait 80. The minor allele of an intronic SNP (rs7551288) within this gene was 
associated with lower amyloid beta load as measured by PiB uptake. Major allele 
homozygotes had higher amyloid beta load as measured by PiB uptake in frontal 
regions. Because of the role of DHCR24 in conferring resistance to amyloid beta and 
oxidative stress-induced apoptosis, the others posit that this result supports a 
neuroprotective role. 
Other genes 
Using structural MRI derived quantitative traits derived from Caucasian subjects from 
ADNI, Shen, et. al. reported genetic associations with SNPs located near EPHA4, TP63 
and NXPH1 74, and another group has shown an association with EFNA5, CAND1, 
MAGI2, ARSB, and PRUNE2 75. These genes are involved in the regulation of protein 
degradation, apoptosis, neuronal loss and neurodevelopment. Thus, they have been 
identified as candidate genes associated with an increased risk of developing AD  
Gene-Gene Interactions 
Exploration beyond single gene association studies is necessary for complex diseases 
with complex etiologies and pathologies. This is just beginning to be explored, using 
quantitative traits derived from imaging modalities as the phenotype of interest. Previous 
gene-gene interaction studies using quantitative traits from brain images of patients with 
LOAD have implicated interactions between: CR1 and APOE, and GSK3B and amyloid 
genes using quantified amyloid-based PET as the outcome variable 81,82, and calcium 
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signaling and axon guidance genes using quantified entorhinal and hippocampal 
volumes 83.  
Gaps in Knowledge Addressed 
Though PET has been approved for clinical detection of amyloid beta plaque pathology 
in vivo, since it involves radiation exposure, it is not ideal for routine screening or 
monitoring of patients, particularly before clinical symptoms are present. New 
biomarkers of amyloid beta pathology are needed and the exploration of the use of T1ρ 
MRI in humans in vivo is the next step to validate its use as a biomarker of this 
pathology. If T1ρ is validated as a proxy for amyloid beta deposition, it could easily be 
implemented to monitor disease progress or classify patients in research and clinical 
trials. Thus, the first goal of this research is to analyze the utility of T1ρ MRI in human 
adults with DS, who have a high probability of amyloid beta deposition compared to 
adults in the general population. 
Further, we will explore the “accelerated brain aging” hypothesis in DS patients put 
forward by Beacher, et.al. 40. We will analyze region of interest volume using T1-
weighted structural MR images in subjects with DS and compare age-related changes in 
these measurements to those in normal control subjects and also in subjects with 
another neurodevelopmental disorder (Williams Syndrome) to further explore this 
hypothesis. With the quantified T1-weighted images, we will extract meaningful 
endophenotypes to evaluate the relationship between both APOE status and dementia 
status as measured by neuropsychological tests and each of these endophenotypes. 
The final goal of this research is to employ imaging genetics techniques in the large, 
publicly available ADNI dataset to tease apart the genetic etiology of the amyloid and 
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neuro-atrophy pathologies of LOAD. As described above, the etiology of LOAD still 
eludes us despite its prevalence and considerable research efforts devoted to it. We will 
employ an innovative strategy to address two major challenges in LOAD research: (1) 
clinical heterogeneity and (2) biological interactions by using PET and MRI derived 
quantitative endophenotypes to dissect clinical heterogeneity, and by directly 
investigating gene-gene interactions for their association with these endophenotypes.    
  
 17 
 
Chapter 2 
VALIDATION OF T1Ρ MAGNETIC RESONANCE IMAGING IN HUMAN ADULTS WITH 
AMYLOID BETA PLAQUE DEPOSITION 
Introduction 
Positron Emission Tomography (PET) has been approved for clinical detection of 
amyloid beta plaque pathology in vivo but because it involves radiation exposure, it is 
not ideal for routine screening or monitoring of patients, particularly before clinical 
symptoms are present. New non-invasive biomarkers of amyloid beta plaque pathology 
are needed.  
T1ρ-weighted Magnetic Resonance Imaging (MRI) is an MR sequence that has been 
validated to detect amyloid beta plaque in vivo in a mouse model of AD 59 (Figure 1), but 
has not yet been validated in humans. In this sequence, instead of allowing transverse 
magnetization (Mxy) to relax undisturbed, a low frequency radio-frequency pulse (RF) is 
applied in the transverse plane for a relatively long period of time, “locking” the spins in 
the orientation of the RF, hence the names of the RF frequency and the duration of its 
application: spin-lock frequency (FSL), and spin-lock time (TSL), respectively 84. This RF 
pulse slows de-phasing and prolongs the decay of magnetization, allowing the 
transverse magnetization to interact with lattice processes occurring at the low frequency 
of the RF. Therefore, T1ρ is sensitive to slow motions with low frequencies, and T1ρ will 
decrease (i.e. protons will relax faster) around lattice processes moving at these low 
frequencies 60,85.  Healthy brain tissue allows for more free motion of water than the 
diseased brain which is overrun with large protein based amyloid beta plaques 60. This 
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high protein content hinders water motion such that theoretically, in the diseased brain, 
T1ρ will be shorter than healthy brain tissue’s T1ρ times 60.  
 
 
 
In a mouse model of AD (APP/PSEN1 transgenic mouse), amyloid beta plaques were 
detectable as hypointensities on the T1ρ-weighted MR images in the AD-related cortical 
and hippocampal regions, which corresponded to shortened T1ρ at the amyloid beta 
plaques and agreed with the theory outlined above (Figure 1) 59. Hypointensities in the 
thalamic/hypothalamic regions also are detected on MRI as seen in Figure 1 but there 
were no stained amyloid plaques in these regions and the authors did not comment on 
Figure 1: T1ρ-weighted MRI validated in a mouse model of Alzheimer’s 
Disease. 
Adapted from Borthakur, et. al. (2006) 59. T1ρ MRI in a mouse model of 
Alzheimer’s Disease (APP/PS1 mouse) (a) and in a control mouse (c). 
Corresponding histologic images immunostained for amyloid beta 
deposits in the APP/PS1 mouse (b) and in the control mouse (d).  
The hypointensities in the T1ρ images align with the immunostained 
amyloid beta in the APP/PS1 mouse, but are absent in the control mouse. 
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this discrepancy. T1ρ could be detecting other low frequency proteins or molecules in 
this region. Very high resolution images were acquired (78 µm x 78 µm x 130 µm) on 
these mice and required the mice to be anesthetized and to be scanned for three hours. 
After MRI acquisition, the mice were sacrificed, and the brains were 
immunohistochemically stained for amyloid beta plaque. The stained brain slices were 
aligned with the MRI slices to compare the exact location of the stained plaque and the 
hypointensities on MRI. There was general congruency between the stained and MR 
slices, validating the ability of T1ρ MRI to pick up an amyloid beta plaque in vivo 59. 
Extension of this validation to humans is necessary for this MR sequence.  
In humans, T1ρ MRI has been used in patients with breast cancer, gliomas, cartilage 
degeneration, Parkinson’s Disease, and AD 86–89. In relation to AD, T1ρ MRI has been 
quantified in patients with AD, MCI, and age matched normal controls, but unlike in the 
mouse studies, T1ρ increased in human subjects with MCI and AD (Figure 2) 89–92. This 
is opposite of what is expected theoretically in subjects with increased amyloid beta load 
and opposite of what was observed in the mouse model study  89–92. This reversal was 
attributed to T1ρ detecting increased extracellular space caused by late stage disease 
related neuronal loss which typically accompanies diagnoses of MCI and AD 89–92. 
Therefore, T1ρ is not validated in humans as of yet. We aimed to avoid the problems 
encountered in this prior human study by attempting to validate T1ρ in subjects adults 
with DS without dementia who have a high probability of having amyloid beta plaque 
load prior to neuronal cell loss, since amyloid beta plaques are expected to deposit prior 
to neuronal cell death 93. 
Further, in each of the prior studies of T1ρ in humans, T1ρ was quantified using one FSL 
(500 Hz) on a 1.5 Tesla (1.5 T) MRI scanner. We were interested in quantifying T1ρ 
across multiple FSLs using a higher field strength scanner, i.e. 3 Tesla (3 T), in order to 
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quantify the T1ρ dispersion curve at higher resolution 84. The dispersion curve can 
characterize the macromolecular make-up of a tissue, and in human brain, the 
dispersion curve has only been quantified in normal subjects 84.  
 
 
 
Figure 2: T1ρ- weighted MRI maps in human subjects with Alzheimer’s Disease.  
Adapted from Haris, et. al. (2009) 91. T1ρ was measured in (A) control and (B) late onset 
AD (LOAD) subjects in the hippocampus at 1.5 Tesla (1.5 T). Higher values are seen in 
the LOAD subjects compared to the control subjects, and this may be due to the 
detection of increased extra-cellular space caused by disease related 
neurodegeneration, instead of plaque burden. 
 
Methods and Materials 
Subjects 
Data from 38 subjects recruited via community-based recruitment and collaborations 
with Vanderbilt clinicians has been analyzed. Subjects are classified as normal cognition 
(NC) or Down Syndrome (DS) based on prior clinical diagnosis and physical 
manifestations (Table 1). Adults with DS and NCs were recruited using flyers and 
website postings with IRB-approved language targeting adults over 18 years of age. 
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Because of the early onset of amyloid pathology in subjects with DS, the DS subjects 
were much younger than the NC subjects. However, all DS subjects were over 18 years 
of age. For adults with DS, we further recruited from local and regional educational 
centers for individuals with intellectual disabilities, community based living centers, 
caregiver support groups, and employment assistance programs.  Diagnosis of normal 
cognition in the general population cohort  is based on a battery of cognitive tests 
administered by a qualified masters-level neuropsychologist. A similar cognitive testing 
battery is also administered to the DS subjects. The cognitive tests applied to these 
subjects quantify cognitive impairment, memory, learning, vocabulary, attention, task 
speed, and comprehension. Participants with NC and the caretakers of the subjects with 
DS were also asked about the presence of first degree family history of AD. Participants 
are free to take as many breaks as needed to avoid exhaustion.  
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Table 1 Demographics for community-based recruitment.  
DS = Down Syndrome. NC = Normal Cognition. N = number of subjects. Age = average 
age of group. CA = Caucasian.  
 
 DS NC 
N 16 22 
Age 43 68 
Race (# not CA) 0 6 
%Female 43.75% 81.82% 
# APOE e4 carriers 4 5 
# e2 APOE carriers 2 2 
 
 
All participants with DS exhibited the physical, cognitive and behavioral profile of DS, 
and they previously had received a clinical diagnosis of the disease.  NC subjects are 
over 65 years of age to avoid subjects with early onset AD. The DS subjects are all over 
18 years of age because of the early onset of amyloid pathology in subjects with DS. 
Subjects recruited from the general population and caregivers of individuals with DS 
gave informed consent, while participants with DS gave assent, for this study which 
included MR imaging, genotyping, and cognitive testing. All study procedures were 
approved by the Vanderbilt University Institutional Review Board. As per this protocol, 
two subjects with incidental findings had their MRIs reviewed by a neuro-radiologist who 
determined if the patient should be contacted for clinical follow-up.  
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MRI 
Adults participated in an magnetic resonance imaging (MRI) scan in a Philips Achieva 3-
Tesla scanner (Philips Medical Systems, Inc., Best, Netherlands) using an eight-channel 
SENSE head coil, housed in the Vanderbilt University Institute of Imaging Science 
(Nashville, TN).   
T1 
Full brain, high-resolution T1-weighted Turbo Field-Echo pulse sequences were 
acquired with the following parameters: Echo Time/Repetition Time (TE/TR) = 4.6 ms / 9 
ms, shot interval/inversion time (TS/TI) = 1166.401 ms / 402.8176 ms, slice thickness = 
1 mm, slices = 150, in-plane voxel size = 1 mm x 1 mm, field of view (FOV) = 25.6 cm x 
25.6 cm x 15 cm.  
T1ρ  
Fluid-attenuated T1ρ pre-encoded Turbo Spin-Echo pulse sequences were acquired, 
modeled after the 1.5 T sequence used in the previous T1ρ human studies 89. Six T1ρ 
images were acquired after application of three different FSLs (0, 275 and 550 Hz) both 
at two different TSLs (20 and 80 ms). All six T1ρ images were acquired with these 
parameters: TE/TR = 15 ms / 2700 ms, slice thickness = 5 mm, slices = 12, in-plane 
voxel size = 2.5 mm x 2.5 mm, FOV = 20.5 cm x 20.5 cm x 6.0 cm with coverage of key 
temporal, parietal, and frontal regions affected in AD Figure 3).  
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Figure 3: Example of image acquisition for T1ρ validation study.  
The T1ρ acquisition area is overlaid in red on a T1-weighted image of an example 
subject. Key structures such as frontal, temporal, and parietal regions, and hippocampus 
are covered by the T1ρ scan. 
 
Imaging Analysis 
Quality Control  
The raw T1- and T1ρ-weighted images were visually inspected for any artifacts and 
subjects were discarded if significant artifact was present in any one of the images. Of 
the 38 subjects analyzed, only 17 have T1- and T1ρ-weighted images that pass quality 
control (8 DS, 9 NC).  Most of the scans were discarded because of ringing artifacts in 
the T1ρ images caused by use of the incorrect “patch” placed on the scanner before MRI 
acquisition. Salvaging the discarded datasets was discussed with VUIIS faculty, and 
they recommended removing the slices of the image that had these artifacts while 
keeping the unaffected slices. After re-visualization of these images, we determined that 
when an image was acquired under the incorrect patch, all slices were affected and had 
ringing artifacts, rendering the entire scan un-usable in these analyses. The subjects 
with NC were further classified by the presence or absence of a family history (at-risk 
(AR) based on a positive first degree family history of AD and NC, respectively). 
Demographics for these subjects can be found in Table 2. 
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Table 2 Demographics for subjects with T1ρ analyzed.  
DS = Down Syndrome. NC = Normal Cognition. N = number of subjects. Age = average 
age of group. CA = Caucasian.  
 
 DS AR NC 
N 8 3 6 
Age 47 65 65 
Race (# not CA) 0 1 2 
%Female 62.50% 100.00% 66.67% 
# APOE e4 carriers 2 2 1 
# APOE e2 carriers 0 0 1 
 
T1ρ Region of Interest-based analysis 
After visual inspection of the 3D T1-weighted images, to parcellate the brain into cortical 
and subcortical tissue classes and derive quantitative estimates of brain volume, we 
used an automated, non-biased atlas-based Bayesian segmentation procedure, applied 
in FreeSurfer v.5.0 (http://surfer.nmr.mgh.harvard.edu/) 94. FreeSurfer preprocessing for 
volumetric T1-weighted images included: motion correction, brain extraction and removal 
of non-brain tissue using a hybrid watershed/surface deformation procedure 95; 
automated spatial transformation and white matter segmentation of subcortical 
volumetric structures 96; intensity normalization, tessellation of gray matter/white matter 
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boundary and automated topology correction 97; and surface deformation following 
intensity gradients to optimally place gray matter/white matter and gray 
matter/cerebrospinal fluid borders at the location where the greatest shift in intensity 
defines the transition to the other tissue class 94. Image outputs from each stage of 
FreeSurfer processing were visually inspected. Only images that passed quality control 
were used. Quantitative estimates of volume were derived in a large set of spatially 
distinct region of interests (ROIs) that covered the entire brain, as specified in the 
Desikan-Killiany Atlas 98. This atlas includes parcellations of gray and white matter and 
segmentations of subcortical gray matter, and also includes summary volumes (i.e. total 
cortex volume). This segmentation is robust to anatomical variability of neurological 
diseases and aging, including ventricular enlargement, which was important in this 
study99.   
The six T1ρ scans (taken at TSL= 20 and 80 ms with FSL= 0, 275 and 550 Hz) for each 
subject were aligned to the T1ρ scan acquired at TSL=20 ms and FSL=275 Hz [T1ρ20, 
275]. For each FSL, voxel-wise T1ρ maps for each subject were generated by solving in 
MATLAB (http://www.mathworks.com/products/MATLAB/) the equation  
 (   )     
    
   ⁄   ................................................................................................... (1) 
which describes T1ρ (Figure 4) 100. S(TSL) is the signal intensity as a function of TSL, 
and So is the baseline signal intensity. Since multiple TSLs were used, the natural 
logarithm of each voxel’s signal intensity was fit as a function of the TSL using a linear 
least-square algorithm in SPM8 (www.fil.ion.ucl.ac.uk/spm/) (Figure 4). The resulting 
slopes of the linear fitted line were negated and inverted to derive T1ρ and negated to 
derive R1ρ. This analysis yielded voxel-wise T1ρ and R1ρ quantitative maps scaled in 
milliseconds and 1/milliseconds, respectively, for each FSL.  
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The automatically generated ROI labels from FreeSurfer were aligned to the original T1-
weighted image. Next, the high resolution T1-weighted image and the ROI label aligned 
to it were co-registered to the lower resolution T1ρ20, 275 to reduce interpolation 
artifacts that occur when registering a lower resolution image to a higher resolution 
image. The ROI labels were then in the same spatial configuration as the R1ρ 
quantitative maps. The ROI labels were applied to these maps for each FSL and the 
mean R1ρ value for each ROI at each FSL was extracted using FreeSurfer. These 
values were then plotted versus FSL in R (http://www.r-project.org/) to create dispersion 
curve plots for each subject for each ROI. Subjects who had less than 95% of an ROI 
covered, as determined by comparing the volume of each ROI covered by the T1ρ 
image with the volume of the ROI covered by the T1 image, had that ROI dropped to 
keep 0-value voxels not covered by the T1ρ-weighted MRI from skewing the ROI 
average. 
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Figure 4: Quantification of T1ρ weighted MRI and the T1ρ dispersion curve 
(A) T1ρ is collected at TSLs of 20 and 80 ms.  
(B) The natural logarithm of each voxel’s intensity is linearly fitted as a function of 
these TSLs and by solving Equation 1.  
(C) (A) and (B) are repeated for each FSL (0, 275, and 550 Hz). The slopes of the 
linearly fitted lines are negated and inverted and negated to derive T1ρ and R1ρ, 
respectively, for each FSL. 
(D) The dispersion curve consists of the quantified R1ρ (1/ T1ρ) values at 0, 275 and 
550 Hz plotted as a function of FSL. 
 
We used an image subtraction method to derive a contrast (exchange rate contrast, 
ERC) based upon the features of the dispersion curves, where  
      
(   (     )    (       ))(   (       )    (       ))
(   (     )    (       )) 
 .......................................  (2)  
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(Figure 5) 101. The ERC characterizes the frequency at which maximum inflection in the 
T1ρ dispersion curve occurs. The average ERC for each ROI for all subjects was 
calculated and the group mean differences were analyzed for significant differences.  
 
 
Figure 5: Exchange rate contrast (ERC) equation and calculation for the T1ρ validation 
study 
T1ρ Voxel-based analyses 
T1ρ was also analyzed at the voxel-wise level. For a voxel-wise analysis, all images 
have to be in the same space, and must be co-registered to a template space, which is a 
disadvantage of this method compared to the ROI based method described previously. 
In exchange, the voxel-wise method allows for voxel-wise differences to be detected, as 
opposed to having to average voxels across an entire ROI as necessary in FreeSurfer.  
As in the ROI based method, the T1ρ-weighted images were all aligned to T1ρ20, 275. 
These realigned images were then normalized to standard Montreal Neurological 
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Institute (MNI) template space, using the Normalize (Estimate + Write) function with the 
T1-weighted image as the source image. As above, for each FSL, voxel-wise T1ρ maps 
for each subject were generated by solving Equation 1 in MATLAB. A voxel based 
analysis was performed on the resulting quantitative T1ρ maps at 0, 275, and 550 Hz 
using a one-way ANOVA comparing DS vs. AR, DS vs. NC and AR vs. NC, using a 
combination of two very liberal thresholds: p < 0.05 and an extent threshold of 1 voxel.   
 
Pipeline 
An automatic pipeline was designed, tested, and implemented to analyze the T1-
weighted and T1ρ-weighted MR images after manual inspection for both the ROI- and 
voxel-based analyses. The code for the entire pipeline can be found in Appendix A. 
Equation 1 was solved via MATLAB scripts provided to us by faculty in the VUIIS and 
code in SPM8 and FreeSurfer was created to complete the analysis pipeline. A Python 
script was created to automatically pull the images from VUIIS to our own servers. This 
entire pipeline is implemented in MATLAB and Unix environments and uses FreeSurfer 
to automatically segment and parcellate the T1-weighted images, align and co-register 
the T1- and T1ρ-weighted images, calculate the T1ρ and R1ρ statistical parametric 
maps, and pull information from these maps so that the dispersion curves can be plotted 
for each subject for each region of interest (Figure 6) and the voxel-wise analysis (Figure 
7) can be run. An overview of both pipelines can be seen in Figure 8. All code for these 
pipelines can be found in Appendix A. 
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Figure 6: Region of interest (ROI) based analysis pipeline using FreeSurfer ROI 
parcellation and segmentation for the T1ρ validation study 
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 Figure 7: Voxel-based analysis pipeline for the T1ρ validation study 
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Figure 8: Overview of both region of interest (ROI) and voxel-based pipelines for the T1ρ 
validation study 
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Results 
Example T1ρ maps determined by solving Equation 1 (Figure 4) for example DS, NC, 
and AR subjects can been seen in Figure 9. In any of the ROIs tested (Table 3), there 
were no differences between the groups when analyzing dispersion curve slope (Figure 
10) nor when comparing ERC across group in any ROI (Figure 11). For the purpose of 
this manuscript, as an example, we will display results from the left hippocampus. In the 
voxel-wise analysis, no voxels were significantly different between the two groups using 
very liberal thresholds of extent = 1 voxel and p < 0.05.  
 
 
 
AR-77 yo DS-49 yo NC-62 yo 
Figure 9: Example calculated T1ρ maps for human subjects.  
Cross-sections of one DS, AR, and NC (left to right) subject. T1ρ maps (550 Hz) are 
overlayed on T1-weighted images. 
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Table 3 Regions of interest (ROIs) tested in T1ρ validation analysis. 
ROIs 
CC_Anterior ctx-lh-precuneus ctx-rh-pericalcarine 
CC_Central ctx-lh-rostralanteriorcingulate ctx-rh-postcentral 
CC_Mid_Anterior ctx-lh-superiorparietal ctx-rh-posteriorcingulate 
CC_Mid_Posterior ctx-lh-superiortemporal ctx-rh-precuneus 
CC_Posterior ctx-lh-supramarginal ctx-rh-rostralanteriorcingulate 
ctx-lh-bankssts ctx-lh-temporalpole ctx-rh-superiorparietal 
ctx-lh-cuneus ctx-lh-transversetemporal ctx-rh-superiortemporal 
ctx-lh-entorhinal ctx-rh-bankssts ctx-rh-supramarginal 
ctx-lh-frontalpole ctx-rh-cuneus ctx-rh-temporalpole 
ctx-lh-fusiform ctx-rh-entorhinal ctx-rh-transversetemporal 
ctx-lh-inferiorparietal ctx-rh-frontalpole Left-Accumbens-area 
ctx-lh-inferiortemporal ctx-rh-fusiform Left-Amygdala 
ctx-lh-insula ctx-rh-inferiorparietal Left-Caudate 
ctx-lh-isthmuscingulate ctx-rh-inferiortemporal Left-Hippocampus 
ctx-lh-lateraloccipital ctx-rh-insula Left-Pallidum 
ctx-lh-lateralorbitofrontal ctx-rh-isthmuscingulate Left-Putamen 
ctx-lh-lingual ctx-rh-lateraloccipital Left-Thalamus-Proper 
ctx-lh-medialorbitofrontal ctx-rh-lateralorbitofrontal Left-VentralDC 
ctx-lh-middletemporal ctx-rh-lingual Right-Accumbens-area 
ctx-lh-parahippocampal ctx-rh-medialorbitofrontal Right-Amygdala 
ctx-lh-parsopercularis ctx-rh-middletemporal Right-Caudate 
ctx-lh-parsorbitalis ctx-rh-parahippocampal Right-Hippocampus 
ctx-lh-parstriangularis ctx-rh-parsopercularis Right-Pallidum 
ctx-lh-pericalcarine ctx-rh-parsorbitalis Right-Putamen 
ctx-lh-postcentral ctx-rh-parstriangularis Right-Thalamus-Proper 
ctx-lh-posteriorcingulate   Right-VentralDC 
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Figure 10: Example of quantified T1ρ dispersion curves plotted in human subjects. 
The dispersion curves are plotted for each subject’s left hippocampus, plotting average 
R1ρ versus spin lock frequency (FSL=0, 275, 550 Hz). Subject group for each subject is 
indicated by line color (red: normal control, green: at risk, blue: Down Syndrome). 
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Figure 11: Example of quantified exchange rate contrast (ERC) values of the left 
hippocampus plotted within groups. 
 
Discussion 
In Figure 9 no apparent differences are visually detected between scans of subjects with 
DS and those who are AR or NC. Because of the size of the voxels in this study, this is 
not indicative of negative results, and further analyses were necessary. The dispersion 
curves were quantified for each subject. The quantified dispersion curves (Figure 10) 
generally fit what was theoretically expected (Figure 4), with R1ρ at 0 Hz greater than 
R1ρ at 275 Hz, which was greater than R1ρ at 550 Hz. There are outlier subjects whose 
dispersion curves do not follow this trend. Interestingly, when removal of these scans 
was performed and this trend was discovered, we found that this trend did not occur for 
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all of the ROIs in one subject, but instead, this occurred across multiple subjects in 
differing ROIs. The deviations from expectations in the dispersion curves presented here 
are most likely due to subtle movement artifacts that were not detected upon visual 
inspection of each image, and in the continuation of this study, as the total number of 
subjects increases over time, subjects whose dispersion curves do not follow this trend 
can be removed from the analysis, or each individual scan that does not follow the trend 
can be removed. Further analysis of these dispersion curves was completed, with 
computation of ERC values. The theoretical trend for ERC values has not been 
established, and discussion with faculty at the VUIIS is ongoing regarding this topic. 
Therefore, in Figure 11, an interesting trend may be forming (two sampled t-test 
comparing NC to DS group: t = 1.0631, p = 0.3105), but in order to definitively draw a 
conclusion, the sample size for each group must increase to inform this discussion.  
These negative and inconclusive results are not necessarily indicative of failure of T1ρ to 
detect amyloid beta plaque in humans, though it is indicative of the failure to validate the 
approach in humans in this study’s sample population.  
There are many potential reasons for these negative results, which leads to future 
directions for this project. First, when computing T1ρ from the slope of the natural 
logarithm of signal as a function of TSL, we were not be able to rule out voxels based on 
r2 value because we only had two TSL values. This would have eliminated voxels that 
are outliers, perhaps due to partial volume effects. Therefore in the future, using more 
than two TSL values in image acquisition would allow for further quality control of the 
images and their quantification. The voxel size of the images acquired on our human 
subjects may have been too large to detect the effects of amyloid beta plaque, as the 
voxels were over four orders of magnitude larger than those seen in the successful 
mouse model study. In the future, this sequence could be validated on an autopsy brain 
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of a patient with clinically diagnosed AD or an elderly individual with DS. A high 
resolution image could be acquired, as these brains can be scanned for hours. These 
brains could then be immunohistochemically stained for amyloid beta plaque to compare 
to the MR images acquired, mimicking the study performed in the mouse model 59. In 
this study, if hypointensities were seen on the T1ρ images of the autopsy brain which 
aligned with the immunohistochemically stained brain slices, this could be repeated in 
control subjects to control for false positive hypointensities. To continue this validation, 
high-resolution T1ρ images could be acquired on live patients who most likely have 
plaque (elderly DS or AD patients). In these patients, since brain samples are not 
practical, this could be validated with amyloid PET imaging. Alternatively, these patients 
could be recruited from hospice care, as was done in previous PET validation studies 55. 
In this study design, T1ρ MRI could be acquired on patients who physicians consider 
nearing the end of life. After death, the brains of these patients would be donated to 
research, and could be immunohistochemically stained for amyloid beta plaque and 
these stained images and the MR images could be compared as described previously.  
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Figure 12: Representative histograms of the T1ρ values in AD-related regions of interest.   
Histograms for the inferior parietal lobe for one Down Syndrome (DS) subject (left) and 
one Normal Control (NC) subject (right) are presented. The x-axis here is T1ρ value in 
milliseconds (ms) and the y-axis is the number of voxels at this value within a given ROI. 
 
The voxel-wise T1ρ maps may still hold important information, even with these relatively 
large voxel sizes. In the ROI-based method the true signal originating from amyloid beta 
plaques may be drowned out by the surrounding normal tissue when taking the mean 
value of an entire ROI. To ameliorate this, we turned to a voxel based approach, but this 
approach may also have been flawed: in theory, we do not expect each individual to 
have amyloid beta plaques at the exact same voxel locations. Therefore, instead of 
looking at differences between each voxel, the distribution, including kurtosis and 
skewness, of T1ρ values within each ROI in the groups should be investigated, using the 
histogram function in MATLAB (see Appendix A for example code). This has been 
explored in two sample subjects, but is being extended to the entire cohort (Figure 12). 
In future analyses, the differences between the groups’ distributions can be tested with a 
two-sample Kolmogorov-Smirnov test.  
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In conclusion, though these results did not validate T1ρ in human subjects, they are not 
necessarily indicative of the failure of T1ρ to detect amyloid beta plaque in general. The 
T1ρ sequence should be pursued as an alternative strategy to PET detection of amyloid 
beta plaque with the changes in sequence parameters and/or methodology as explained 
above. 
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Chapter 3 
DIFFERENCES IN AGE-RELATED EFFECTS ON BRAIN VOLUME IN DOWN 
SYNDROME AS COMPARED TO WILLIAMS SYNDROME AND TYPICAL 
DEVELOPMENT 
Introduction  
It has been suggested that individuals with Down Syndrome (DS) experience 
accelerated brain aging as evidenced by significant age-related reduction in brain 
volume, but to date, it is not known whether this is an effect of neurotoxic pathology 
evident in DS or a pre-existing feature of impaired neurodevelopment 40. In the current 
study, we aimed to dissociate the contribution of neurodevelopment versus 
neurodegeneration in regional brain volume in DS.  We compared a wide age range of 
adults with DS to adults with a second neurodevelopmental disorder, Williams Syndrome 
(WS), and we also compared both neurodevelopmental disorders to a typically 
developing (TD) control group. 
Etiology and Presentation of Down Syndrome and Williams Syndrome 
DS is a neurodevelopmental disorder caused by the presence of three copies of 
chromosome 21 (trisomy 21). It occurs in one in every 691 live births in the US 18 and is 
the most common genetic cause of intellectual disability 19,20. The degree of cognitive 
impairment associated with DS ranges from mild to severe, with the mean IQ of 50, or 
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moderate intellectual disability 20. Individuals with DS exhibit deficits in language, verbal 
short term-memory, and explicit long-term memory; whereas visuospatial short-term 
memory, associative learning, and implicit memory are relatively preserved 21.  
Advances in the treatment of medical comorbidities, such as heart defects and digestive 
malformations, have resulted in dramatic improvements in life expectancy for individuals 
with DS living in the U.S., rising from 9 years in the early-twentieth century 22 to nearly 
60 years in 2010 102.  Although individuals with DS present with a unique cognitive and 
behavioral profile, they do share some basic characteristics with individuals who have 
Williams Syndrome. 
Williams Syndrome (WS) is a neurodevelopmental disorder caused by the hemizygous 
deletion of 26-28 genes on chromosome 7 103. The prevalence of WS is one in every 
7,500 live births 104. As with DS, WS is associated with cognitive impairment. The 
average IQ for individuals with WS is approximately 50-60, indicating mild to moderate 
intellectual disability 105,106. The WS cognitive profile is characterized by deficits in 
visuospatial and implicit memory and strengths in language, verbal short-term memory, 
face and object recognition, and music processing skills 107–111. In addition, individuals 
with WS often demonstrate increased non-social anxiety and phobias, paired with hyper-
sociability and heightened empathy 112–114.  Similar to individuals with DS, persons with 
WS have experienced a significant increase in mean life expectancy following advances 
in treatment for medical comorbidities, particularly cardiac defects.  There is very little 
literature on aging or life expectancy in WS, but there are documented cases of persons 
with WS who lived to be 70 years old 115.     
  
 44 
 
Brain Morphometry in Down Syndrome and Williams Syndrome  
On average, children and young adults with DS  or WS have an overall smaller brain 
volume compared to  TD individuals of similar age 116; however the specific brain areas 
that show significant volumetric differences compared to TD are distinct for each of the 
neurodevelopmental disorders.  Individuals with DS tend to have smaller frontal, 
amygdalar, and cerebellar volumes compared to TDs; whereas individuals with WS on 
average have smaller midbrain, thalamic, basal ganglia, and occipital and superior 
parietal lobe volumes compared to age-matched TDs 117,118.  It is important to also note 
that as a group, individuals with DS have an increase in parahippocampal volume and 
relatively preserved lenticular nuclei, basal ganglia, and occipital lobe volumes20,21,119 
while young adults with WS have relatively preserved frontal lobe, anterior cingulate, 
superior temporal gyrus, fusiform gyrus, amygdalar, and cerebellar volumes compared 
to TDs 21,117,119.   
In addition to the pre-existing smaller volumes of frontal, amygdalar and cerebellar 
structures,  non-demented older adults with DS (> 50 years of age) also have smaller 
whole prefrontal, posterior cingulate, hippocampal, and parahippocampal volumes when 
compared to age-matched TD adults 21. Studies have shown that as individuals with DS 
age, they exhibit a similar pattern of neurodegeneration to that seen in the early stages 
of AD in the general population, in which the earliest neuropathological changes present 
in the medial-temporal lobe (MTL) and progress to neocortex and subcortical regions 39. 
However, in individuals with DS these neuropathological changes happen at a much 
younger age compared to the general population, which has been attributed to 
accelerated brain aging 40. 
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At present, very few studies have assessed changes in brain morphology in older adults 
with WS 120. One study showed an overall 15% smaller brain volume in individuals with 
WS compared to TD controls; however, they found no difference in the magnitude of this 
finding between older individuals with WS and a group of younger persons with WS, 
suggesting the effect might not be age-related 115.  
Study Aims 
The aims of the current study were to: (1) confirm previous findings of accelerated brain 
aging in DS versus TD, (2) document any age-related differences in brain volume seen 
in WS versus TD, and (3) test for age-related effects that are unique to DS. If 
accelerated brain aging seen in DS is primarily due to DS-specific neurodegenerative 
processes, then we would hypothesize that in the DS group, the age-related effects 
would be greater than those in the TD and WS groups. If, however, the accelerated brain 
aging is instead associated with a non-specific vulnerability due to atypical 
neurodevelopment, then we would hypothesize that both DS and WS groups would have 
greater age-related differences as compared to TD adults than they would compared to 
each other.   
Methods 
Study Participants 
The current study included 14 Caucasian, DS adults (7 males; mean age 39.0; age 
range: 19-63), 58 WS adults (38 males; mean age 25.4, age range: 16-58), and 81 TD 
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adults (39 males; mean age 36.1, age range: 18-89.5). Demographic characteristics 
along with their corresponding statistical values are detailed in Table 4. Adults with DS or 
TD were recruited using flyers and website postings with IRB-approved language 
targeting adults over 18 years of age. For adults with DS, we further recruited from local 
and regional educational centers for individuals with intellectual disabilities, community 
based living centers, caregiver support groups, and employment assistance programs. 
Participants with WS were recruited through the annual Academy of Country Music 
Lifting Lives Music Camp, which is organized by the Vanderbilt Kennedy Center for 
Research on Human Development.  All participants with WS or DS exhibited the 
physical, cognitive and behavioral profile of WS and DS, respectively, and they 
previously had received a clinical diagnosis of the disease.  Adults with typical 
neurodevelopment were ascertained either as age-matched controls for study 
participants with WS or as healthy older adults who served as controls for a general 
population study of age-related cognitive impairment.  The three groups were tested for 
differences in age and sex, using an independent samples t-test and a chi-square test, 
respectively. 
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Table 4 Demographics for volume analysis 
Down syndrome (DS), Williams’s syndrome (WS), and typically developing (TD) controls. SD= standard deviation, N=number, t=t-
statistic. 
                    Group Contrasts 
  DS (N=14)  TD (N=82)  WS (N=41)  DS v TD WS v TD  DS v WS  
  Range Mean  SD  Range Mean  SD  Range Mean  SD  t p-value t p-value t p-value 
Age 
(years) 19 - 63 39 13 18 - 90 36 18 16 - 58 26 8 0.61 0.54 -3.44 1.0E-03 4.31 7.1E-05 
                    DS v WS v TD 
    N %   N  %   N  %     2 p-value     
Male Sex   7 50   40 49   24 59     1.89 0.39     
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Participants with TD and caregivers of individuals with DS or WS gave informed consent, 
while participants with DS or WS gave informed assent for this study. All study 
procedures were approved by the Vanderbilt University Institutional Review Board.  
Magnetic Resonance Imaging Acquisition 
Adults participated in an magnetic resonance imaging (MRI) scan in a Philips Achieva 3-
Tesla scanner (Philips Medical Systems, Inc., Best, Netherlands) using an eight-channel 
SENSE head coil, housed in the Vanderbilt University Institute of Imaging Science 
(Nashville, TN).  High-resolution three-dimensional anatomical T1-weighted MRI images 
were acquired using a turbo field echo (TFE) sequence with full brain coverage and the 
following parameters: field of view = 256×256 mm2; in plane voxel resolution = 1×1 mm2; 
repetition time (TR) = 8.9 ms; echo time (TE) = 4.6 ms; flip angle = 8°; slice thickness = 
1 mm and 170 slices with no slice gap.  
Neuroimaging Analysis 
As described in Chapter 2, FreeSurfer processing was utilized to parcellate the brain into 
cortical and subcortical tissue classes and derive quantitative estimates of brain volume 
94. Image outputs from each stage of FreeSurfer processing were visually inspected 
independently by two imaging analysts (Courtney Edwards, Mary Ellen Koran). The raw 
T1-weighted images were visually inspected for any artifacts and subjects were 
discarded if significant artifact was present in any one of the images. The FreeSurfer 
output was visualized using FreeSurfer’s tkmedit command and following the FreeSurfer 
Troubleshooting Reconstruction Work Flow on the FreeSurfer homepage 
(https://surfer.nmr.mgh.harvard.edu/fswiki/) to ensure that the parcellation and 
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segmentation steps were properly completed. Only images that passed quality control by 
both analysts were used; seven DS, five WS, and five TD adults were not included in the 
analysis because of failure to pass quality control, leaving a total of 14, 58 and 81 adults 
in each category, respectively. Quantitative estimates of volume were derived in a large 
set of spatially distinct region of interests (ROIs) that covered the entire brain, as 
specified in the Desikan atlas 98. This atlas includes parcellations of gray and white 
matter and segmentations of subcortical gray matter, and also includes summary 
volumes (i.e. total cortex volume). Parcellations of the gray and white matter and 
segmentations of subcortical gray matter were included, along with two summary 
measurements of total gray and total white matter. See Table 5 and Table 6 for complete 
lists of ROIs included and excluded in the following analyses, respectively. The regions 
excluded from the analysis were either not of interest (i.e. choroid plexus) or were 
summation measures of sub-regions that were already included (i.e. total gray volume). 
Total intracranial volume (ICV) was also estimated in FreeSurfer, and all ROI measures 
were normalized to ICV. 
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Table 5 Regions of interest included in volume analysis 
 
 
  
3rdVentricle lh_lingual_volume rh_medialorbitofrontal_volume
4thVentricle lh_medialorbitofrontal_volume rh_middletemporal_volume
5thVentricle lh_middletemporal_volume rh_paracentral_volume
BrainStem lh_paracentral_volume rh_parahippocampal_volume
CC_Anterior lh_parahippocampal_volume rh_parsopercularis_volume
CC_Central lh_parsopercularis_volume rh_parsorbitalis_volume
CC_Mid_Anterior lh_parsorbitalis_volume rh_parstriangularis_volume
CC_Mid_Posterior lh_parstriangularis_volume rh_pericalcarine_volume
CC_Posterior lh_pericalcarine_volume rh_postcentral_volume
LeftAccumbensarea lh_postcentral_volume rh_posteriorcingulate_volume
LeftAmygdala lh_posteriorcingulate_volume rh_precentral_volume
LeftCaudate lh_precentral_volume rh_precuneus_volume
LeftCerebellumCortex lh_precuneus_volume rh_rostralanteriorcingulate_volume
LeftCerebellumWhiteMatter lh_rostralanteriorcingulate_volume rh_rostralmiddlefrontal_volume
LeftHippocampus lh_rostralmiddlefrontal_volume rh_superiorfrontal_volume
LeftInfLatVent lh_superiorfrontal_volume rh_superiorparietal_volume
LeftLateralVentricle lh_superiorparietal_volume rh_superiortemporal_volume
LeftPallidum lh_superiortemporal_volume rh_supramarginal_volume
LeftPutamen lh_supramarginal_volume rh_temporalpole_volume
LeftThalamusProper lh_temporalpole_volume rh_transversetemporal_volume
LeftVentralDC lh_transversetemporal_volume RightAccumbensarea
lh_bankssts_volume rh_bankssts_volume RightAmygdala
lh_caudalanteriorcingulate_volume rh_caudalanteriorcingulate_volume RightCaudate
lh_caudalmiddlefrontal_volume rh_caudalmiddlefrontal_volume RightCerebellumCortex
lh_cuneus_volume rh_cuneus_volume RightCerebellumWhiteMatter
lh_entorhinal_volume rh_entorhinal_volume RightHippocampus
lh_frontalpole_volume rh_frontalpole_volume RightInfLatVent
lh_fusiform_volume rh_fusiform_volume RightLateralVentricle
lh_inferiorparietal_volume rh_inferiorparietal_volume RightPallidum
lh_inferiortemporal_volume rh_inferiortemporal_volume RightPutamen
lh_insula_volume rh_insula_volume RightThalamusProper
lh_isthmuscingulate_volume rh_isthmuscingulate_volume RightVentralDC
lh_lateraloccipital_volume rh_lateraloccipital_volume CortexVol
lh_lateralorbitofrontal_volume rh_lateralorbitofrontal_volume CorticalWhiteMatterVol
rh_lingual_volume
Included Regions of Interest
 51 
 
Table 6 Regions of interest not included in volume analysis 
 
  
Not Included
CSF
Leftchoroidplexus
LeftnonWMhypointensities
Leftvessel
LeftWMhypointensities
lhCortexVol
lhCorticalWhiteMatterVol
nonWMhypointensities
OpticChiasm
rhCortexVol
rhCorticalWhiteMatterVol
Rightchoroidplexus
RightnonWMhypointensities
Rightvessel
RightWMhypointensities
SubCortGrayVol
SupraTentorialVol
TotalGrayVol
WMhypointensities
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Genotyping 
Adults with DS had blood drawn for DNA extraction, which was directly genotyped for 
APOE using pre-made TaqMan single nucleotide polymorphism (SNP) genotyping 
assays of rs7412 and rs429358 from Applied Biosystems (ABI; Foster City, California). 
Negative controls (no template) and positive controls (DNA samples with known 
genotypes from Coriell Institute for Medical Research, Camden, New Jersey) were 
included on the plate for assay validation. Since genotyping was performed in a research 
laboratory that is not CLIA-certified, genotyping results were not returned to patients or 
their clinicians. 
Cognitive Testing 
For all participants with DS, we conducted a comprehensive battery of cognitive and 
neuropsychological tests, including the Dementia Questionnaire for People with Learning 
Disabilities (DLD) 26.  Although there is no “gold standard” for assessing dementia in 
individuals with DS, studies have shown that the DLD is useful in the differential 
diagnosis of dementia 27,121. The DLD is a 50-item questionnaire that consists of eight 
subtests (short-term memory, long-term memory, spatial and temporal orientation, 
speech, practical skills, mood, activity and interest, and behavioral disturbance) that 
assess both cognition and social skills. The sum of cognitive scores (SCS) is calculated 
from the short-term memory, long-term memory, spatial and temporal orientation 
subtests. The sum of social scores (SOS) is calculated from the speech, practical skills, 
mood, activity, and interest and behavioral disturbance subtests. Higher scores on each 
subtest indicate greater impairment.  A masters-level study coordinator with training and 
experience in cognitive and neuropsychological assessment administered the DLD. 
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Statistical Analysis 
Our first two aims were to confirm previous findings of accelerated aging in DS 
compared to TD and to test for a comparable effect in WS relative to TD. In order to 
approach these aims we implemented a general linear model in R (http://www.R-
project.org) across 103 separate regions of interest (ICV-corrected volume of each ROI 
= Diagnosis + Age + Sex + Diagnosis x Age).  Diagnosis was dummy coded in the 
regression model with TD set as the reference category. Thus, our model included two 
diagnosis main effects (DS as 0 or 1 and WS as 0 or 1) and two interaction terms: age x 
DS and age x WS which statistically compare the age-related slopes of regional volume 
between the respective diagnostic category and typically developing controls.   This 
method and a three category method in ANCOVA are statistically equivalent 122.  
However, in the linear regression method used here, the t-tests based on dummy coded 
variables directly tests the alternative hypothesis that the coded group differs from the 
reference group (in this case, TD controls), which aids in the interpretation of results.  
Sex was coded as a binary discrete variable (male as 0; female as 1).  A Bonferroni 
corrected significance threshold of p<4.85 x 10-4 was applied to the interaction terms in 
order to correct for the 103 ROIs tested (see Table 5 for list of ROIs tested). A post hoc 
analysis was conducted to determine the sensitivity of results due to outliers. Outliers 
were defined as adults with ICV-corrected total gray matter volume outside of the grand 
mean +/- 2 standard deviations, a relatively strict correction (calculated in SPSS, 
www.ibm.com/software/analytics/spss/ ).  
A final aim was to test for age-related effects unique to DS. The same general linear 
model was used (ICV-corrected volume of each ROI = Diagnosis + Age + Sex + 
Diagnosis x Age), but we only included DS and WS in our diagnostic category (WS = 0 
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and DS = 1). The same Bonferroni correction was applied to determine the significant 
interaction terms and again a post hoc analysis was performed after removing statistical 
outliers. 
Secondary Exploratory Analyses 
In order to further explore age-related volume that is specific to DS, we performed linear 
regression to test for an association between brain volume and other cognitive and 
genetic risk factors.  To control for Type I error, we restricted our analysis to brain 
regions that showed significant age-related effects, which were stronger in DS relative to 
TD or WS. Predictors included age, sex, and the variable of interest. For each ROI we 
tested for an association with DLD-SOS or DLD-SCS as the continuous variable of 
interest. Since DLD data were only collected for participants with DS, analyses were 
restricted to the DS group. We report the t-statistic for the variable of interest (DLD-SOS 
or DLD-SCS), along with its unadjusted p-value, and we report the change in R2 
comparing the full model with the variable of interest to the reduced model (Table 7). 
Next we performed an exploratory analysis to determine the relationship between APOE 
genotype and age-related volume effects in DS.   The absence/presence of APOE 4 
alleles was coded as 0/1 respectively. We report the R2 of the full model with APOE, the 
change in R2 with the addition of APOE, and the unadjusted p-value of the APOE term 
(Table 7). 
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Table 7 Relationship between volume and DLD cognitive scores or APOE in brain regions showing a correlation with age in Down 
Syndrome participants. p-values are uncorrected and those < 0.05 are bolded.  
Region of Interest 
DLD-SCS DLD-SOS APOE 
t 
Change 
in R2 p-value t 
Change 
in R2 p-value t 
Change 
in R2 p-value 
LILV 2.37 0.21 0.042 4.72 0.38 0.001 2.61 0.22 0.026 
RILV 2.56 0.25 0.031 4.01 0.38 0.003 2.47 0.22 0.033 
Left Superior Parietal -1.32 0.06 0.219 0.41 0.01 0.693 
-
1.06 
0.04 0.315 
Left Pars orbitalis -1.66 0.08 0.131 -1.32 0.06 0.220 
-
1.23 
0.10 0.247 
Left Inferior Parietal -1.21 0.07 0.256 -1.59 0.10 0.146 
-
1.87 
0.06 0.091 
Right Post Central Gyrus -0.54 0.01 0.604 -1.11 0.05 0.294 0.05 0.00 0.961 
Left Ventricle 0.57 0.01 0.582 2.06 0.13 0.069 1.45 0.07 0.178 
Right Ventricle 0.91 0.03 0.386 2.59 0.15 0.029 1.78 0.08 0.105 
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Table 8 Brain regions where volume had a significant relationship with age between 
participants with Down Syndrome and typically developing controls in the model Volume 
of ROI = Age + Sex + Diagnosis + Diagnosis x Age. p-values are uncorrected, 103 tests 
were analyzed. 
Region of Interest  
DS x Age Interaction Term 
t 
Change 
in R2 p-value 
LILV 4.31 0.09 3.25E-05 
RILV 4.05 0.10 9.03E-05 
Left Superior Parietal -4.02 0.08 1.01E-04 
Left Inferior Parietal -3.97 0.08 1.23E-04 
Left Pars Orbitalis  -3.82 0.07 2.11E-04 
Right Post Central Gyrus -3.67 0.07 3.58E-04 
 
 
Table 9 Brain regions where volume had a significant relationship with age between 
participants with Down Syndrome and Williams Syndrome in the model Volume of ROI = 
Age + Sex + Diagnosis + Diagnosis x Age. p-values are uncorrected, 103 tests were 
analyzed. 
 
Region of Interest 
Diagnosis Term (DS vs. WS) 
t 
Change 
in R2 p-value 
Right Lateral Ventricle 4.42 0.14 8.64E-05 
Left Lateral Ventricle 3.75 0.12 1.35E-04 
 
 
Results 
Our first analysis attempted to replicate previous findings of accelerated aging in DS and 
to test for similar effects in WS. Consistent with previous findings, the DS group showed 
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significantly greater age-related effects on grey matter volume relative to TD controls in 
the regions of the orbitofrontal cortex (the left pars orbitalis) and the parietal cortex (the 
left superior parietal lobe, the left inferior parietal lobe and the right post central gyrus) 
(see Table 8, full results in supplementary Appendix B 
SUPPORTING INFORMATION FOR CHAPTER 3 
Table 20).  Individuals with DS also showed significantly increased age-related effects 
on volume of the left and right inferior lateral ventricles (LILV and RILV, respectively).  In 
contrast, there were no significant differences in age-related volume between WS and 
TD controls. The summary measurements of total white matter and total gray matter 
volumes were also analyzed, and the DS group showed greater age-related effects on 
total grey matter volume (unadjusted-p=0.007) while there was no significant effect in the 
total white matter volume measure (unadjusted-p=0.055). As a post-hoc analysis, older 
TD subjects were dropped in order to analyze only those subjects whose ages 
overlapped (subjects older than the oldest DS subject were dropped (63 years)). Only 
the left superior parietal lobe remains significant at the Bonferroni corrected level (p = 
4.49x10-4). 
Our second analysis compared age-related volume in DS to age-related volume in WS 
(Table 9). The DS group showed a stronger relationship between age and volume for the 
left and right lateral ventricles relative to WS, and this difference remained significant 
after correcting for multiple comparisons. Plots of age versus volume for all significant 
ROIs are presented in Figure 13 and Figure 14.  
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To investigate whether outliers were driving the observed effects, we removed the 
participants whose ICV-corrected total gray matter volume was outside of two standard 
deviations of the grand mean, and we repeated our analyses. One DS subject and four 
WS adults were removed, but no outliers were identified for the TD group. The 
interaction model term (Diagnosis x Age) remained significant after Bonferroni correction 
for the left superior parietal lobe and the right lateral ventricle, and in all the other ROIs 
found significant in primary analyses, the interaction term was significant at a nominal 
(unadjusted) p<0.05. No additional ROIs reached Bonferroni significance. These results 
are presented in Table 10, Table 11, and Figure 15. 
 
 
Figure 13: Relationship between inferior lateral ventricle volume and age in Down 
Syndrome, Williams Syndrome, and typically developing controls.  
Regional brain volumes normalized to ICV are plotted in relationship to age across the 
three subject groups (Down syndrome (DS) in red, typical development (TD) in green, 
and William syndrome (WS) in blue) in: (a) left inferior lateral ventricle (LILV) and (b) 
right inferior lateral ventricle (RILV) 
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Figure 14: Relationship between regional brain volumes and age in Down Syndrome, 
Williams Syndrome, and typically developing controls.  
Regional brain volumes normalized to ICV are plotted in relationship to age across the 
three subject groups (Down syndrome (DS) in red, typical development (TD) in green, 
and William syndrome (WS) in blue) in (a) left inferior parietal lobe, (b) left pars orbitalis, 
(c) left superior parietal lobe, and (d) right post central gyrus. 
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Table 10 Brain regions where volume had a significant relationship with age between 
participants with Down Syndrome and typically developing controls after outliers 
removed.   
Bolded p-values still pass Bonferroni correction (p<4.85 x 10-4). 
 
ROI 
DS x Age 
t 
Change 
in R2 p-value 
LILV 2.39 0.04 1.8E-02 
RILV 2.12 0.05 3.6E-02 
Left Superior Parietal -3.64 0.07 4.0E-04 
Left Inferior Parietal -3.48 0.07 7.1E-04 
Left Pars Orbitalis  -3.20 0.06 1.7E-03 
Right Post Central Gyrus -3.26 0.06 1.4E-03 
 
 
 
Table 11 Brain regions where volume had a significant relationship with age between 
participants with Down Syndrome and Williams Syndrome after outliers removed.   
Bolded p-values still pass Bonferroni correction. 
 
ROI 
DS vs. WS 
t 
Change 
in R2 p-value 
Right Lateral Ventricle 4.20 0.024 1.34E-04 
Left Lateral Ventricle 3.73 0.022 5.50E-04 
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Figure 15: Relationship between regional brain volumes and age in Down Syndrome, 
Williams Syndrome, and typically developing controls after outliers were removed.  
This figure shows results from analyses which excluded adults with gray matter volumes 
normalized to intracranial volume (ICV) that fell outside two standard deviations of the 
grand mean. Regional brain volumes normalized to ICV are plotted in relationship to age 
across the three subject groups (Down syndrome (DS) in red, typical development (TD) 
in green, and William syndrome (WS) in blue) in (a) the left inferior lateral ventricle 
(LILV), (b) right inferior lateral ventricle (RILV), (c) left inferior parietal lobe, (d) left pars 
orbitalis, (e) left superior parietal lobe, and (f) right post central gyrus. 
 
In secondary analyses, we explored the relationships between brain volume in the eight 
significant ROIs reported above and the DLD-SOS score, the DLD-SCS score, and 
APOE status in DS adults using linear regression. Two, or 14%, of the subjects with DS 
had APOE e2 alleles, and three, or 21%, had e4 alleles. These frequencies are slightly 
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higher than expected from the allele frequencies in the general or DS populations, but 
this differential may be due to small sample size 123,124. Full results are presented in 
Table 7. All three variables were significantly associated with LILV and RILV volume 
(p<0.05). DLD-SCS and -SOS scores were significantly correlated (r2=0.770, p=0.002) 
and explained similarly high rates of variability in regional brain volume. DLS-SCS 
scores explained 20.6 and 24.7% of the variance in LILV and RILV volume, respectively 
(p=0.042 and p=0.031; Figure 16). DLD-SOS scores explained 38.3 and 37.6% of 
variance in LILV and RILV volume, respectively (p=0.001 and p=0.003; Figure 17).  
DLD-SOS was also significantly associated with the overall right ventricular volume 
(p=0.029) and explained 15% of right ventricular volume variance.  APOE explained 
22% of the variance in LILV and RILV volume with p=0.026 and 0.033, respectively 
(Figure 18). 
After the one DS subject who could be considered an outlier based on gray matter 
volume (as described above) was removed, the relationships between DLD-SCS and 
RILV and between DLD-SOS and LILV remained significant (p=0.037 and 0.009, 
respectively).  However, the associations in all other ROIs that were significant in 
primary analyses were no longer significant after outlier removal. The removed subject 
was one of three adults who had an 4 allele. 
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Figure 16: Regional brain volumes in relation to Dementia Questionnaire for People with 
Learning Disabilities-sum of cognitive scores (DLD-SCS) in the Down Syndrome cohort.  
Regional brain volumes normalized to ICV are plotted in relationship to DLD-SCS across 
the Down syndrome subject group in:  (a) Right inferior lateral ventricle (LILV) and (b) 
Left inferior lateral ventricle (RILV).  Subject data points are marked as APOE 4 carriers 
(x) or non-carriers (o).  For visualization purposes, we have overlaid a linear trend line 
for all data points, but note this line does not reflect covariate adjustments in the 
statistical model tested. 
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Figure 17: Regional brain volumes in relation to Dementia Questionnaire for People with 
Learning Disabilities-sum of social scores (DLD-SOS) in the Down Syndrome cohort.  
Regional brain volumes normalized to ICV are plotted in relationship to DLD-SOS across 
the Down syndrome subject group in: (a) Right inferior lateral ventricle (LILV) and (b) 
Left inferior lateral ventricle (RILV).  Subject data points are marked as APOE 4 carriers 
(x) or non-carriers (o). For visualization purposes, we have overlaid a linear trend line for 
all data points, but note this line does not reflect covariate adjustments in the statistical 
model tested. 
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Figure 18: Relationship between age and brain region volumes stratified by APOE risk 
allele carrier status. 
For the purpose of visualization, regional brain volumes normalized to ICV are plotted in 
relationship to age across the Down syndrome subject group, with adults marked as 
APOE 4 carriers (x) or non-carriers (o) in: (a) Left inferior lateral ventricle (LILV) and (b) 
Right inferior lateral ventricle (RILV). For visualization purposes, we have overlaid a 
linear trend line for all data points reflecting APOE e4 presence (dotted line) or absence 
(non-dotted line), but note this line does not reflect covariate adjustments in the 
statistical model tested. Also note that there are three APOE e4 carriers. 
 
 
 
Discussion 
The first aim of the current study was to confirm previous findings of accelerated brain 
aging in DS 40. In previous studies, adults with DS had significantly stronger relationships 
between age and volume in the frontal, parietal, and temporal lobes, and the lateral 
ventricles 40. We replicated these findings in the frontal lobe (specifically, the left pars 
orbitalis gyri frontalis inferioris), the parietal lobe (specifically, the left superior and left 
inferior parietal cortices and the right post central gyrus), and in the lateral ventricles 
(specifically, the LILV and RILV).   
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Interestingly, atrophy in these grey matter regions may be explained by the link between 
DS and Alzheimer’s Disease (AD).  Individuals with DS are at a greatly increased risk of 
developing AD, with up to 70 percent developing dementia by the age of 70 24.  In fact, 
adults with DS account for up to 60% of individuals with developmental disabilities who 
exhibit signs of AD 25.  The risk for AD in DS is primarily linked to triplication of the 
amyloid precursor protein (APP), which is on chromosome 21 33.  However, one’s 
genotype at the apolipoprotein E (APOE) gene, whose protein product is involved in the 
processing of amyloid beta isoforms, modulates risk for developing AD in the DS 
population 36,37. Postmortem studies have revealed that plaque load in adults with DS 
increases with age and by 40 years of age, nearly all individuals with DS have amyloid 
beta plaques in the brain 32, and this characteristic feature of AD has neurotoxic effects 
that can lead to neurodegeneration and loss in brain volume 125. More specifically, both 
the frontal and parietal lobes have shown increased amyloid load as measured by 
positron emission tomography (PET) in participants with DS 58. Therefore, the age-
related affects detected in this study may be due to the neurotoxic effects of age-related 
increases in amyloid load in adults with DS.   
Age-related volume in DS relative to WS adults was significant in the left and right total 
lateral ventricles, even after Bonferroni correction for multiple comparisons, and there 
was a stronger relationship between age and volume in the inferior lateral ventricles 
when comparing the DS and TD groups.  Both of these results are particularly interesting 
given the high prevalence of AD in DS and the association between ventricular dilation 
and AD.  Volume of the lateral ventricles has repeatedly shown a relationship to AD 
status and disease progression in the general population 48–51.  The lateral ventricles 
normally dilate over time with age, as brain tissue volume decreases, but in patients with 
mild cognitive impairment (MCI) or AD, the rate of ventricular dilation is much greater 
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than in the general aging population 52. The inferior lateral ventricles are surrounded by 
subcortical gray matter structures and these structures, particularly the hippocampus, 
entorhinal cortex, and amygdala, accumulate amyloid beta plaques and exhibit atrophy 
in AD 4,52 and DS 126–130. Since ventricular dilation is cumulatively and inversely reflective 
of atrophy of these surrounding structures 131, and since we found that the strong 
relationship between age and ventricular volume is specific to DS (and not present in 
WS), the results seen in this study may be reflective of the neurotoxic effects of AD 
pathology in the structures surrounding the ventricles. 
We also investigated whether  the WS group experienced accelerated aging  compared 
to the TD group, but we did not find evidence to support this hypothesis, which is in line 
with the one previously reported finding of aging WS adults 115.  This may be due to the 
difference in age ranges between the WS and TD groups (Table 4), and further 
investigation of age-related volume in WS in a larger study, preferably with longitudinal 
data, is warranted.   
As an exploratory analysis in the DS cohort only, regions with significant age-related 
changes (in DS vs. TD and DS vs. WS) were evaluated for association with DLD-SOS 
and DLD-SCS tests and APOE 4 carrier status. We observed a significant relationship 
between inferior lateral ventricle volume and both the cognitive and social scores on the 
DLD, a test that measures dementia-related impairments in the DS population.  The 
social sub-score of the DLD was also significantly associated with right ventricular 
volume. Previous studies have shown that individuals with DS have increased regional 
brain atrophy with onset of dementia 126,128,129,132, and in the current study, we observed 
that higher levels of dementia symptomology (as measured by the DLD) were 
associated with increased ventricular volume, an MRI biomarker of neurodegeneration.  
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APOE is a very strong genetic risk factor predisposing patients to AD-associated 
neurodegeneration, with even TD adults who are carriers of the 4 risk allele showing 
greater neurodegeneration before symptom onset 133.  While APOE is also associated 
with further increased risk of AD in the DS population, to our knowledge, this is the first 
study in DS to investigate the association of APOE 4 carrier status with MRI volume 
data. The observed 4 carrier frequency was 3/28 alleles, or 11%, which is similar to the 
frequency observed in the general population (13%).  However, one of the three 4 
carriers was the DS group outlier, and it was this subject who drove the difference in 
brain volume by APOE genotype.  Thus, we are not able to make a strong conclusion 
based on these data, and future analyses with larger sample sizes will be necessary to 
confirm an effect of APOE on brain volume in Down syndrome.   
The present results must be interpreted within the framework of our statistical models. 
The WS and DS groups differed in mean age, but in all cases, we included covariates 
related to neurodegeneration including age and sex in an effort to control for these 
factors. The highly significant p-values we observed seem to be driven in part by one DS 
outlier, as evidenced in Table 10 and Table 11, but the effect sizes (i.e., the differences 
in the volume versus age trends) do not change when the outliers are removed (Figure 
15). Furthermore, though this study found a significant age-related difference in DS 
adults in AD-related regions, we may have been underpowered to detect more subtle 
AD-related changes due to 1) the relatively small sample size of the DS group, 2) the 
strict statistical threshold used for significance, and 3) the fact that FreeSurfer parameter 
estimates for smaller subcortical areas, such as the entorhinal cortex and hippocampus, 
are known to exhibit greater error 134. Despite this, some AD-related regions were 
nominally significant at an unadjusted p<0.005 (left hippocampus: p=0 .0023, right 
amygdala: p=0.0042, left amygdala: p=0.0042). These results warrant further analysis of 
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age-related affects in AD-related regions in a larger cohort of DS adults. In the future, to 
optimize this study, we would ideally want to age-match the populations under study.  
In conclusion, we used a whole-brain ROI approach to investigate the relationship 
between age and MRI-derived brain volume across adults with a neurodevelopmental 
disorder (DS and WS) or typical development.  We also incorporated cognitive test data 
and genetic risk data in a secondary exploratory analysis of the DS group. We found that 
adults with DS had profound age-related effects in grey matter regions of the 
orbitofrontal cortex (the left pars orbitalis) and the parietal cortex (the left superior 
parietal lobe, the left inferior parietal lobe and the right post central gyrus), and in the left 
and right inferior lateral ventricles, as compared to WS adults.  By combining imaging 
and cognitive testing data, we concluded that the inferior lateral ventricles, which are 
surrounded by structures that typically atrophy in normal aging and also in diseased 
states like AD, were also associated with dementia rating scores in the DS group.  While 
APOE also showed a trend for association with regional brain volume, a larger sample 
size will be needed to accurately estimate this effect.  
Supporting Information 
Example code used in this analysis is available in Appendix B. 
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Chapter 4 
GENETIC INTERACTIONS ASSOCIATED WITH LONGITUDINAL CHANGES IN 
VENTRICLE SIZE IN ALZHEIMER’S DISEASE 
Adapted from: 
Koran ME, Hohman TJ, Meda SA, Thornton-Wells TA. Genetic Interactions within 
Inositol-Related Pathways are Associated with Longitudinal Changes in Ventricle Size. 
Journal of Alzheimer’s Disease. In Press.  
Introduction 
Late onset Alzheimer’s disease (LOAD) is a devastating, degenerative neurological 
disease that affects over 5 million people in the United States alone, an already 
substantial statistic that is expected to triple by 2050 (www.alz.org) 3. The complex 
genetics of LOAD have proven difficult to unravel due to the disease’s clinical and 
genetic heterogeneity. To date, 21 genes/genomic loci have been confirmed by 
replication and meta-analysis to be associated with LOAD 11,14. Of these genes, only 
APOE has a large effect with an odds ratio of about 3.7 for one copy of the high risk 4 
allele; the remaining genes exhibit small effect sizes, with odds ratios hovering between 
0.73 and 1.22 11,14. In order to increase our power and biological interpretability of this 
complex disease, we expanded our analysis beyond the traditional approach of testing 
for single marker effects using binary disease status as the primary outcome.  In this 
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study, we include rich phenotypic information derived from magnetic resonance imaging 
(MRI) quantitative traits (QTs) as our outcomes, which addresses the problem of clinical 
heterogeneity, and we explicitly test for gene-gene interactions, which confronts the 
issue of genetic heterogeneity 135.   
Though these have not been replicated, interactions have shown significant associations 
in many other complex diseases such as schizophrenia 136, autism 137 and type 2 
diabetes 138.  In LOAD, previous gene-gene interaction studies have implicated 
interactions between CR1 and APOE 81, cholesterol trafficking genes 139,140, tau 
phosphorylation genes 141, and calcium signaling and axon guidance genes 83. These 
studies demonstrate that important mechanistic insight can be garnered from 
investigating higher order genetic relationships in complex diseases like LOAD.  
For LOAD and other brain-based diseases, brain structure derived from imaging 
modalities can be the source of relevant QTs or endophenotypes. Endophenotypes are 
biological measurements that are more proximal to genetic function and pathology than 
disease status 62 and can provide increased statistical power (and therefore decreased 
sample size requirements) over dichotomous outcome variables 64. Many measurements 
of brain structures correlate with LOAD status and to have greater sensitivity in detecting 
early pathological changes 142.  QTs from structural MRI have been used as 
endophenotypes in LOAD GWAS previously 74, and in this study, we extend that work by 
investigating associations of an endophenotype of LOAD with gene-gene interactions.  
The lateral ventricles have repeatedly shown a relationship to Alzheimer’s disease (AD) 
status and progression 48–51.  The lateral ventricles normally dilate over time with age, as 
brain tissue volume decreases, but in patients with mild cognitive impairment (MCI) or 
AD, the rate of ventricular dilation is much greater than in the normal aging population 52. 
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MRI measurements of lateral ventricle expansion correlate with disease status, with 
ventricular volumes and rates of dilation increasing from healthy controls (HC) to MCI 
and from MCI to AD 52. The inferior horns of the lateral ventricles are surrounded by gray 
and white matter structures (corpus callosum, hippocampus, amygdala, caudate 
nucleus, deep white matter, and thalamus).  These structures, particularly the 
hippocampus and amygdala, often deteriorate in AD, and patients with AD and MCI 
have significantly higher rates of tissue atrophy in these structures than normal aging 
adults 52, and ventricular dilation is inversely reflective of atrophy of these surrounding 
structures 131. Ventricular dilation is evident 10 years before clinical symptoms, and 
dilation rate rapidly accelerates two years prior to initial MCI diagnosis, making 
longitudinal MRI measurement of ventricular dilation a plausible clinical trial biomarker 
for disease inclusion or progression criteria 52.  Because of the evidence demonstrating 
atrophy of brain structures surrounding the inferior lateral ventricles (ILVs) in LOAD and 
because changes in these structures are reflected and magnified in the ILVs, we chose 
to investigate genetic associations with longitudinal change in volume of these 
structures.  
While correction for multiple testing in single-marker genome-wide association analysis 
is highly burdensome, due to combinatorics, in genome-wide interaction analyses it is 
essentially prohibitive except perhaps for very large datasets 143.  However, interaction 
analyses limited to known candidate genes are unduly constrained by information from 
previously published studies 144.  Alternative strategies may instead conduct intelligent 
variable selection based on prior biological knowledge assembled from a wide variety of 
scientific disciplines 145.  In this study, we selected genes participating in common 
biological pathways for investigation of gene-gene interactions associated with the 
endophenotype of ILV atrophy rate.  By doing so, we aimed to increase the biological 
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plausibility of interactions that are novel to AD, while decreasing computational burden. 
We hypothesized that novel gene-gene interactions would be significantly associated 
with the dilation of the ILVs and that the novel interactions will generate new or altered 
hypotheses regarding the etiology of this disease.   
Materials and Methods   
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.ucla.edu). The ADNI was launched in 2003 by the National Institute on Aging 
(NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food 
and Drug Administration (FDA), private pharmaceutical companies and non-profit 
organizations, as a $60 million, 5-year public-private partnership. The primary goal of 
ADNI has been to test whether serial magnetic resonance imaging (MRI), PET, other 
biological markers, and clinical and neuropsychological assessment can be combined to 
measure the progression of MCI and early AD. Determination of sensitive and specific 
markers of very early AD progression is intended to aid researchers and clinicians in 
developing new treatments and monitoring their effectiveness, as well as lessening the 
time and cost of clinical trials. 
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center 
and University of California – San Francisco. ADNI is the result of efforts of many co-
investigators from a broad range of academic institutions and private corporations, and 
subjects have been recruited from over 50 sites across the U.S. and Canada. The initial 
goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research, 
approximately 200 cognitively normal older individuals to be followed for 3 years, 400 
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people with MCI to be followed for 3 years and 200 people with early AD to be followed 
for 2 years. Further information on ADNI can be found here 146.  
Subjects 
Participants were enrolled based on the criteria outlined in the ADNI-1 protocols 
(http://www.adni-info.org/Scientists/AboutADNI.aspx). Information on ADNI subject 
protocols can be found here 147. To minimize population stratification, only Caucasian 
subjects who had both genotype data and T1-weighted MRI data were included. 
Demographic data are presented in Table 12.  
 
Table 12 Demographic data for genetic interaction association with longitudinal inferior 
lateral ventricle volume change 
 
 
Clinical Diagnosis
#
 
Normal Control
 Mild Cognitive 
Impairment
 Alzheimer’s Disease
 
Number of Patients 187 191 352 
Number of APOE-4 Carriers 45 81 231 
Number of Females 85 61 146 
Mean Baseline Age (SD
^
) 75.98 (5.61) 75.79 (7.09) 75.13 (7.33) 
Mean Years of Education (SD
^
) 16.11 (2.79) 15.73 (3.01) 15.32 (2.97) 
Mean RILV slope* (SD
^
)
 
  70.55 (77.37) 119.85 (123.15) 237.67 (185.37) 
Mean LILV slope* (SD
^
)
  68.52 (78.63) 121.65 (110.92) 237.55 (179.6) 
 
Clinical Diagnosis
 #
: 
Normal Control subjects had a Mini-Mental Status Examination (MMSE) score between 24 and 30, a 
Clinical Dementia Rating (CDR) score of 0, and were not depressed (Geriatric Depression Scale score < 6).  
Mild Cognitive Impairment subjects had a MMSE score between 24 and 30; objective memory 
impairment, subjective memory impairment, and a CDR score of 0.5.  
Alzheimer’s Disease subjects met clinical criteria for dementia, had an MMSE of between 20 and 26, and 
had CDR score of .5 or 1. 
SD
^
: standard deviation. 
LILV/RILV*: Left/Right inferior lateral ventricles.  
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Genotyping   
Genotyping was performed by the ADNI Genetics Core using the Illumina Infinium 
Human-610-Quad BeadChip. Further information about the ADNI Genetics Core efforts 
can be found here 148.  ADNI quality control (QC) steps included removing copy number 
variant probes, strand checking, base pair position checking, and allele specificity 
checking 149. Further QC was performed using PLINK software (version 1.07; 150), 
excluding SNPs with a genotyping efficiency < 95%, out of Hardy Weinberg Equilibrium 
(p<1x10-6), or with a minor allele frequency (MAF) of < 5%. Subjects were excluded if 
they had a call rate < 95%, if there was a reported versus genetic sex inconsistency, or if 
relatedness was established (PI_HAT > 0.5). After QC, 515,839 SNPs and 730 subjects 
remained available for discovery analyses.  
Analysis of Imaging Data 
Structural T1-weighted MRI scans were acquired on subjects at baseline, 12, 24, and 36 
month follow-up appointments as per the ADNI protocol 151. Further information on 
ADNI’s MRI protocols can be found here 151,152. Cortical reconstruction and volumetric 
segmentation of these images were performed with the FreeSurfer 153 image analysis 
suite version 4.3 by the ADNI consortium which has been described in detail elsewhere 
154. An early version of the longitudinal image processing framework was used to 
process the sequential scans 155. Volumes of the right and left ILV (RILV and LILV, 
respectively) were calculated in FreeSurfer (in mm3) for every scan available for each 
individual in the dataset and slopes of change in RILV and LILV volume over time were 
calculated in SAS 9.3 (SAS Institute Inc., Cary, NC) using mixed model regression 
(PROC MIXED) to leverage the longitudinal data available in ADNI-1. We used the 
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slopes of change of the LILV and RILV as our primary outcome measurement 
(mm3/year) and included a measurement of intracranial volume (ICV in mm3) as a 
covariate in all volume analyses, which was also defined with FreeSurfer.  
SNP-SNP Interaction Analysis 
Genotype data that passed QC were analyzed in a pathway-based interaction analysis 
using the publicly available InterSNP v1.0.10 program 156. We took advantage of 
InterSNP’s pathway based option that tests SNP-SNP pairs between genes that belong 
to a common biological pathway derived from all of the pathways in the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/). 
The KEGG database is a collection of manually curated pathways based on published 
literature for metabolism, genetic and environmental information processing, and human 
diseases, including AD 157,158. This option decreases the number of tests performed and 
also increases the interpretability of an interaction based on a priori information.  SNP-
SNP interaction effects were explored using a dominant model and a linear regression 
framework for QTs 156. A total of 130,512,955 SNP-SNP interaction pairs were tested for 
each region of interest (ROI), and SNP-SNP pairs were considered significant after 
Bonferroni correction accounting for the number of pairs tested (p < 3.83x10-10). All 
SNPs were entered into the model as binary variables (minor allele absent or present) to 
attenuate the problem of data sparsity commonly confronted in interaction analyses. 
Model covariates included: baseline age (in years), sex, education (in years), APOE 
status (number of 4 risk alleles), and last diagnosis recorded as of January 2013 (1= 
Normal, 2=MCI, 3=AD).  Each of these covariates was chosen to avoid confounding, 
with the goal of identifying interactions which explain variance beyond these known risk 
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factors. The brain is known to atrophy over time even in normal aging 159, and the rate of 
change differs by sex 160. Education level is correlated with age of disease onset 161. 
APOE is a very strong genetic risk factor predisposing patients to LOAD, with even 
normal subjects who are carriers of the risk allele showing greater neurodegeneration 
before any symptom onset 133. And finally, atrophy rates are known to trend with disease 
status, wherein AD>MCI>HC 48–50,162.  
Significant SNP-SNP interactions were annotated to their gene-gene pairs using dbSNP 
(Homo sapiens, updated in build 137) and their common pathways using KEGG.  
InterSNP calculates contingency tables which can be seen in Table 13. The difference in 
R2 for these models was calculated in SPSS as R2 = R2(full model with interaction term) – R
2
(reduced 
model without interaction term). Visualization of interaction effects was created in SPSS as well, 
showing rate of change by allelic combination (Figure 19, Figure 20, Figure 21, Figure 
22).  
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Table 13 Contingency tables for significant SNP-SNP interactions from genetic 
interaction association with longitudinal inferior lateral ventricle volume change 
  
rs178051(PI4KA) 
 
Total 
  
T C 
  
rs9295289(SYNJ2) 
T 552 107 
 
659 
C 61 9 
 
70 
 
     Total 
 
613 116 
 
729 
      
  
rs3744566(MYH2) 
 
Total 
  
C T 
  
 rs11596284(PARD3) 
A 557 98 
 
655 
C 63 10 
 
73 
 
     Total 
 
620 108 
 
728 
      
  
 
rs7154732(ABHD12B)  Total 
  
T C 
  
rs11614805(PDE3A) 
C 579 60 
 
639 
T 81 5 
 
86 
 
     Total 
 
660 65 
 
725 
      
  
rs1922127(PRKG1) 
 
Total 
  
G A 
  
rs11590865(OR2L13) 
A 460 194 
 
654 
G 56 18 
 
74 
 
     Total 
 
516 212 
 
728 
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Results  
Pathway Based Interaction Analysis: 
Demographic information is presented in Table 12. The study sample included 187 NC, 
191 MCI, and 352 AD subjects. The number of APOE-4 carriers is enriched in the AD 
and MCI subjects. The slopes of the RILV and LILV increased from NC to MCI to AD 
subjects. We identified four Bonferroni-corrected significant SNP-SNP interactions in the 
RILV corresponding to the gene-gene pairs: SYNJ2-PI4KA, PARD3-MYH2, PDE3A- 
ABHD12B, and OR2L13-PRKG1, in order of significance (Table 15). None of the SNPs 
involved had significant main effects in the dominant model (all main effects had 
uncorrected p ≥ 0.01).   
One Bonferroni-corrected (p < 3.83x10-10) significant SNP-SNP interaction was 
discovered in the LILV corresponding to SYNJ2-PI4KA. The specific SNP-SNP 
interaction corresponding to SYNJ2-PI4KA was the same in both the RILV and LILV and 
was the most significant in both hemispheres (RILV: p = 9.13x10-12; LILV: p = 8.17x10-
13). This gene-gene pair belongs to the metabolic, the inositol phosphate metabolism and 
the phosphatidylinositol signaling system pathways in KEGG (hsa001100, hsa00562 and 
hsa04070, respectively), and neither gene is involved in additional KEGG pathways 
independently.  The effect of this interaction was in the same direction for both 
hemispheres (LILV=352.44 and RILV=351.88) and explained >4% of the variance in both 
the RILV and LILV (R2RILV  = 0.043, R
2
LILV  = 0.046). As seen in Figure 19 and Figure 20, 
having the minor allele for both genes corresponded to an increased rate of change in 
both ILVs. This interaction was consistent across subjects with MCI and AD diagnoses 
(Figure 21 and Figure 22). Contingency tables showing sample sizes by genotype 
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combination are presented in Table 13, and contingency tables by diagnosis status are 
shown in Table 14. 
 
Table 14 Contingency tables for SNP-SNP interaction between SYNJ2 and PI4KA for 
association study with longitudinal inferior lateral ventricle volume change.  
NC: Normal Control; MCI: Mild Cognitive Impairment; AD: Alzheimer’s Disease. Cells 
represent count, or number of subjects in each category. 
    Diagnosis 
    NC MCI AD 
    rs9295289 SYNJ2 
    
Minor 
Allele 
Absent 
Minor Allele 
Present 
Minor 
Allele 
Absent 
Minor Allele 
Present 
Minor 
Allele 
Absent 
Minor Allele 
Present 
PI4KA 
rs178051 
Minor 
Allele 
Absent 
148 15 147 14 257 32 
Minor 
Allele 
Present 
23 1 29 1 55 7 
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Figure 19: Effect of SYNJ2 and PI4KA interaction on right inferior lateral ventricle volume 
change. The model included volume change as the outcome variable, and SNP effects 
and SNPxSNP interactions, and covariates of baseline age, sex, education in years, 
APOE status, and diagnosis.  p = 9.13x10-12. Contingency tables showing sample sizes 
by genotype combination are presented in Table 13.  
Bars represent one standard error. 
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Figure 20: Effect of SYNJ2 and PI4KA interaction on left inferior lateral ventricle volume 
change. The model included volume change as the outcome variable, and SNP effects 
and SNPxSNP interactions, and covariates of baseline age, sex, education in years, 
APOE status, and diagnosis.  p = 8.17x10-13. Contingency tables showing sample sizes 
by genotype combination are presented in Table 13.  
Bars represent one standard error. 
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Figure 21: Effect of SYNJ2 and PI4KA interaction on right inferior lateral ventricle volume 
change across diagnoses. The model included volume change as the outcome variable, 
and SNP effects and SNPxSNP interactions, and covariates of baseline age, sex, 
education in years, APOE status, and diagnosis.  p = 9.13x10-12. Contingency tables by 
diagnosis status are shown in  Table 14. 
 
Table 14. 
Bars represent one standard error. 
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Figure 22: Effect of SYNJ2 and PI4KA interaction on left inferior lateral ventricle volume 
change across diagnoses. The model included volume change as the outcome variable, 
and SNP effects and SNPxSNP interactions, and covariates of baseline age, sex, 
education in years, APOE status, and diagnosis. p = 8.17x10-13. Contingency tables by 
diagnosis status are shown in  Table 14. 
 
Table 14. 
Bars represent one standard error. 
 
The PDE3A- ABHD12B interaction that was significantly associated at the Bonferroni-
corrected level with change in the RILV did not pass Bonferroni correction in the LILV 
(p=1.59x10-8). The other SNP-SNP interactions associated with the RILV did not show a 
strong trend in the LILV. Full results can be seen in Table 15. As a post-hoc analysis, we 
examined the effect of the significant interactions between SYNJ2-PI4KA, PARD3-
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MYH2, PDE3A- ABHD12B, and OR2L13-PRKG1 on the average volume of RILV and 
LILV combined (p=1.52x10-13, 3.49x10-8, 1.34x10-10, 1.85x10-7, respectively, Table 22). 
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Table 15 Full results with Bonferroni corrected significant SNP-SNP interactions for genetic interaction association with longitudinal 
inferior lateral ventricle volume change. 130,512,955 interactions were tested, leading to a threshold of p < 3.83x10-10. 
   Gene 1  Gene 2  Interaction Term 
ROI 
 
SNP Gene 
Main  
SNP Gene 
Main  
p-value R
2
 t  Effect  Effect  
 p-value  p-value  
     
RILV 
 rs9295289 SYNJ2 0.10  rs178051 PI4KA 0.04  9.10E-12 0.04 7 
 rs11596284 PARD3 0.30  rs3744566 MYH2 0.89  3.20E-10 0.04 6 
 
rs11614805 PDE3A 0.78 
 
rs7154732 ABHD12B 0.91 
 
3.60E-10 0.04 6 
 rs11590865 OR2L13 0.01  rs1922127 PRKG1 0.19  3.60E-10 0.04 6 
     
LILV  rs9295289 SYNJ2 0.14  rs178051 PI4KA 0.34  8.20E-13 0.05 7 
  
ROI: region of interest. RILV: Right inferior lateral ventricle. LILV: Left inferior lateral ventricle. Chr: Chromosome. SNP: reference 
SNP number of first SNP in SNP-SNP pair. Gene: gene corresponding to SNP. Main Effect p-value: Main effect of SNP on ROI. P-
value: nominal p value. R2= R2 for full model –R2 for reduced model (without interaction term). t: t-statistic for interaction term. Bolded 
interaction was significant at Bonferroni corrected levels in both the RILV and LILV
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Discussion  
In this study, we focused on the ILVs, which are used frequently as a source of 
quantitative endophenotypes for LOAD 48–50,162, and we limited hypothesis testing to 
SNP-SNP pairs within KEGG pathways.  Our quantitative trait and pathway-based 
interaction analysis yielded several interesting candidate gene-gene interactions, one of 
which was significantly associated with change in both the right and left ILV. Using 
existing biological knowledge, we were able to deduce a plausible biological context for 
these significant interactions.  
The SNP-SNP interaction rs9295289-rs178051 are both intronic to the genes SYNJ2 
andPI4KA, respectively, and have minor allele frequencies of 9.6% and 15.9%, 
respectively. The interaction was significantly associated with change in the RILV and 
LILV, and with the average rate of change in the combined ILV. Below we present 
evidence suggesting that the biological mechanism for this statistical interaction may 
involve the perturbation of the phosphatidylinositol (PI) signaling system that results in a 
down-regulation of the Akt cell survival pathway, resulting in decreased neuronal survival 
as reflected by increased volume of the ventricles. 
Both SYNJ2 and PI4KA are involved in the synthesis of 1-Phosphatidyl-1D-myo-inositol-
4P (PIP) (Figure 23).  SYNJ2 (MIM: 609410) encodes synaptojanin-2, which is a 
ubiquitously expressed inositol polyphosphate 5-phosphatase that dephosphorylates 1-
Phosphatidyl-1D-myo-inositol-4,5P2 (PI-4,5P2) to PIP, and PI4KA (MIM: 600286) 
encodes PI 4-kinase, which phosphorylates phosphatidylinositol (PI) to PIP (Figure 23).    
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Figure 23: Phosphatidylinositol and Akt/PKB Survival Signaling Pathway. 
Adapted from the KEGG Phosphatidylinositol signaling system (hsa04070, found at 
http://www.genome.jp/dbget-bin/www_bget?hsa04070) 
 
In multiple cohorts, PIP levels were observed to be reduced in the temporal cortices of 
patients with LOAD 163,164.  Further, PI kinase activity was decreased while PIP kinase 
activity remained stable, suggesting that PI kinases, like that encoded by PI4KA, have a 
specific functional relevance to LOAD 163,165. PIP is important because it can be 
phosphorylated to form 1-Phosphatidyl-1D-myo-inositol-3,4P2 (PI-3,4P2), which activates 
the protein Akt, also known as Protein Kinase B (PKB) 166. Akt/PKB has proliferative and 
anti-apoptotic cell response function 166 and regulates neuronal survival 167, protect from 
the neurotoxic effects of AD associated amyloid beta protein 168, and mediate neuronal 
cell death when its activation is inhibited 169. Thus, a decrease in PIP synthesis could 
disrupt a vital mechanism of neuroprotection.  Variation in either SYNJ2 or PI4KA might 
modulate the efficiency of PIP synthesis, but perhaps disruption of both routes of PIP 
synthesis is required to have detrimental effects seen in our study as increased ventricle 
dilation. 
Evidence that PI4KA is involved in LOAD derives primarily from its role in the synthesis 
of PIP.  However, there is some additional literature linking SYNJ2 to cognitive function, 
which would lend further support for a role in Alzheimer disease. The protein 
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synaptojanin-2 is localized at nerve terminals in the brain 170. The gene is differentially 
expressed in hippocampal sub-regions of the marmoset primate 171 and shows 
decreased expression in the human temporal cortex in persons with major depressive 
disorder 172. SYNJ2 has been associated with cognitive abilities in two independent 
elderly cohorts 173. Finally, haploinsufficiency of SYNJ2 due to a microdeletion on 6q is 
associated with a syndrome that presents with microencephaly, developmental delay 
and agenesis of the corpus callosum 174. 
Thus, the genetic interactions associated with ILV atrophy rate in this study may be 
mapping variants in SYNJ2 and PI4KA that interact to decrease synthesis of PIP and its 
phosphorylated form (PI-3,4P2), which is required for activation of the neuroprotective, 
Akt-mediated, cell survival signaling pathway.  
Conclusions 
In conclusion, by using a pathway based approach, we identified four SNP-SNP 
interactions significantly associated with AD related quantitative endophenotypes, one of 
which was significantly associated with bilateral volume change of the inferior lateral 
ventricles. Focusing on this interaction, we used existing biological knowledge of within-
pathway interactions and proposed a plausible biological context for this statistical 
interaction, which suggests that volume change in the LOAD brain might be mediated by 
alterations of the inositol signaling pathway, leading to deficits in neuroprotective 
mechanisms.   
The most common variable selection strategy for interaction studies only selects SNPs 
with main effects to test for interactions.  It is important to emphasize that such an 
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approach would not have discovered any of the Bonferroni-significant interactions 
presented here, highlighting the strength of the pathway-based approach we took.  
The present results must be interpreted within the framework of our statistical models. In 
all cases, we included covariates related to disease status and progression including 
age, sex, education, diagnosis and APOE status. Thus, all significant interactions are 
explaining variance beyond known predictors of risk, and while the contributions of these 
interactions appear to be meaningful, the implications should not be extended without 
considering the variance accounted for by the other factors in our model. The 
interactions in this study represent dominant effects (carriers versus non-carriers), and 
the results were interpreted accordingly. Because of the sheer number of tests, we were 
not able to curate the number of other interactions mapping to the gene-gene interaction 
between SYNJ2 and PI4KA that did not reach Bonferroni significance.  
In the future, the interactions found in this study should be replicated in independent 
datasets to confirm the SNP-SNP associations.  Furthermore, functional analyses could 
help clarify the basis of these statistical genetic interactions and provide greater 
specificity for identification of targets for clinical intervention or diagnosis. Further 
molecular studies on the relationship between SYNJ2 and PI4KA and the PI / PI-3,4P2 / 
Akt balance are warranted to draw definite conclusions about the relationship between 
risk variants in SYNJ2 and PI4KA causing downstream decreases in PI-3,4P2, Akt 
mediated cell survival signaling and, ultimately, increased neurodegeneration.  
We limited our studies to interactions within pathways, but interactions between genes 
across pathways may be related to disease risk as well and warrant further exploration. 
By using KEGG pathways, we also biased our results toward mechanisms that are well-
studied. As a result, there may be other novel interactions in other realms of biology that 
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this strategy did not discover. While the sample size utilized in this study is considered 
large for imaging studies, it is still modest compared with most case-control genetic 
association studies being conducted at this time, and this is a limitation of the current 
study as well. We advocate for similar analyses in other complex neurological or 
neuropsychiatric disorders to improve our understanding of the mechanisms underlying 
genetic risk for disease. We continued to explore this using other endophenotypes from 
imaging modalities in the following chapter. 
Supporting Information 
Example code used in this analysis is available in Appendix C. 
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Chapter 5 
GENETIC INTERACTIONS FOUND BETWEEN CALCIUM CHANNEL GENES 
MODULATE AMYLOID LOAD MEASURED BY POSITRON EMISSION TOMOGRAPHY 
Adapted from: 
Koran ME, Hohman TJ, Thornton-Wells TA. Genetic interactions found between calcium 
channel genes modulate amyloid load measured by positron emission tomography. 
Human Genetics. In Press.  
Introduction 
The complex genetic etiology of late onset Alzheimer’s disease (LOAD) has proven 
difficult to unravel, with the most significant ten genes associated with LOAD explaining 
only 35% of the variability in disease risk 11. For complex diseases like LOAD, it is 
imperative that we look beyond single marker analyses to explore biologically-plausible 
interactions and that we address the considerable heterogeneity present in disease 
status information by using meaningful intermediate phenotypes.  In this study, we 
investigate the influence of interactions between genes previously associated with 
Alzheimer’s Disease (AD) on amyloid beta load in an effort to better understand the 
genetic etiology of amyloid beta deposition and, by extension, risk for LOAD.  
Previous gene-gene interaction studies in LOAD have implicated interactions between: 
CR1 and APOE using quantified amyloid beta Positron Emission Tomography (PET) as 
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the outcome variable 81; and between cholesterol trafficking genes (Rodríguez-
Rodríguez et al. 2009; 2010), and tau phosphorylation genes (Mateo et al. 2009) in 
case-control analyses. These studies indicate the important information that can be 
garnered from investigating higher order genetic relationships in complex diseases like 
LOAD.  The current study aims to conduct a more comprehensive analysis of gene-gene 
interactions between variants associated with AD risk, while leveraging quantitative 
measurements of AD-associated neuropathology, which can increase statistical power 
64. For brain-based diseases, quantitative data can be derived from neuroimaging, such 
as PET. PET imaging can be used to quantify levels of amyloid in the brain by utilizing a 
radiotracer such as florbetapir (18F-AV-45 or AV-45) or and Pittsburgh Compound-B 
(PiB, N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole). These tracers 
selectively bind to amyloid beta in living patients, have been correlated with disease 
onset and progression, have been validated post-mortem, and have been included as 
biomarkers for classifying patients with AD in research studies 53–56.  
Genetic interaction studies are prone to the problem of over fitting, which can result in 
spurious associations that are not replicated in independent datasets.  This problem is 
exaggerated when large-scale (e.g., genome-wide) explorations are conducted, since 
the number of false positive findings is greatly increased.  However, by focusing on 
interactions between genes known to be involved in disease-related biological 
processes, one can maximize a priori biological plausibility and post-hoc interpretability 
while reducing the multiple testing correction threshold and computational burden  175. 
Because of the smaller number of subjects in ADNI with PET scans versus MRI studied 
in the previous chapter, only interactions between genes from the AD pathway of the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database were investigated. The 
AD KEGG pathway (hsa05010) includes genes related to amyloid and tau processing, 
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apoptosis, mitochondrial dysfunction, free radical production, and calcium homeostasis 
(http://www.genome.jp/kegg/pathway/hsa/hsa05010.html).  
Though this study had relatively smaller sample size compared to the previous study 
outlined in chapter 4, in this study, there were multiple cohorts of subjects with PET 
scans and therefore, we were able to attempt to replicate any interactions discovered. 
Replication is a challenge for genetic interaction analysis because the biological “unit” or 
level at which one tries to replicate or validate findings is debatable. Attempts to replicate 
at the SNP level are rife with problems unrelated to verification of a true biological effect 
176.  SNP-level replication is problematic largely due to the fact that most genotyped 
SNPs are not functional and are merely tagging a putative functional element.  
Differences in linkage disequilibrium patterns across samples from a single population 
can result in variable efficiency of tag SNPs and even reverse directionality of effects, 
wherein a tag SNP is in linkage disequilibrium to the risk allele in one sample but the 
reference or protective allele in another sample 176.  Likewise, allelic heterogeneity, in 
which multiple SNPs in a gene have a similar effect, can result in reduced statistical 
power and a failure to confirm an association with any particular SNP, even when all are 
associated with the disease of interest 176.  Indeed, since SNPs generally exert their 
effects either by altering the structure of a protein, the probability of transcription, or the 
efficiency of translation, their biological relevance is properly interpreted at the gene 
level (i.e., whether a protein is functional, whether it is present in deficient or excessive 
levels, etc.) as long as the proper annotation between SNP and gene is made. Thus, in 
this study, we use a gene-based approach to validate significant interactions from the 
discovery set in two additional independent datasets. A similar replication approach was 
previously successful in validating a novel gene-gene interaction underlying high density 
lipoprotein cholesterol 143,145.  
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Methods 
Data used in the preparation of this article were obtained from the ADNI database 
(adni.loni.ucla.edu) as described previously in chapter 4.  
Subjects 
Participants were enrolled based on the criteria outlined in the ADNI protocols 
(http://www.adni-info.org/Scientists/AboutADNI.aspx; http://adni.loni.ucla.edu/wp-
content/uploads/2008/07/ADNI2_Protocol_FINAL_20100917.pdf; 
http://adni.loni.ucla.edu/wp-content/uploads/2008/07/ADNI_Go_Protocol.pdf). Only 
subjects in the ADNI cohorts who had both genotype data and either PiB or AV-45 PET 
scans and were Caucasian (in order to minimize population stratification) were included 
in analyses. Subjects from ADNI-1 with AV-45 PET imaging data were included in the 
discovery data set. The Stage 1 validation dataset included subjects from ADNI-GO and 
ADNI-2 with AV-45 PET imaging data, excluding all participants who were also present 
in the discovery dataset. The Stage 2 validation dataset included subjects from ADNI-1 
with PiB PET imaging data, while excluding subjects from either of the previous two 
datasets. Demographic data are presented in Table 16. 
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Table 16 Demographic data for genetic interaction association with PET amyloid load 
Discovery Dataset 
Clinical Diagnosis 
Normal Control# 
Mild Cognitive 
Impairment# 
Alzheimer’s Disease# 
Number of Patients 67 53 43 
Number of APOE-4 Carriers 14 17 28 
Number of Females 33 16 15 
Mean Baseline Age (SD*) 76.52 (5.171) 74.92 (7.372) 72.70 (6.383) 
Mean Years of Education (SD*) 16.10 (3.036) 15.58 (3.207) 16.02 (2.866) 
Mean AV-45 SUVR** (SD*)
  
1.22 (0.188) 1.35 (0.288) 1.47 (0.270) 
Stage 1 Validation Dataset  
Number of Patients 110 223 40 
Number of APOE-4 Carriers 28 90 29 
Number of Females 56 94 15 
Mean Baseline Age (SD*) 74.03 (5.725) 72.10 (7.445) 73.10 (9.342) 
Mean Years of Education (SD*) 16.42 (2.579) 16.12 (2.658) 15.53 (2.641) 
Mean AV-45 SUVR** (SD*) 1.28 (0.237) 1.35 (0.251) 1.54 (0.225) 
Stage 2 Validation Dataset  
Number of Patients 17 59 19 
Number of APOE-4 Carriers 4 34 11 
Number of Females 6 19 7 
Mean Baseline Age (SD*) 77.59 (5.161) 75.97 (8.049) 73.47 (8.746) 
Mean Years of Education (SD*) 15.65 (2.668) 16.14 (2.726) 15.00 (2.828) 
Mean PiB SUVR** (SD*) 1.56 (0.355) 1.81 (0.368) 1.88 (0.305) 
* SD – standard deviation  
** SUVR - Standardized uptake value ratio normalized composite score for amyloid 
tracer 
# Normal Control subjects had a Mini-Mental Status Examination (MMSE) score 
between 24 and 30, a Clinical Dementia Rating (CDR) score of 0, and were not 
depressed (Geriatric Depression Scale score < 6).  
Mild Cognitive Impairment subjects had a MMSE score between 24 and 30; objective 
memory impairment, subjective memory impairment, and a CDR score of 0.5.  
Alzheimer’s Disease subjects met clinical criteria for dementia, had an MMSE of 
between 20 and 26, and had CDR score of .5 or 1. 
 
Genotyping 
Genotyping in the ADNI-1 discovery dataset was performed using the Illumina Infinium 
Human-610-Quad BeadChip. Quality control (QC) was performed using PLINK software 
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(version 1.07; 150) as described in chapter 4, excluding SNPs with a genotyping 
efficiency < 95%, out of Hardy Weinberg Equilibrium (p<1x10-6), or with a minor allele 
frequency (MAF) of < 5%. Subjects were excluded if they had a genotyping call rate < 
95%, if there was a reported-versus-genetic sex inconsistency, or if relatedness with 
another subject was established (PI_HAT > 0.5). After QC, 515,839 SNPs and 163 
subjects remained available for discovery analyses. For the Stage 1 validation dataset, 
DNA samples from ADNI-GO and ADNI-2 were genotyped on the Illumina 
HumanOmni1-Quadv1 array. QC was performed in PLINK with the same criteria as the 
discovery data set, resulting in 605,317 SNPs and 373 subjects available for validation 
analyses. Genotyping on the subjects included in the Stage 2 validation dataset was 
performed using the Illumina Infinium Human-610-Quad BeadChip and the same QC 
measures were applied (leaving 95 subjects and 515,839 SNPs). 
Effects of interactions on amyloid deposition  
Quantification of amyloid deposition 
Amyloid deposition was quantified using the AV-45 or PiB tracers. Methods relating to 
PiB data acquisition and calculation have been extensively described 177,178, as have 
methods relating to AV-45 data acquisition 179. In summary, for both datasets, 
Standardized Uptake Value Ratio (SUVR) images were normalized to the cerebellum 
(PiB) or cerebellar gray matter (AV-45) and co-registered to the subject-specific T1-
weighted structural MRI images. A composite score was calculated as the mean 
normalized SUVR across the anterior cingulate, frontal, lateral temporal, middle 
temporal, parietal, precuneus, and occipital cortices (PiB) and the cingulate (anterior and 
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posterior), frontal, lateral temporal, middle temporal, and lateral parietal (including the 
precuneus and supramarginal gyrus) cortices (AV-45).  These regions were parcellated 
using FreeSurfer image analysis suite 153. The composite score for each subject was 
used as the outcome measure of amyloid deposition in all three analyses.  
SNP-SNP interaction analysis: Discovery  
Genotype data that passed QC were analyzed in an interaction analysis using the 
publicly available InterSNP program v1.0.10 156.  We tested the hypothesis that gene-
gene interactions explain variance in amyloid pathology beyond variance related to age, 
sex, education, disease status, and APOE genotype.  Only SNPs that were in a gene in 
the AD KEGG Pathway were analyzed, and only interactions between (not within) genes 
were tested. To maximize post-hoc biological interpretability, only SNPs that were in a 5’ 
untranslated region (UTR), 3’ UTR, intron, or exon of a gene (annotated using the 
product support files available for download at Illumina.com) were included. 1196 SNPs 
that mapped to 43 genes were available in the discovery dataset (  
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Table 17). Across all possible gene-gene pairs from the AD KEGG Pathway, 634,864 
SNP-SNP interactions were tested. All SNPs were modeled as binary variables (minor 
allele absent or present) to attenuate the problem of data sparsity commonly confronted 
in interaction analyses. The outcome measure was the composite mean normalized 
SUVR (as described above). The covariates included were: baseline age in years, last 
diagnosis recorded as of the January 2013 data release (1= Normal, 2=MCI, 3=AD), 
education in years, sex, and APOE status (number of 4 risk alleles).  SNP-SNP 
interaction effects were explored using a genotypic model and a linear regression 
framework for quantitative traits 156. Interactions were considered of interest if their p-
value exceeded a moderate threshold of  < 5x10-6. A t-test statistic and R2 effect size 
for each SNP-SNP interaction of interest were calculated in SPSS (http://www-
01.ibm.com/software/analytics/spss/) using the same covariate, phenotype, and 
genotype files as used in InterSNP.  Effects were plotted in SPSS as well.  
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Table 17 Genes included in discovery dataset of the genetic interaction association with 
PET amyloid load. 
Chr: Chromosome number. # of SNPs: Number of SNPs tested per gene.  
Gene Chr # of SNPs 
ATF6 1 55 
CALML6 1 5 
CASP9 1 21 
NCSTN 1 18 
CASP8 2 24 
EIF2AK3 2 18 
IL1B 2 7 
GSK3B 3 30 
ITPR1 3 345 
MME 3 69 
CASP3 4 20 
SNCA 4 40 
TNF 6 19 
CDK5 7 6 
CYCS 7 9 
LPL 8 38 
GNAQ 9 91 
GRIN1 9 14 
CASP7 10 30 
FAS 10 34 
IDE 10 36 
APBB1 11 19 
BACE1 11 20 
BAD 11 13 
CAPN1 11 22 
FADD 11 3 
APAF1 12 30 
CACNA1C 12 478 
LRP1 12 41 
NOS1 12 117 
PSEN1 14 20 
ADAM10 15 55 
CHP 15 22 
RYR3 15 623 
ATP2A1 16 12 
NAE1 16 6 
ERN1 17 39 
MAPT 17 31 
APOE 19 3 
PLCB1 20 539 
APP 21 125 
BID 22 40 
MAPK1 22 43 
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SNP-SNP interaction analysis: Stage 1 Validation 
We used gene-based replication strategy in our subsequent validation analyses (Neale 
and Sham, 2004), such that only gene-gene pairs represented in significant interactions 
from discovery analyses were tested in the first validation set. In order to further reduce 
multiple testing, within each gene, we selected only independent SNPs using LD pruning 
implemented in PLINK with an r2 threshold of 0.6 (--indep-pairwise 50 5 .6), resulting in 
31,068 total SNP-SNP tests.  Pairwise LD was calculated with SNAP (SNP Annotation 
and Proxy Search, available at http://www.broadinstitute.org/mpg/snap/) using data from 
the European (CEU) population in 1000 Genomes Pilot 1. We used a conservative 
Bonferroni correction for gene-level multiple comparisons based on the number of SNP-
SNP interactions tested within each gene-gene pair. SPSS was used to calculate the t-
test statistic and R2 effect size and to plot the effects.  
SNP-SNP interaction analysis: Stage 2 Validation 
Further validation of the gene-gene interaction was conducted in a post hoc analysis. 
We tested the SNPs that passed correction in the discovery and Stage 1 validation 
datasets that corresponded to the gene-gene interaction validated in Stage 1.  
Interactions between the SNPs were tested in SPSS using the identical model with the 
same covariates as in the previous analyses with PiB SUVR measure as the outcome 
variable. A conservative Bonferroni correction for the 4 SNP-SNP interactions tested 
was employed (p < 0.0125).  SPSS was used to calculate the t-test statistic and R2 effect 
size and to plot the effects of these interactions as well. 
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Results 
Discovery Dataset 
The model we tested included the major AD risk factors of age, sex, education, 
diagnosis, and APOE status, such that all significant interaction terms explained 
additional variance beyond these strong risk factors. Six SNP-SNP pairs that mapped to 
four gene-gene interactions were noted of interest at   < 5x10-6: CACNA1C-ATF6 (2 
SNP-SNP interactions), NOS1-GNAQ (1 SNP-SNP interaction), PLCB1-CACNA1C (2 
SNP-SNP interactions), and RYR3-CACNA1C (1 SNP-SNP interaction). All main effects 
for these SNPs were not significant (p > 0.05).  
Stage 1 Validation Dataset 
All SNP-SNP pairs that mapped to the four gene-gene interactions found in discovery 
were tested in the Stage 1 validation data set (31,068 total independent tests: 
CACNA1C-ATF6 (1,010 tests), NOS1-GNAQ (364 tests), PLCB1-CACNA1C (12,019 
tests), and RYR3-CACNA1C (17,675 tests)). One SNP-SNP interaction mapping to 
RYR3-CACNA1C was significant after Bonferroni correction (Table 18). The effect of this 
interaction was in the same direction for both discovery and Stage 1 validation (Table 
18, discovery = 0.43 and validation = 0.25), and as seen in Figure 24, Figure 25, and Figure 
26. In both the discovery and Stage 1 validation interaction models, a minor allele in both 
genes corresponded to higher amyloid load (Figure 24, Figure 25, Figure 26) versus a 
minor allele in only one or none of the genes.  This interaction explained 9% and 4% of 
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the variance in amyloid load in the discovery and Stage 1 validation datasets, 
respectively.  
Stage 2 Validation Dataset 
The four SNPs mapping to RYR3-CACNA1C from the discovery and Stage 1 validation 
datasets were tested for interactions in the Stage 2 validation dataset (4 total 
independent tests, Table 19; gene mapping can be seen in Table 23). None of these 
SNPs were in strong LD with each other (using a threshold of r2>0.6).  One SNP-SNP 
interaction (rs16972835-rs7132154) was significant after Bonferroni correction 
(p=0.0077, Table 18). The effect of this interaction was in the same direction as the 
interactions found in the Discovery and Stage 1 validation (Table 18, discovery = 0.43, 
Stage1-validation = 0.25, Stage2-validation= 0.45), and as seen in Figure 24, Figure 25, and 
Figure 26, in all three datasets, a minor allele in both genes corresponded to higher 
amyloid load versus a minor allele in only one or none of the genes.  This interaction 
explained 6% of the variance in amyloid load in the Stage 2 validation dataset (Table 
18).  
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Table 18 Significant SNP-SNP Interactions in RYR3-CACNA1C from discovery and 
validation analyses from genetic interaction association with PET amyloid load 
 
 
 MAF: Minor Allele Frequency for each SNP# : beta coefficient in linear regression 
model for SNP (in Main Effect) or SNP-SNP interaction (in Interaction Term) 
representing effect on amyloid deposition 
* p: nominal p-value of interaction term  
## R2: R2 (full model) – R2 (model without interaction included) 
N: number of subjects 
 
 
Table 19 SNP-SNP Interactions in RYR3-CACNA1C from Stage 2 validation of genetic 
interaction association with PET amyloid load 
    Validation-Stage 2 
    Main Effect Interaction Term  
    # p* # R2 ## p* 
RYR3 rs16972835 -0.15 0.21 
0.45 0.06 7.70E-03 
CACNA1C rs7132154 -0.18 0.02 
RYR3 rs16972835 0.04 0.70 
0.13 0.01 3.03E-01 
CACNA1C rs2302729 <0.01 0.99 
RYR3 rs12901404 0.13 0.24 
-0.10 4.00E-03 5.11E-01 
CACNA1C rs7132154 -0.06 0.48 
RYR3 rs12901404 0.12 0.20 
-0.17 0.01 3.22E-01 
CACNA1C rs2302729 0.14 0.16 
#  : beta coefficient for SNP (Main Effect) or SNP-SNP interaction (Interaction Term) 
representing effect on amyloid deposition. 
* p: nominal p-value of interaction term  
## R2: R2 (full model) – R2 (model without interaction included) 
Interactions significant at Bonferroni corrected level are highlighted 
 
  
      Main Effect Interaction Term  
  N Gene SNP MAF # P* # R2 ## p* 
Discovery 163 
RYR3 rs16972835 0.09 -0.12 0.04 
0.43 0.09 2.49E-06 
CACNA1C rs2302729 0.17 -0.06 0.14 
Stage 1 
Validation 
373 
RYR3 rs12901404 0.14 -0.06 0.05 
0.25 0.04 2.22E-06 
CACNA1C rs7132154 0.21 -0.08 0.003 
Stage 2 
Validation 
95 
RYR3 rs16972835 0.12 -0.13 0.21 
0.45 0.06 7.70E-03 
CACNA1C rs7132154 0.25 -0.18 0.02 
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Figure 24: Discovery dataset results from study of gene-gene interactions associated 
with amyloid load.  
Effect of RYR3 (rs16972835) and CACNA1C (rs2302729) on Amyloid Deposition 
(measured by AV-45 ligand) in Discovery Dataset. Bars represent one standard error 
and N is the number of subjects in each group. 
 
 
Figure 25: Stage 1 validation dataset results from study of gene-gene interactions 
associated with amyloid load.  
Effect of RYR3 (rs12901404) and CACNA1C (rs7132154) on Amyloid Deposition 
(measured by AV-45 ligand) in Stage 1 Validation Dataset. Bars represent one standard 
error and N is the number of subjects in each group. 
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Figure 26: Stage 2 validation dataset results from study of gene-gene interactions 
associated with amyloid load.  
Effect of RYR3 (rs16972835) and CACNA1C (rs7132154) on Amyloid Deposition 
(measured by PiB ligand) in Stage 2 Validation Dataset. Bars represent one standard 
error and N is the number of subjects in each group. 
 
 
Discussion 
Calcium homeostasis and its relationship to amyloidogenesis 
In the present work, a genetic interaction between the RYR3 and CACNA1C genes 
explained variance in amyloid deposition above and beyond other major known risk 
factors for LOAD. Such an interaction is biologically feasible given that the proteins 
encoded by CACNA1C and RYR3 interact to maintain calcium homeostasis necessary 
for normal brain function 180,181 and that many studies outlined below have shown a 
relationship between calcium homeostasis and amyloidogenesis, whereby increased 
intracellular calcium levels lead to increased amyloid beta deposition. An increase in 
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amyloid beta is considered a key event in AD etiology (e.g., Jack et al. 2013), and 
calcium dysregulation is thought to assist in amyloid formation and deposition and has 
been hypothesized to be very important in the etiology of AD 183. Increases in 
intracellular calcium increase amyloid beta production in human cell lines 184. High levels 
of intracellular calcium also induce transient phosphorylation of amyloid precursor 
protein in neurons, leading to increased production of amyloid beta 185. Lastly, calcium 
ions themselves promote the formation of neurotoxic amyloid beta oligomers in vitro 186.  
Our findings are further strengthened by accumulating evidence that RYR3 modulates 
amyloid beta plaque deposition 187–189 and that CACNA1C increases intracellular calcium 
levels in the presence of amyloid beta 190–192. 
This interaction could have an important clinical application, since both proteins encoded 
by these two genes are calcium channels that have FDA approved channel blocking 
drugs and blocking either channel has been proposed as a therapy for AD pathology 
193,194. A combination of these therapies could be investigated as an enhanced approach 
to AD treatment. 
RYR3 and CACNA1C  
RYR3 encodes ryanodine receptor (RyR)-3, which is a receptor expressed in the brain 
195 located on the endoplasmic reticulum (ER) that regulates intracellular calcium 
homeostasis 183. CACNA1C encodes the pore-forming alpha 1C subunit of voltage-
dependent L-type calcium channels (LTCCs) which are also expressed in the brain 196. 
The major characteristics of this channel, including voltage-sensitivity, ion selectivity, 
and pharmacological responsivity to calcium channel blockers, are encoded by 
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CACNA1C 197. This subunit forms a pore in the cell membrane through which calcium 
ions flow into the cell 197.  
RYR3 in Alzheimer’s Disease pathogenesis 
In animal models of AD, the relationship between RyR and amyloid beta has been 
extensively explored. Transgenic mice which overexpress the precursor of amyloid beta 
(APP, encoding amyloid precursor protein (APP)) have increased RyR expression in 
their neuroblastoma cell lines 189. Specifically, extracellular amyloid selectively increases 
RyR-3 (but not RyR-1 or -2) isoform expression in cortical neurons of both wild type and 
AD-model mice 188. Transgenic mice that harbor human APP mutations have increased 
RyR expression in isolated cortical neurons, and this overexpression of RyR disrupts 
calcium homeostasis by increasing ER calcium release 189. Furthermore, this relationship 
between RyR and amyloid beta is bi-directional, such that RyRs can also affect amyloid 
beta levels. Dantrolene is a pharmacological agent that blocks calcium release from 
RyR-1 and RyR-3 and has been used in cell and animal models to diminish cell death 
resulting from neuronal injury 194. Interestingly, when it was used to block RyR and 
decrease calcium release in mouse models that either overexpressed APP or had an 
APP mutation, this decrease in calcium level reduced levels of intracellular and 
extracellular amyloid beta, as well as the number of amyloid beta plaques 189. Thus, 
RyR-induced calcium levels seem to influence amyloid beta levels. This has also been 
shown in human cell lines: in human neuroglioma and embryonic cell lines transfected 
with APP, amyloid beta production increased as levels of intracellular calcium increased 
and RyR-mediated calcium release increased 184,198. In summary, the existing literature 
indicates that there is a bi-directional relationship between RyR and amyloid beta, such 
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that increased amyloid beta has been associated with increased RyR expression, and 
RyR-driven calcium release has been associated with increased amyloid beta levels.   
CACNA1C in Alzheimer’s Disease pathogenesis 
CACNA1C encodes the pore-forming subunit of voltage-dependent LTCCs. Its role in 
AD etiology can be better understood through its relationship with amyloid beta and its 
effects on calcium dysregulation. In rat cortical cell lines, the presence of amyloid beta 
increased calcium uptake by LTCCs by almost two-fold 190. In human cerebral cortical 
cell lines, amyloid beta destabilized neuronal calcium regulation and rendered neurons 
more vulnerable to environmental stimuli that elevate intracellular calcium levels 191. Up-
regulation of the expression of CACNA1C  was observed in human neuroblastoma cell 
lines after treatment with amyloid beta 193, and amyloid beta promotes the insertion of 
the subunit encoded by CACNA1C into the plasma membrane 192. In summary, amyloid 
beta modulates LTCC function to increase intracellular calcium and as described above, 
this increase in intracellular calcium can further increase amyloid beta production and 
deposition.  
RYR3-CACNA1C interaction and amyloid load  
Both of the products of RYR3 and CACNA1C have a relationship with cellular amyloid 
beta. These products physically interact with each other: in a study of cerebellar granule 
cells, RyRs and LTCCs are functionally coupled, with RyRs controlling the activity of 
LTCCs 199. In a separate study in in vitro rat neuronal cell lines, immunoprecipitation 
revealed an association between LTCCs and RyRs, and immunohistochemistry 
confirmed the co-localization of LTCC and RyR clusters on axons 181. In that same study, 
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depolarization sensed by LTCCs activated RyRs, which caused the release of toxic 
levels of calcium 181. This interaction was also demonstrated in a study of rat 
hippocampal tissue, where a physical interaction between the N-terminus of the LTCC 
and the N-terminus of a RyR was observed 180. Finally, an interaction between RyRs and 
LTCCs has been observed in cardiac and skeletal muscle, where these proteins are also 
expressed 200,201.  
With the evidence of physical interaction between the RyR and LTCC proteins and the 
evidence outlined above relating RyR, LTCC, calcium release, and amyloid beta to each 
other, the statistical genetic interaction we report herein might be reflective of causal 
variants in RYR3 and CACNA1C interacting to cause disruption of calcium homeostasis 
and to increase intracellular calcium levels leading to increased amyloid beta production 
and deposition as detected by PET.  
Conclusion 
In this study, we have explored the relationship between genes within the AD pathway 
and their relationships to amyloid beta plaque levels in humans. We found evidence for a 
statistical association between calcium dysregulation and amyloid beta deposition as 
detected by PET amyloid imaging. In light of prior studies associating the products of 
RYR3 and CACNA1C with each other and with AD pathology, this result is certainly 
biologically plausible.  This interaction is of particular clinical significance because 
pharmacological manipulation of the two channels involved is feasible for future AD 
treatment. Combined therapy, using LTCC- and RyR-blockers, could first be tested in 
cell lines and animal models to determine its effect on amyloid beta plaque load and 
neuronal cell death.  
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Fine-mapping and functional analysis of the SNPs identified could help clarify the 
implications of these statistical genetic interactions and provide greater specificity when 
attempting to leverage these results to identify targets for clinical intervention. Because 
we validated our results at the gene-gene level and not the SNP-SNP level, further 
delving into the function of each of these SNPs or the causal variant these SNPs are 
tagging would be necessary to understand whether the discovery and validation models 
represent the same effect. For example, if each SNP increases the expression of its 
respective gene, we could conclude that the effect was truly replicated and that 
increased expression of both genes is associated with increased amyloid load 
(regardless of which SNP caused the over expression).  In summary, the effect that each 
SNP has on expression level or function would have to be explored to determine true 
replication of effect.  
The exact SNP-SNP interactions do not replicate across the samples, but we would 
argue (as others have) this lack of replication does not necessarily indicate a false 
positive result and may instead be due to one or several biological reasons 176, including 
allelic heterogeneity (wherein different alleles at the same locus are each responsible for 
increased disease risk in different subjects), differences in minor allele frequency, or 
differences in LD structure across samples. The power to replicate at the SNP level 
drops dramatically with a change in allele frequency between datasets, and there were 
differences in allele frequency across the three data sets used here (Table 18) 202. 
Differences in LD structure across the two samples between each tag-SNP and the 
causal variant could cause the same high-risk allele to have different patterns of 
association with the marker alleles 176.  The gene-based replication approach we 
employed here attenuates these issues and has been proposed as the “gold standard” 
for replication and the “natural end point for association analysis” 176. This is perhaps 
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especially important in gene-gene interaction studies where these issues are amplified. If 
the datasets had been genotyped on the same chip, an analysis on a combined dataset 
would be of interest, and would have alleviated this issue.  
The present results must be interpreted within the framework of our statistical models. In 
all cases, we included covariates related to disease status and progression, including 
age, education, diagnosis, sex, and APOE status. Thus, all significant interactions 
explained variance beyond known predictors of risk, and while the contributions of these 
interactions appear to be meaningful, the implications should not be extended without 
considering the variance accounted for by the other factors in our model. The 
interactions in this study represent dominant effects (carriers versus non-carriers), and 
the results have been interpreted accordingly. We did not test mitochondrial genes in 
this study. This could be explored in a further analysis 
Supporting Information 
Example code used in this analysis is available in Appendix D
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Chapter 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
Alzheimer’s Disease (AD) is a devastating, incurable, degenerative neurological disease 
and is the most common cause of dementia in both the general population and in 
patients with Down Syndrome (DS). The etiology of this disease still eludes us despite 
its prevalence and considerable research efforts dedicated to its discovery. The research 
described in the preceding chapters employed an innovative strategy combining imaging 
and genetic data to address three major challenges in AD research: (1) validating non-
invasive biomarkers of neuropathology, (2) dis-entangling clinical heterogeneity of the 
disease, and (3) discovering biological interactions contributing to this disease’s initiation 
and progression.  I have investigated the use of a novel non-invasive biomarker of 
amyloid beta in humans (Chapter 2) and the use of T1-weighted Magnetic Resonance 
Imaging (MRI) to capture age related volumetric changes in brain structure in DS 
subjects (Chapter 3). I also have used quantitative endophenotypes to dissect clinical 
heterogeneity, and have directly investigated genetic interactions for their association 
with disease pathologies (Chapters 4 and 5).    
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Summary and Future Directions for Chapter 2 
Validation of T1ρ Magnetic Resonance Imaging in human adults with amyloid beta 
plaque deposition 
Prior to this research, the results from the mouse model studies of amyloid beta detected 
by T1ρ-weighted MRI had not been validated in human subjects. We were able to apply 
this sequence to patients with DS, who, due to triplication of the APP gene encoded on 
chromosome 21, have a high probability of amyloid plaque load. Though we were not 
able to validate its use as it was unable to distinguish DS subjects from subjects in the 
general population, this might indicate suboptimal optimization of the sequence 
parameters to accurately detect amyloid beta load. Further optimization of the sequence 
parameters is warranted before we can draw definitive conclusions about the ability of 
T1ρ to detect amyloid plaques in humans in vivo. This could include: 1) using more than 
two spin lock time values in image acquisition or 2) changing voxel size in order to allow 
detection of amyloid beta plaque. When computing T1ρ from the slope of the natural 
logarithm of signal as a function of TSL, we were not be able to rule out voxels based on 
r2 value because we only had two TSL values. This would have eliminated voxels that 
are outliers, perhaps due to partial volume effects. Therefore in the future, using more 
than two TSL values in image acquisition would allow for further quality control of the 
images and their quantification. The voxel size of the images acquired on our human 
subjects may have been too large to detect the effects of amyloid beta plaque, as the 
voxels were over four orders of magnitude larger than those seen in the successful 
mouse model study. Alternative strategies for analyzing these images, including 
analyzing the distribution, or kurtosis and skewness, of T1ρ values within each region of 
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interest across the groups, are being investigated. Early indications suggest that the two 
distributions between the DS and normal control groups may be different. Furthermore, 
the theoretical trend for ERC values has not been well established, and discussion with 
faculty at the VUIIS is ongoing regarding this topic. In our results of ERC, an interesting 
trend may be forming, but in order to definitevely draw a conclusions, the sample size for 
each group must be increased to inform this discussion. In the future, this sequence 
could be validated on an autopsy brain of a patient with clinically diagnosed AD or an 
elderly individual with DS, using a study design similar to that which was performed in 
the mouse model 59 or in previous PET validation studies 55.  
Summary and Future Directions for Chapter 3 
DIFFERENCES IN AGE-RELATED EFFECTS ON BRAIN VOLUME IN DOWN 
SYNDROME AS COMPARED TO WILLIAMS SYNDROME AND TYPICAL 
DEVELOPMENT 
In this chapter, we used a whole-brain region of interest approach to explore the 
relationship between age and MRI-derived brain volume across adults with DS, adults 
with another neurodevelopmental disorder (William Syndrome, WS), and adults with 
typical development, while incorporating cognitive data and genetic risk data in a 
secondary exploratory analysis of the DS cohort. We were able to validate that subjects 
with DS showed significant age-related effects in grey matter regions of the orbitofrontal 
cortex and the parietal cortex, and in the left and right inferior lateral ventricles, when 
compared to adults with WS. When imaging and cognitive data were combined in the DS 
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group, we discovered that the inferior lateral ventricles were associated with dementia 
rating scores.  APOE, a risk gene for AD and brain atrophy, also showed a trend for 
association with regional brain volume. With the sample size currently analyzed, we 
were likely underpowered to detect more subtle AD-related changes. Each of these 
studies would benefit from a larger sample size to accurately estimate the effects. These 
conclusions were drawn based on cross-sectional data, and longitudinal T1-weighted 
MRI scans on these subjects should be acquired and analyzed in the future to determine 
the effect of aging on these subjects’ brain volumes. Alternatively, other MRI 
intermediate phenotypes could be utilized in these studies including cortical thickness or 
density from the T1-weighted images, or phenotypes derived from other MRI sequences 
including FLAIR which can detect white matter disease, diffusion tensor imaging (DTI) 
which can give information on white matter structure, or functional MRI (fMRI), which can 
measure brain activity during tasks. 
Summary and Future Directions for Chapter 4 
GENETIC INTERACTIONS ASSOCIATED WITH LONGITUDINAL CHANGES IN 
VENTRICLE SIZE IN ALZHEIMER’S DISEASE 
This study was the first to complete a comprehensive analysis of gene-gene interactions 
in relation to the dilation of the inferior lateral ventricles, with data available on a large 
number of subjects in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort.  
We conducted a genetic interaction analysis on these existing data in order to derive 
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knowledge of the genetic etiology of AD and neuroatrophy, as it relates to AD and 
perhaps other neurodegenerative diseases. 
We used a pathway based approach to identify four SNP-SNP interactions significantly 
associated with volume change of the inferior lateral ventricles. One SNP-SNP 
interaction was significantly associated with both the right and left inferior lateral 
ventricles, and we focused our literature review on this interaction between the SYNJ2 
and PI4KA genes, and based on this review, we suggested that volume change in the 
brain might be mediated by alterations of the inositol signaling pathway, leading to 
deficits in neuroprotective mechanisms.  
In the future, the interactions found in this study should be tested for replication. 
Functional analyses are also warranted to elucidate the physiological basis of these 
interactions. Molecular studies on the relationship between the products of SYNJ2 and 
PI4KA could greatly inform the relationship between these genes and increased 
neurodegeneration. These studies could elucidate whether variation in either SYNJ2 or 
PI4KA might modulate the efficiency of the inositol signaling pathway, and if disruption of 
both enzymes is required to have detrimental effects seen in our study as increased 
ventricle dilation. 
Summary and Future Directions for Chapter 5 
Genetic Interactions Found Between Calcium Channel Genes Modulate Amyloid Load 
Measured by Positron Emission Tomography 
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Prior to this study, there had been no comprehensive analyses of gene-gene interactions 
in relation to quantitative measurements of amyloid beta pathology.  We used Positron 
Emission Tomography (PET) data available on a large number of subjects in the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort and conducted a genetic 
interaction analysis on these existing data in order to explore genetic mechanisms 
behind amyloid beta deposition. 
We found a statistical association between calcium dysregulation and amyloid beta 
deposition, specifically between the RYR3 and CACNA1C calcium channel genes. 
Based on prior research associating the products of these two genes with each other 
and with AD pathology, this result is certainly biologically plausible. This interaction is of 
particular clinical significance because pharmacological manipulation of the two 
channels involved is feasible for future AD treatment. In the future, combined therapy, 
using calcium channel blocking drugs could first be tested in cell lines and animal 
models to determine its effect on amyloid beta plaque load and neuronal cell death.  
Fine-mapping and functional analysis of the SNPs identified here could also be 
performed to clarify the implications of these statistical genetic interactions and provide 
greater specificity when attempting to leverage these results to identify targets for clinical 
intervention. Further, analysis for statistical interactions beyond those between genes in 
the AD KEGG pathway should be performed. For instance, we could use the same 
strategy from the analysis presented in Chapter 4, looking within all known pathways, or 
we could look at interactions between genes that arise in any pathway or between genes 
in the AD pathway with genes that arise in any other pathway. 
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In all of these instances, and in both the studies outlined in chapters 4 and 5, we limited 
our studies to interactions within pathways, but interactions between genes across 
pathways may be related to disease risk as well and warrant further exploration. It is 
perhaps likely that variants in genes across pathways interact as well, but these 
interactions have yet to be discovered. The challenge of such an analysis is largely 
computational and only increases the burden of correcting for multiple tests. Some 
possible strategies for investigating these issues are using empirical significance 
strategies like permutation testing or bootstrapping or investigating an a priori specified 
hypothesis to limit test number.  
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Conclusions 
We focused our studies in imaging genetics on two amyloid based diseases, Alzheimer’s 
Disease and Down Syndrome. We were able to draw interesting conclusions from these 
investigations, and we advocate for similar analyses in larger cohorts of these diseases 
or in other complex neurological or neuropsychiatric disorders to improve our 
understanding of the mechanisms underlying genetic risk for disease. There are most 
certainly more genetic associations to be found. Future work should use alternative 
strategies for discovering additional gene-gene interactions and for exploring gene-
environment or even higher order (i.e. gene-gene-gene) interactions.   
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Appendix A 
SUPPORTING INFORMATION FOR CHAPTER 2 
Other images acquired/analyzed  
T1 and T2 
Three full brain Echo Planar T1 images were acquired in the same space as the T1ρ 
images, with TR = 100 ms and TE = 2.4, 2.4, 3.0 ms corresponding to images with flip 
angles of 15, 30, and 60 degrees respectively.  
Six full brain T2 Turbo Spin-Echo pulse sequences were acquired in the same space as 
the T1ρ and T1 images, with TR = 2700 ms and TE = 15, 30, 45, 60, 75, and 90 ms.  
The T1 and T2 images were originally included in the analysis before deciding to discard 
them from further analyses. Code for their analysis can be found in this appendix. Each 
T1 and T2 image was aligned in SPM to the first T1 and T2 image acquired, 
respectively, which were then all aligned to the first T1ρ image acquired. T1 was 
quantified by solving:  
 (  )      
(   
 
  
  )
(   
( 
  
  
)
     )
                                                                                           (3) 
with MATLAB code provided by VUIIS faculty, where α is the flip angle and TR is the 
repetition time with which each of the three images is acquired. These quantified images 
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were theoretically representative of T1ρ at infinite Hz, and therefore were plotted far from 
the collected FSL values at 2000 Hz.  
T2 was quantified by solving:  
 (  )       
  
                                                                                                            (4) 
in SPM, where TE are the echo times with which each of the six images is acquired. 
Since T1ρ approaches T2 as FSL goes to 0 Hz 203 these quantified images were plotted 
at 0 Hz in the dispersion curve plots.  
The T1 images were discarded from analysis because their quantified values drown out 
the signal from the quantified T1ρ images (Figure 27).  
 
Figure 27: Dispersion curves with quantified T1 images included at 2000 Hz.  
 
The T2 images were discontinued and replaced by T1ρ acquired with an FSL of 0 Hz. 
T1ρ approaches T2 as FSL goes to 0 Hz, and the results from the quantified T2 images 
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were distorted by inherent inhomogeneities in the MRI machine, which caused a 
deviation from the expected dispersion curve, where T2 was less than T1ρ (Figure 28) 
203. After inclusion of acquiring T1 at 0 Hz, the dispersion curve behaved as expected 
(Figure 29). 
 
Figure 28: Example of discrepancy between expected and actual dispersion curve when 
R2 (1/T2) was used.  
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Figure 29: Dispersion curve with both R2 and R1ρ collected at 0Hz plotted. 
R2 is plotted at x-axis = 0 and R1ρ (0Hz) plotted at x-axis = 50. The dispersion curve 
with R1ρ (0Hz) shows congruency with the expected result. 
Region of Interest Based Analysis 
FreeSurfer Log Creation Code 
#!/bin/tcsh 
#PBS -M mike.sivley@vanderbilt.edu 
#PBS -m bae 
#PBS -l walltime=48:00:00 
#PBS -l mem=5000mb 
#PBS -l nodes=vision.mc.vanderbilt.edu 
setenv FREESURFER_HOME /usr/analysis/software/FreeSurfer_v.5.1.0 
source $FREESURFER_HOME/SetUpFreeSurfer.csh 
mkdir -p /projects/twells/Data/%(study)s/FreeSurfer/ 
setenv SUBJECTS_DIR /projects/twells/Data/%(study)s/FreeSurfer/ 
recon-all -i %(file)s -all -s %(scanid)s -hippo-subfields > 
/projects/twells/sivleyrm/mario/log/t1w_3d_%(scanid)s_%(iter)s.lo
g 
 125 
 
FreeSurfer Template and Recon-All code 
 
#!/bin/tcsh 
#PBS -M mike.sivley@vanderbilt.edu 
#PBS -m bae 
#PBS -l nodes=vision.mc.vanderbilt.edu 
#PBS -l walltime=2:00:00:00 
#PBS -l mem=8000mb 
 
## Setup FreeSurfer variables 
setenv FREESURFER_HOME /usr/analysis/software/FreeSurfer_v.5.1.0 
source $FREESURFER_HOME/SetUpFreeSurfer.csh 
setenv SUBJECTS_DIR /labs/twells/data/%(study)s/FreeSurfer 
setenv ANALYSIS_DIR /labs/twells/data/%(study)s/t1rho/%(scanid)s 
 
# Ensure the directories exist 
mkdir -p $SUBJECTS_DIR 
mkdir -p $ANALYSIS_DIR/275 
mkdir -p $ANALYSIS_DIR/550 
 
setenv T1W275 $ANALYSIS_DIR/275/%(t1w_filename)s 
setenv T1W550 $ANALYSIS_DIR/550/%(t1w_filename)s 
 
cp -f %(t1w_abs)s $T1W275 
cp -f %(t1w_abs)s $T1W550 
 
## Run recon-all 
recon-all -i $T1W275 -all -s %(scanid)s -hippo-subfields –nowmsa 
FreeSurfer Post-Processing and Analysis Template 
 
#!/bin/tcsh 
#PBS -M mike.sivley@vanderbilt.edu 
#PBS -m bae 
#PBS -l nodes=vision.mc.vanderbilt.edu 
#PBS -l walltime=1:00:00:00 
#PBS -l mem=8000mb 
 
## Setup FreeSurfer variables 
setenv FREESURFER_HOME /usr/analysis/software/FreeSurfer_v.5.1.0 
source $FREESURFER_HOME/SetUpFreeSurfer.csh 
setenv SUBJECTS_DIR /labs/twells/data/%(study)s/FreeSurfer 
 126 
 
setenv ANALYSIS_DIR 
/labs/twells/data/%(study)s/t1rho/%(roi_type)s/%(scanid)s/%(hz)s 
 
# Ensure the directories exist 
mkdir -p $ANALYSIS_DIR 
 
## Setup script variables 
setenv T1W      $ANALYSIS_DIR/%(t1w_filename)s 
setenv T2    $ANALYSIS_DIR/%(t2_filename)s 
 
if ( "%(roi_type)s" == "largeROI" ) then 
  setenv mgzLABELFILE
 $SUBJECTS_DIR/%(scanid)s/mri/aparc.a2009s+aseg.mgz 
else if ( "%(roi_type)s" == "smallROI" ) then 
  setenv mgzLABELFILE $SUBJECTS_DIR/%(scanid)s/mri/aparc+aseg.mgz 
endif 
 
setenv mgzT1W_MASK $SUBJECTS_DIR/%(scanid)s/mri/brainmask.mgz 
setenv T1W_MASK 
 $ANALYSIS_DIR/%(scanid)smri_convertbrainmaskRAS.nii 
setenv LABELFILE
 $ANALYSIS_DIR/%(scanid)smri_convertaparc.a2009s+asegRA
S.nii 
setenv rLABELFILE
 $ANALYSIS_DIR/r%(scanid)smri_convertaparc.a2009s+asegR
AS.nii 
setenv T1RHO20 
 $ANALYSIS_DIR/%(t1rho_20_filename)s 
setenv T1RHO50 
 $ANALYSIS_DIR/%(t1rho_50_filename)s 
setenv T1RHO80 
 $ANALYSIS_DIR/%(t1rho_80_filename)s 
setenv T1RHO  $ANALYSIS_DIR/Thornton-
Wells_%(roi_type)s_%(scanid)s_%(hz)sHz_t1-rho.nii 
setenv T1FLIP15 
 $ANALYSIS_DIR/%(t1_flip_15_filename)s 
setenv T1FLIP30 
 $ANALYSIS_DIR/%(t1_flip_30_filename)s 
setenv T1FLIP60 
 $ANALYSIS_DIR/%(t1_flip_60_filename)s 
setenv T1   $ANALYSIS_DIR/Thornton-
Wells_%(roi_type)s_%(scanid)s_t1.nii 
setenv INVBETAIMG $ANALYSIS_DIR/inv_beta.img 
setenv MATLAB  %(matlab)s 
 
setenv T1rCOREGT1
 $ANALYSIS_DIR/r_T1rcoregT1%(t1rho_20_filename)s 
setenv BINMULT 
 $ANALYSIS_DIR/binmult_%(scanid)s.nii 
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setenv SEGSTAT1 
 $ANALYSIS_DIR/%(scanid)s_20T1ρ_stats 
setenv SEGSTAT2 
 $ANALYSIS_DIR/%(scanid)s_T1xT1ρbinary_stats 
setenv SEGSTAT3 
 $ANALYSIS_DIR/%(scanid)s_T1_stats 
setenv SEGSTAT4 
 $ANALYSIS_DIR/%(scanid)s_T2beta_stats 
setenv SEGSTAT5 
 $ANALYSIS_DIR/%(scanid)s_T1flip_stats 
 
## Setup log variable 
setenv LOG  
 $MARIO/log/t1rho_%(scanid)s_%(hz)s.log 
 
## Copy all input images to the analysis folder 
 
cp -f %(t1w_abs)s $T1W 
cp -rf %(t2_abs)s $T2 
cp -f %(t1rho_20_abs)s $T1RHO20  
%(comment_50_0)scp -f %(t1rho_50_abs)s $T1RHO50  
cp -f %(t1rho_80_abs)s $T1RHO80  
cp -f %(t1_flip_15_abs)s $T1FLIP15 
cp -f %(t1_flip_30_abs)s $T1FLIP30 
cp -f %(t1_flip_60_abs)s $T1FLIP60 
 
## Marker 
echo "MRI Convert: " >> $LOG 
 
## Run mri_convert 
mri_convert --in_type mgz --out_type nii --out_orientation RAS 
$mgzLABELFILE $LABELFILE 
mri_convert --in_type mgz --out_type nii --out_orientation RAS 
$mgzT1W_MASK $T1W_MASK 
 
## Have to change to a directory with SPM in it.  
##cd $ANALYSIS_DIR 
cd %(matlab_pathdef)s 
 
## marker 
echo "T1 Rho Calculation: " >> $LOG 
 
## ----- Start matlab ---- ## 
$MATLAB -nodisplay -nodesktop -nosplash < %(t1rho_matlab)s 
 
mri_segstats --seg $rLABELFILE --ctab 
$FREESURFER_HOME/FreeSurferColorLUT.txt --empty --excludeid 0 --
sum $SEGSTAT1 --i $T1RHO 
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mri_segstats --seg $LABELFILE --ctab 
$FREESURFER_HOME/FreeSurferColorLUT.txt --empty --excludeid 0 --
sum $SEGSTAT2 --i $BINMULT 
 
mri_segstats --seg $mgzLABELFILE --ctab 
$FREESURFER_HOME/FreeSurferColorLUT.txt --empty --excludeid 0 --
sum $SEGSTAT3 --i $mgzT1W_MASK 
 
mri_segstats --seg $rLABELFILE --ctab 
$FREESURFER_HOME/FreeSurferColorLUT.txt --empty --excludeid 0 --
sum $SEGSTAT4 --i $INVBETAIMG 
 
mri_segstats --seg $rLABELFILE --ctab 
$FREESURFER_HOME/FreeSurferColorLUT.txt --empty --excludeid 0 --
sum $SEGSTAT5 --i $T1 
MATLAB and SPM Code for T1ρ, T1, and T2 calculation 
try      
      
     
 ANALYSIS_DIR = 
'/labs/twells/data/%(study)s/t1rho/%(roi_type)s/%(scanid)s/%(hz)s'; 
  
 T1W       = strcat(ANALYSIS_DIR,'/%(t1w_filename)s'); 
 T2_PATH   = strcat(ANALYSIS_DIR,'/%(t2_filename)s'); 
 T1W_MASK  = 
strcat(ANALYSIS_DIR,'/%(scanid)smri_convertbrainmaskRAS.nii'); 
 LABELFILE = 
strcat(ANALYSIS_DIR,'/%(scanid)smri_convertaparc.a2009s+asegRAS.nii'); 
 T1RHO20   = strcat(ANALYSIS_DIR,'/%(t1rho_20_filename)s'); 
 T1RHO50   = strcat(ANALYSIS_DIR,'/%(t1rho_50_filename)s'); 
 T1RHO80   = strcat(ANALYSIS_DIR,'/%(t1rho_80_filename)s'); 
 T1RHO     = strcat(ANALYSIS_DIR,'/Thornton-
Wells_%(roi_type)s_%(scanid)s_%(hz)sHz_t1-rho.nii'); 
 T1FLIP15  = strcat(ANALYSIS_DIR,'/%(t1_flip_15_filename)s'); 
 T1FLIP30  = strcat(ANALYSIS_DIR,'/%(t1_flip_30_filename)s'); 
 T1FLIP60  = strcat(ANALYSIS_DIR,'/%(t1_flip_60_filename)s'); 
 T1        = strcat(ANALYSIS_DIR,'/Thornton-
Wells_%(roi_type)s_%(scanid)s_t1.nii'); 
  
 T1rCOREGT1 = 
strcat(ANALYSIS_DIR,'/r_T1rcoregT1%(t1rho_20_filename)s'); 
 BINMULT   = strcat(ANALYSIS_DIR,'/binmult_%(scanid)s.nii'); 
 BETAIMG   = strcat(ANALYSIS_DIR,'/spm/beta_0002.img'); 
 INVBETAIMG= strcat(ANALYSIS_DIR,'/inv_beta.img'); 
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 %% Realign 
 clear matlabbatch; 
 spm_jobman('initcfg'); 
 spm('defaults', 'FMRI'); 
  
 matlabbatch{1}.spm.spatial.coreg.estimate.ref = { 
      
      
   T1RHO20 
      
      
 }; 
 matlabbatch{1}.spm.spatial.coreg.estimate.source = { 
      
      
   T1W_MASK 
      
      
    }; 
 matlabbatch{1}.spm.spatial.coreg.estimate.other = { 
      
      
     LABELFILE 
      
      
   }; 
 matlabbatch{1}.spm.spatial.coreg.estimate.eoptions.cost_fun = 'nmi'; 
 matlabbatch{1}.spm.spatial.coreg.estimate.eoptions.sep = [4 2]; 
 matlabbatch{1}.spm.spatial.coreg.estimate.eoptions.tol = [0.02 0.02 0.02 
0.001 0.001 0.001 0.01 0.01 0.01 0.001 0.001 0.001]; 
 matlabbatch{1}.spm.spatial.coreg.estimate.eoptions.fwhm = [1 1]; 
  
 matlabbatch{2}.spm.spatial.realign.estimate.data = {   
   
                                                     {    
  
                                                     T1RHO20    
                                                     %(comment_50_1)sT1RHO50  
  
                                                     T1RHO80   
                                                     }    
  
                                                    }';    
  
 matlabbatch{2}.spm.spatial.realign.estimate.eoptions.quality = 0.9;  
 matlabbatch{2}.spm.spatial.realign.estimate.eoptions.sep = 4;  
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 matlabbatch{2}.spm.spatial.realign.estimate.eoptions.fwhm = 1;  
  
 matlabbatch{2}.spm.spatial.realign.estimate.eoptions.rtm = 1;  
  
 matlabbatch{2}.spm.spatial.realign.estimate.eoptions.interp = 2;   
 matlabbatch{2}.spm.spatial.realign.estimate.eoptions.wrap = [0 0 0]; 
 matlabbatch{2}.spm.spatial.realign.estimate.eoptions.weight = ''; 
  
 matlabbatch{3}.spm.spatial.realign.write.data = { 
      
      
   T1RHO20 
      
      
   LABELFILE 
      
      
 }; 
 matlabbatch{3}.spm.spatial.realign.write.roptions.which = [1 0]; 
 matlabbatch{3}.spm.spatial.realign.write.roptions.interp = 0; 
 matlabbatch{3}.spm.spatial.realign.write.roptions.wrap = [0 0 0]; 
 matlabbatch{3}.spm.spatial.realign.write.roptions.mask = 1; 
 matlabbatch{3}.spm.spatial.realign.write.roptions.prefix = 'r'; 
  
 matlabbatch{4}.spm.spatial.realign.estimate.data = {   
   
                                                     {    
  
                                                     T1FLIP15    
                                                     T1FLIP30   
                                                     }    
  
                                                    }';    
  
 matlabbatch{4}.spm.spatial.realign.estimate.eoptions.quality = 0.9;  
 matlabbatch{4}.spm.spatial.realign.estimate.eoptions.sep = 4;  
  
 matlabbatch{4}.spm.spatial.realign.estimate.eoptions.fwhm = 1;  
  
 matlabbatch{4}.spm.spatial.realign.estimate.eoptions.rtm = 1;  
  
 matlabbatch{4}.spm.spatial.realign.estimate.eoptions.interp = 2;   
 matlabbatch{4}.spm.spatial.realign.estimate.eoptions.wrap = [0 0 0]; 
 matlabbatch{4}.spm.spatial.realign.estimate.eoptions.weight = ''; 
  
 matlabbatch{5}.spm.spatial.realign.estimate.data = {   
   
                                                     {    
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                                                     T1FLIP15    
                                                     T1FLIP60   
                                                     }    
  
                                                    }';    
  
 matlabbatch{5}.spm.spatial.realign.estimate.eoptions.quality = 0.9;  
 matlabbatch{5}.spm.spatial.realign.estimate.eoptions.sep = 4;  
  
 matlabbatch{5}.spm.spatial.realign.estimate.eoptions.fwhm = 1;  
  
 matlabbatch{5}.spm.spatial.realign.estimate.eoptions.rtm = 1;  
  
 matlabbatch{5}.spm.spatial.realign.estimate.eoptions.interp = 2;   
 matlabbatch{5}.spm.spatial.realign.estimate.eoptions.wrap = [0 0 0]; 
 matlabbatch{5}.spm.spatial.realign.estimate.eoptions.weight = ''; 
  
 matlabbatch{6}.spm.spatial.coreg.estimate.ref = { 
      
      
   T1RHO20 
      
      
 }; 
 matlabbatch{6}.spm.spatial.coreg.estimate.source = { 
      
      
   T1FLIP15 
      
      
    }; 
 matlabbatch{6}.spm.spatial.coreg.estimate.other = { 
      
      
     T1FLIP30 
      
      
     T1FLIP60 
      
      
   }; 
 matlabbatch{6}.spm.spatial.coreg.estimate.eoptions.cost_fun = 'nmi'; 
 matlabbatch{6}.spm.spatial.coreg.estimate.eoptions.sep = [4 2]; 
 matlabbatch{6}.spm.spatial.coreg.estimate.eoptions.tol = [0.02 0.02 0.02 
0.001 0.001 0.001 0.01 0.01 0.01 0.001 0.001 0.001]; 
 matlabbatch{6}.spm.spatial.coreg.estimate.eoptions.fwhm = [1 1]; 
 spm_jobman('run',matlabbatch);    
      
  
 132 
 
     
  
 %% Calculate T1ρ and T1   
  
 addpath('/labs/twells/mario/src');   
      
      
   
 V = {T1RHO20;...    
      
       
   %(comment_50_1)sT1RHO50;... 
      
     
   T1RHO80};   
      
      
  
 calc_t1_rho(V,T1RHO); 
  
 V = {T1FLIP15;... 
   T1FLIP30;... 
   T1FLIP60}; 
 calc_t1(V,T1) 
  
  
 %% Binarize and mask 
  
 clear matlabbatch; 
 matlabbatch{1}.spm.spatial.coreg.estimate.ref = {T1RHO20}; 
 matlabbatch{1}.spm.spatial.coreg.estimate.source = {T1W_MASK}; 
 matlabbatch{1}.spm.spatial.coreg.estimate.other = {''}; 
 matlabbatch{1}.spm.spatial.coreg.estimate.eoptions.cost_fun = 'nmi'; 
 matlabbatch{1}.spm.spatial.coreg.estimate.eoptions.sep = [4 2]; 
 matlabbatch{1}.spm.spatial.coreg.estimate.eoptions.tol = [0.02 0.02 0.02 
0.001 0.001 0.001 0.01 0.01 0.01 0.001 0.001 0.001]; 
 matlabbatch{1}.spm.spatial.coreg.estimate.eoptions.fwhm = [1 1]; 
 matlabbatch{2}.spm.spatial.coreg.write.ref = {T1W_MASK}; 
 matlabbatch{2}.spm.spatial.coreg.write.source = {T1RHO20}; 
 matlabbatch{2}.spm.spatial.coreg.write.roptions.interp = 1; 
 matlabbatch{2}.spm.spatial.coreg.write.roptions.wrap = [0 0 0]; 
 matlabbatch{2}.spm.spatial.coreg.write.roptions.mask = 0; 
 matlabbatch{2}.spm.spatial.coreg.write.roptions.prefix = 'r_T1rcoregT1'; 
 matlabbatch{3}.spm.util.imcalc.input = {T1W_MASK 
      
     T1rCOREGT1 
      
     }; 
 matlabbatch{3}.spm.util.imcalc.output = BINMULT; 
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 matlabbatch{3}.spm.util.imcalc.outdir = {ANALYSIS_DIR}; 
 matlabbatch{3}.spm.util.imcalc.expression = 'i1.*(i2>0)'; 
 matlabbatch{3}.spm.util.imcalc.options.dmtx = 0; 
 matlabbatch{3}.spm.util.imcalc.options.mask = 0; 
 matlabbatch{3}.spm.util.imcalc.options.interp = 1; 
 matlabbatch{3}.spm.util.imcalc.options.dtype = 16; 
 
 spm_jobman('run',matlabbatch); 
  
  
 %% T2 Analysis 
  
 %% Sanitize the T2 images to only those ending in -0001.nii 
 list_dir = dir(T2_PATH); 
 san_dir = {}; 
 [len n] = size(list_dir); 
 for i=3:len 
  token = strtok(list_dir(i).name,'.'); 
  if token(end) == '1' 
   san_dir{end+1} = list_dir(i).name; 
  end 
 end 
 san_dir = san_dir'; 
  
 %% Take the log of all T2 images ending in -0001.nii 
 log_dir = {}; 
 [len n] = size(san_dir); 
 for i=1:len 
  log_dir{end+1} = strcat(T2_PATH,'/log',san_dir{i}); 
  
  clear matlabbatch; 
  matlabbatch{1}.spm.util.imcalc.input = 
{strcat(T2_PATH,'/',san_dir{i})}; 
  matlabbatch{1}.spm.util.imcalc.output = 
strcat(T2_PATH,'/log',san_dir{i}); 
  matlabbatch{1}.spm.util.imcalc.outdir = {ANALYSIS_DIR}; 
  matlabbatch{1}.spm.util.imcalc.expression = 'log(i1)'; 
  matlabbatch{1}.spm.util.imcalc.options.dmtx = 0; 
  matlabbatch{1}.spm.util.imcalc.options.mask = 0; 
  matlabbatch{1}.spm.util.imcalc.options.interp = 1; 
  matlabbatch{1}.spm.util.imcalc.options.dtype = 16; 
   
  spm_jobman('run',matlabbatch); 
 end 
 log_dir = log_dir'; 
  
 clear matlabbatch; 
 mkdir(strcat(ANALYSIS_DIR,'/spm')); 
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 matlabbatch{1}.spm.stats.factorial_design.dir = 
{strcat(ANALYSIS_DIR,'/spm')}; 
 matlabbatch{1}.spm.stats.factorial_design.des.mreg.scans = log_dir; 
 matlabbatch{1}.spm.stats.factorial_design.des.mreg.mcov.c = [15 
                                                              30 
                                                              45 
                                                              60 
                                                              75 
                                                              90]; 
 matlabbatch{1}.spm.stats.factorial_design.des.mreg.mcov.cname = 'TEs'; 
 matlabbatch{1}.spm.stats.factorial_design.des.mreg.mcov.iCC = 5; 
 matlabbatch{1}.spm.stats.factorial_design.des.mreg.incint = 1; 
 matlabbatch{1}.spm.stats.factorial_design.cov = struct('c', {}, 'cname', {}, 
'iCFI', {}, 'iCC', {}); 
 matlabbatch{1}.spm.stats.factorial_design.masking.tm.tm_none = 1; 
 matlabbatch{1}.spm.stats.factorial_design.masking.im = 1; 
 matlabbatch{1}.spm.stats.factorial_design.masking.em = {''}; 
 matlabbatch{1}.spm.stats.factorial_design.globalc.g_omit = 1; 
 matlabbatch{1}.spm.stats.factorial_design.globalm.gmsca.gmsca_no = 1; 
 matlabbatch{1}.spm.stats.factorial_design.globalm.glonorm = 1; 
 matlabbatch{2}.spm.stats.fmri_est.spmmat = 
{strcat(ANALYSIS_DIR,'/spm/SPM.mat')}; 
 matlabbatch{2}.spm.stats.fmri_est.method.Classical = 1; 
 matlabbatch{3}.spm.util.imcalc.input = {BETAIMG}; 
 matlabbatch{3}.spm.util.imcalc.output = INVBETAIMG; 
 matlabbatch{3}.spm.util.imcalc.outdir = {ANALYSIS_DIR}; 
 matlabbatch{3}.spm.util.imcalc.expression = '-1./i1'; 
 matlabbatch{3}.spm.util.imcalc.options.dmtx = 0; 
 matlabbatch{3}.spm.util.imcalc.options.mask = 0; 
 matlabbatch{3}.spm.util.imcalc.options.interp = 1; 
 matlabbatch{3}.spm.util.imcalc.options.dtype = 16; 
 
  
 spm_jobman('run',matlabbatch); 
  
catch 
 disp('There was an error in the first-level matlab call.'); 
end 
quit;  
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Voxel Based Analysis  
Analysis Template 
 
#!/bin/tcsh 
#PBS -M maryellen.koran@gmail.com 
#PBS -m bae 
#PBS -l nodes=vision.mc.vanderbilt.edu 
#PBS -l walltime=1:00:00:00 
#PBS -l mem=8000mb 
 
## Setup FreeSurfer variables 
setenv ANALYSIS_DIR 
/labs/twells/data/%(study)s/t1rho_voxel/%(scanid)s/%(hz)s 
 
# Ensure the directories exist 
mkdir -p $ANALYSIS_DIR 
 
## Setup script variables 
setenv T1W      $ANALYSIS_DIR/%(t1w_filename)s 
 
setenv T1RHO20 
 $ANALYSIS_DIR/%(t1rho_20_filename)s 
setenv T1RHO80 
 $ANALYSIS_DIR/%(t1rho_80_filename)s 
setenv T1RHO  $ANALYSIS_DIR/Thornton-
Wells_%(scanid)s_%(hz)sHz_t1-rho-voxel.nii 
setenv T1FLIP15 
 $ANALYSIS_DIR/%(t1_flip_15_filename)s 
setenv T1FLIP30 
 $ANALYSIS_DIR/%(t1_flip_30_filename)s 
setenv T1FLIP60 
 $ANALYSIS_DIR/%(t1_flip_60_filename)s 
setenv T1   $ANALYSIS_DIR/Thornton-
Wells_%(scanid)s_t1-voxel.nii 
setenv MATLAB  %(matlab)s 
 
## Setup log variable 
setenv LOG  
 $MARIO/log/t1rho_voxel_%(scanid)s_%(hz)s.log 
 
## Copy all input images to the analysis folder 
 
cp -f %(t1w_abs)s $T1W 
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cp -f %(t1rho_20_abs)s $T1RHO20  
cp -f %(t1rho_80_abs)s $T1RHO80  
cp -f %(t1_flip_15_abs)s $T1FLIP15 
cp -f %(t1_flip_30_abs)s $T1FLIP30 
cp -f %(t1_flip_60_abs)s $T1FLIP60 
 
##cd $ANALYSIS_DIR 
cd %(matlab_pathdef)s 
 
## marker 
echo "T1 Rho Calculation: " >> $LOG 
 
## ----- Start matlab ---- ## 
$MATLAB -nodisplay -nodesktop -nosplash < %(t1rho_matlab)s 
MATLAB and SPM Code for T1ρ, T1, and T2 calculation 
try      
      
     
 ANALYSIS_DIR = 
'/labs/twells/data/%(study)s/t1rho_voxel/%(scanid)s/%(hz)s'; 
  
 T1W       = strcat(ANALYSIS_DIR,'/%(t1w_filename)s'); 
 T1RHO20   = strcat(ANALYSIS_DIR,'/%(t1rho_20_filename)s'); 
 T1RHO80   = strcat(ANALYSIS_DIR,'/%(t1rho_80_filename)s'); 
 T1RHO     = strcat(ANALYSIS_DIR,'/Thornton-Wells 
_%(scanid)s_%(hz)sHz_t1-rho-voxel.nii'); 
 T1FLIP15  = strcat(ANALYSIS_DIR,'/%(t1_flip_15_filename)s'); 
 T1FLIP30  = strcat(ANALYSIS_DIR,'/%(t1_flip_30_filename)s'); 
 T1FLIP60  = strcat(ANALYSIS_DIR,'/%(t1_flip_60_filename)s'); 
 T1        = strcat(ANALYSIS_DIR,'/Thornton-Wells _%(scanid)s_t1-
voxel.nii'); 
  
 wT1RHO20   = strcat(ANALYSIS_DIR,'/w','%(t1rho_20_filename)s'); 
 wT1RHO80   = strcat(ANALYSIS_DIR,'/w','%(t1rho_80_filename)s'); 
 wT1FLIP15  = strcat(ANALYSIS_DIR,'/w','%(t1_flip_15_filename)s'); 
 wT1FLIP30  = strcat(ANALYSIS_DIR,'/w','%(t1_flip_30_filename)s'); 
 wT1FLIP60  = strcat(ANALYSIS_DIR,'/w','%(t1_flip_30_filename)s'); 
      
     
 %% Realign 
 clear matlabbatch; 
 spm_jobman('initcfg'); 
 spm('defaults', 'FMRI'); 
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matlabbatch{1}.spm.spatial.realign.estimate.data = { 
                                                    { 
                                                    T1RHO20  
T1RHO80                                                          
} 
                                                    }'; 
matlabbatch{1}.spm.spatial.realign.estimate.eoptions.quality = 0.9; 
matlabbatch{1}.spm.spatial.realign.estimate.eoptions.sep = 4; 
matlabbatch{1}.spm.spatial.realign.estimate.eoptions.fwhm = 1; 
matlabbatch{1}.spm.spatial.realign.estimate.eoptions.rtm = 0; 
matlabbatch{1}.spm.spatial.realign.estimate.eoptions.interp = 2; 
matlabbatch{1}.spm.spatial.realign.estimate.eoptions.wrap = [0 0 0]; 
matlabbatch{1}.spm.spatial.realign.estimate.eoptions.weight = ''; 
matlabbatch{2}.spm.spatial.realign.estimate.data = { 
                                                    { 
T1FLIP15                                                      
T1FLIP30   
T1FLIP60   
                                                    } 
                                                    }'; 
matlabbatch{2}.spm.spatial.realign.estimate.eoptions.quality = 0.9; 
matlabbatch{2}.spm.spatial.realign.estimate.eoptions.sep = 4; 
matlabbatch{2}.spm.spatial.realign.estimate.eoptions.fwhm = 1; 
matlabbatch{2}.spm.spatial.realign.estimate.eoptions.rtm = 0; 
matlabbatch{2}.spm.spatial.realign.estimate.eoptions.interp = 2; 
matlabbatch{2}.spm.spatial.realign.estimate.eoptions.wrap = [0 0 0]; 
matlabbatch{2}.spm.spatial.realign.estimate.eoptions.weight = ''; 
matlabbatch{3}.spm.spatial.coreg.estimate.ref = { T1W       }; 
matlabbatch{3}.spm.spatial.coreg.estimate.source = {T1RHO20}; 
matlabbatch{3}.spm.spatial.coreg.estimate.other = { 
                                                   T1RHO80                                                   }; 
matlabbatch{3}.spm.spatial.coreg.estimate.eoptions.cost_fun = 'mi'; 
matlabbatch{3}.spm.spatial.coreg.estimate.eoptions.sep = [4 2]; 
matlabbatch{3}.spm.spatial.coreg.estimate.eoptions.tol = [0.02 0.02 0.02 0.001 0.001 
0.001 0.01 0.01 0.01 0.001 0.001 0.001]; 
matlabbatch{3}.spm.spatial.coreg.estimate.eoptions.fwhm = [7 7]; 
matlabbatch{4}.spm.spatial.coreg.estimate.ref = { T1W       }; 
matlabbatch{4}.spm.spatial.coreg.estimate.source = { T1FLIP15                                                      
}; 
matlabbatch{4}.spm.spatial.coreg.estimate.other = { 
T1FLIP30   
T1FLIP60   
                                                   }; 
matlabbatch{4}.spm.spatial.coreg.estimate.eoptions.cost_fun = 'mi'; 
matlabbatch{4}.spm.spatial.coreg.estimate.eoptions.sep = [4 2]; 
matlabbatch{4}.spm.spatial.coreg.estimate.eoptions.tol = [0.02 0.02 0.02 0.001 0.001 
0.001 0.01 0.01 0.01 0.001 0.001 0.001]; 
matlabbatch{4}.spm.spatial.coreg.estimate.eoptions.fwhm = [7 7]; 
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matlabbatch{5}.spm.spatial.normalise.estwrite.subj.source = { T1W       }; 
matlabbatch{5}.spm.spatial.normalise.estwrite.subj.wtsrc = ''; 
%% 
matlabbatch{5}.spm.spatial.normalise.estwrite.subj.resample = { 
                                                               T1FLIP15                                                      
T1FLIP30   
T1FLIP60   
T1RHO20  
T1RHO80                                                          
                                                               }; 
%% 
matlabbatch{5}.spm.spatial.normalise.estwrite.eoptions.template = 
{'/home/pryweljr/spm8/templates/T1.nii,1'}; 
matlabbatch{5}.spm.spatial.normalise.estwrite.eoptions.weight = ''; 
matlabbatch{5}.spm.spatial.normalise.estwrite.eoptions.smosrc = 8; 
matlabbatch{5}.spm.spatial.normalise.estwrite.eoptions.smoref = 0; 
matlabbatch{5}.spm.spatial.normalise.estwrite.eoptions.regtype = 'mni'; 
matlabbatch{5}.spm.spatial.normalise.estwrite.eoptions.cutoff = 25; 
matlabbatch{5}.spm.spatial.normalise.estwrite.eoptions.nits = 16; 
matlabbatch{5}.spm.spatial.normalise.estwrite.eoptions.reg = 1; 
matlabbatch{5}.spm.spatial.normalise.estwrite.roptions.preserve = 0; 
matlabbatch{5}.spm.spatial.normalise.estwrite.roptions.bb = [-78 -112 -50 
                                                             78 76 85]; 
matlabbatch{5}.spm.spatial.normalise.estwrite.roptions.vox = [2 2 2]; 
matlabbatch{5}.spm.spatial.normalise.estwrite.roptions.interp = 1; 
matlabbatch{5}.spm.spatial.normalise.estwrite.roptions.wrap = [0 0 0]; 
matlabbatch{5}.spm.spatial.normalise.estwrite.roptions.prefix = 'w'; 
spm_jobman('run',matlabbatch);     
       
     
  
 %% Calculate T1ρ and T1   
  
 addpath('/labs/twells/mario/src');   
      
      
   
  V = {wT1RHO20;...   
      
      
  
   %(comment_50_1)sT1RHO50;... 
      
     
   wT1RHO80};   
      
      
 
 calc_t1_rho(V,T1RHO); 
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 V = {wT1FLIP15;... 
   wT1FLIP30;... 
   wT1FLIP60}; 
 calc_t1(V,T1) 
  
  
  
catch 
 disp('There was an error in the first-level matlab call.'); 
end 
quit;      
  
Quantifying Images 
Quantification of T1ρ-weighted Images 
function calc_t1_rho(V,outfile) 
 
% T1ρ Calculation 2.0 
% Includes Normalization 
% 
% Requires SPM 
% 
% Jared Cobb, VUIIS 
% Adapted by Manus J. Donahue 
% Adapted by R. Michael Sivley, CHGR 
 
%% Ensure we do not get stuck in MATLAB 
try 
 
[NUM_FILES,dim] = size(V); 
if NUM_FILES < 1 
    disp('Too few files. Terminating...'); 
    return 
end 
 
FileName = cell(1,NUM_FILES); 
PathName = cell(1,NUM_FILES); 
 
for i = 1:NUM_FILES 
    [pth,nam,ext] = spm_fileparts(V{i}); 
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    FileName{i} = strcat(nam,ext); 
    PathName{i} = pth; 
    if exist(fullfile(pth,[nam ext])) ~= 2 
        disp('File does not exist. Terminating...'); 
        return 
    end 
end 
 
if NUM_FILES == 3 
 SLT = {'20';'50';'80'}; 
else if NUM_FILES == 2 
 SLT = {'20';'80'}; 
else 
 disp('Number of files not recognized'); 
 disp('Terminating...'); 
 return 
    end 
end 
 
%reformat from column vector to row vector 
SLT = transpose(SLT); 
 
%convert to matrix 
SLT = cellfun(@str2num,SLT); 
 
IM = vuOpenImage(fullfile(PathName{1},FileName{1})); 
[i,j,k] = size(IM.Data); 
 
% initialize the final t1-rho image 
t1_rho = zeros(i,j,k); 
 
for i = 1:NUM_FILES 
    IM = vuOpenImage(fullfile(PathName{i},FileName{i})); 
    % all 3D data from all images 
    full_stack(:,:,:,i) = IM.Data(:,:,:); 
end 
 
 
%Loop for each slice 
for sl = 1:k 
     
    % local stack contains 1 2D slice per image 
    stack(:,:,:) = full_stack(:,:,sl,:); 
 
 
    %% 
    %close all; clc; 
 
    % slice is chosen above for simplicity 
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    [nRows nCols numEcho] = size(stack); 
 
 
    %create threshold mask 
    firstImage_m = squeeze(stack(:,:,numEcho)); 
    maxValue = max(firstImage_m(:)); 
    %mask_m = (firstImage_m > 0.05 * maxValue ); % 5% mask 
    mask_m = (firstImage_m > 0); 
 
    % COBBJG : START Single Parm MonoExponential Fit MAP 
    warning off all 
    %Initial Conditions & Settings 
 
 
    t2_m = zeros(nRows, nCols); 
    s0_m = zeros(nRows, nCols); 
    R_m = zeros(nRows,nCols); 
    t2lim = 500;  % upper limit based on type o scan / tissue 
    echoes = SLT'; 
 
 
    for row = 1:nRows 
        for col = 1:nCols 
            % is this mask what accounts for black pixels? 
            if (mask_m(row,col) == 1) 
                % stack is a stack of scans 
                % signal_v is the stack of voxels at row,col 
                signal_v = squeeze(stack(row, col, :)); 
                % the log of the images is taken at the last second 
                signal_v(isfinite(signal_v)==0)=500; 
                coeff_v = polyfit(echoes, max(0,log(signal_v)), 1); 
                slope = coeff_v(1); 
                logS0 = coeff_v(2); % Intercept. 
                fit = polyval(coeff_v, echoes); 
                R_squared = corrcoef(signal_v, fit); 
                t2 = -1 / slope; 
                % Force a lower limit on the slope: 
                if (isfinite(t2)==0) 
                    t2 = t2lim; 
                end 
                if (t2 > t2lim) 
                    t2 = t2lim; 
                end 
                if (t2 < 0) 
                    t2 = 0; 
                end 
                %end slope limit 
                t2_m(row,col) = t2; 
                s0_m(row,col) = exp(logS0); 
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                R_m(row,col) = R_squared(2); 
            end 
        end 
    end 
    % assign the t2_m to the current t1_rho slice 
    t1_rho(:,:,sl) = t2_m(:,:); 
    warning on all 
     
end % end the slice loop 
 
% Optimize the output parameters for T1-Rho 
IM.Parms.datatype = 16; 
IM.Parms.bitpix = 32; 
IM.Parms.scl_slope = 1; 
IM.Parms.scl_inter = 0; 
 
% Or building a more unique name for the output 
[path,descrip,ext] = fileparts(outfile); %must be 80 characters 
for ii = size(descrip,2)+1:80 
        descrip = [descrip ' ']; 
end 
IM.Parms.descrip = descrip; 
 
% copy the computed t1_rho into the image data 
IM.Data(:,:,:) = t1_rho(:,:,:); 
 
vuWriteImage(IM,outfile); 
 
catch 
disp('There was an error while computing T1ρ.'); 
end 
 
 
Quantification of T1 Images 
%  
% T1 MAP from dynamic flip angle diminish data 
%Provided by E. Brian Welch, PhD 
% 
function calc_t1(V,outfile) 
 
%% Ensure we do not get stuck in MATLAB 
try 
 
na = length(V); 
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FileName = cell(1,na); 
PathName = cell(1,na); 
 
for i = 1:na 
 [pth,nam,ext] = spm_fileparts(V{i}); 
 FileName{i}   = strcat(nam,ext); 
 PathName{i}   = pth; 
 if exist(fullfile(pth,[nam ext])) ~= 2 
  disp('File does not exist. Terminating...'); 
  return 
 end 
end 
 
IM = vuOpenImage(fullfile(PathName{1},FileName{1})); 
[nx,ny,nz] = size(IM.Data); 
 
%%[info] = loadPARREC('parfile_prefixes{1}'); 
%%nx = info.datasize(1); 
%%ny = info.datasize(2); 
%%nz = info.datasize(3); 
%%na = length(parfile_prefixes); 
 
data_total = zeros([nx ny nz na],'double'); 
 
%%flip_angles_degrees = zeros(length(parfile_prefixes),1); 
flip_angles_degrees = [15 30 60]; 
 
%%tr = str2num(info.pardef.Repetition_time_ms) / 1000; % grab TR from info struct 
tr = .1; %TR in seconds here so T1 should be in seconds  
 
%% load all of the data 
for a=1:na, 
    %%[data,info] = loadPARREC(parfile_prefixes{a}); 
    IM = vuOpenImage(fullfile(PathName{a},FileName{a})); 
    data = IM.Data; 
    data_total(:,:,:,a) = data; 
    %%flip_angles_degrees(a) = info.imgdef.image_flip_angle_in_degrees.uniq(1); 
end 
 
%% find a mask using Otsu's method for fasting execition 
data_total = data_total - min(data_total(:)); 
data_total = data_total / max(data_total(:)); 
data_sum_all_angles = sum(data_total,4); 
otsu_level = graythresh(data_sum_all_angles); 
mask_xyz = data_sum_all_angles > otsu_level; 
 
%% setup for the lsqcurvefit 
xdata = flip_angles_degrees(:) * pi/180.0; 
LB=[]; UB=[]; 
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m0 = zeros(nx,ny,nz,'double'); 
t1 = zeros(nx,ny,nz,'double'); 
resnorm_array = zeros(nx,ny,nz,'double'); 
residual_array = zeros(nx,ny,nz,na,'double'); 
exitflag_array = zeros(nx,ny,nz,'double'); 
 
% turn warnings off 
warning off; 
 
try 
  options = optimset('lsqcurvefit'); 
catch 
  options = []; 
end 
options = optimset(options,'Display','off'); 
options = optimset(options,'Algorithm','levenberg-marquardt'); 
 
%% Loop over 3D volume 
for xidx=[1:nx], 
    for yidx=[1:ny], 
        for zidx=[1:nz], 
             
            ydata = data_total(xidx,yidx,zidx,:); 
            ydata = ydata(:); 
             
            if mask_xyz(xidx,yidx,zidx), 
                x0 = [1]; 
                [x,resnorm,residual,exitflag,output] = lsqcurvefit(@(x,xdata) 
ssi(x,xdata,tr,ydata),x0,xdata,ydata,LB,UB,options); 
                 
                t1(xidx,yidx,zidx) = x(1); 
                 
                resnorm_array(xidx,yidx,zidx) = resnorm; 
                residual_array(xidx,yidx,zidx,:) = residual; 
                exitflag_array(xidx,yidx,zidx) = exitflag; 
                 
                E1 = exp(-tr/ t1(xidx,yidx,zidx) ); 
                F = sin(xdata) .* (1-E1)./(1-E1.*cos(xdata)); 
                m0(xidx,yidx,zidx) = F\ydata; 
            end 
        end   
    end 
    disp( sprintf('Completed %03d of %03d', xidx, nx) ); 
end 
 
%% make an r1 map 
r1 = zeros(nx,ny,nz); 
r1(mask_xyz) = 1./( t1(mask_xyz) + eps); 
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% Optimize the output parameters for T1 
IM.Parms.datatype = 16; 
IM.Parms.bitpix = 32; 
IM.Parms.scl_slope = 1; 
IM.Parms.scl_inter = 0; 
 
% Or building a more unique name for the output 
[path,descrip,ext] = fileparts(outfile); %must be 80 characters 
for ii = size(descrip,2)+1:80 
        descrip = [descrip ' ']; 
end 
IM.Parms.descrip = descrip; 
 
% copy the computed t1_rho into the image data 
IM.Data(:,:,:) = t1(:,:,:); 
 
vuWriteImage(IM,outfile); 
 
%% turn warnings back on 
warning on; 
 
catch 
disp('An error occured while calculating T1.'); 
end 
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Appendix B 
SUPPORTING INFORMATION FOR CHAPTER 3 
Table 20 Results from analysis of relationship between volume and age using typically 
developing controls as the control group. DS = Down Syndrome. WS = William’s 
Syndrome.  
ROI Group t p-value 
LeftInfLatVent   DS 4.32 3.21E-05 
RightInfLatVent   DS 4.05 8.85E-05 
lh_superiorparietal_volume   DS -4.04 9.26E-05 
lh_inferiorparietal_volume   DS -3.98 1.16E-04 
lh_parsorbitalis_volume   DS -3.81 2.21E-04 
rh_postcentral_volume   DS -3.67 3.56E-04 
nonWMhypointensities   DS 3.41 8.84E-04 
lh_precuneus_volume   DS -3.39 9.29E-04 
lh_medialorbitofrontal_volume   DS -3.37 1.01E-03 
LeftPallidum   DS -3.28 1.35E-03 
rh_cuneus_volume   DS -3.25 1.46E-03 
rh_superiorfrontal_volume   DS -3.25 1.46E-03 
RightPallidum   DS -3.22 1.61E-03 
lh_isthmuscingulate_volume   DS -3.18 1.84E-03 
rh_lateralorbitofrontal_volume   DS -3.14 2.09E-03 
lh_parstriangularis_volume   DS -3.13 2.21E-03 
LeftHippocampus   DS -3.11 2.30E-03 
RightLateralVentricle   DS 3.05 2.78E-03 
rh_paracentral_volume   DS -3.02 3.10E-03 
rh_parsorbitalis_volume   DS -3.00 3.28E-03 
RightThalamusProper   DS -3.00 3.31E-03 
rhCortexVol   DS -2.98 3.47E-03 
CortexVol   DS -2.97 3.60E-03 
CC_Mid_Anterior   DS -2.95 3.80E-03 
rh_rostralmiddlefrontal_volume   DS -2.95 3.82E-03 
lhCortexVol   DS -2.94 3.89E-03 
RightAmygdala   DS -2.91 4.22E-03 
LeftAmygdala   DS -2.91 4.23E-03 
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rh_precuneus_volume   DS -2.91 4.33E-03 
lh_postcentral_volume   DS -2.86 4.97E-03 
lh_rostralmiddlefrontal_volume   DS -2.85 5.09E-03 
LeftLateralVentricle   DS 2.78 6.27E-03 
rh_entorhinal_volume   DS -2.78 6.37E-03 
RightAccumbensarea   DS -2.77 6.46E-03 
TotalGrayVol   DS -2.77 6.54E-03 
lh_middletemporal_volume   DS -2.76 6.58E-03 
rh_temporalpole_volume   DS -2.73 7.20E-03 
rh_medialorbitofrontal_volume   DS -2.73 7.20E-03 
lh_paracentral_volume   DS -2.71 7.60E-03 
lh_lateralorbitofrontal_volume   DS -2.69 8.08E-03 
LeftThalamusProper   DS -2.69 8.22E-03 
rh_frontalpole_volume   DS -2.69 8.23E-03 
rh_parstriangularis_volume   DS -2.62 9.97E-03 
rh_isthmuscingulate_volume   DS -2.61 1.00E-02 
rh_inferiorparietal_volume   DS -2.58 1.11E-02 
lh_parahippocampal_volume   DS -2.57 1.13E-02 
rh_superiortemporal_volume   DS -2.53 1.27E-02 
rh_insula_volume   DS -2.47 1.50E-02 
SupraTentorialVol   DS -2.45 1.56E-02 
lh_superiorfrontal_volume   DS -2.45 1.58E-02 
lh_fusiform_volume   DS -2.43 1.66E-02 
lh_parsopercularis_volume   DS -2.33 2.12E-02 
lh_lateraloccipital_volume   DS -2.32 2.22E-02 
rh_lateraloccipital_volume   DS -2.25 2.60E-02 
rh_posteriorcingulate_volume   DS -2.22 2.79E-02 
rh_fusiform_volume   DS -2.17 3.21E-02 
lh_superiortemporal_volume   DS -2.13 3.49E-02 
rh_middletemporal_volume   DS -2.02 4.52E-02 
lh_posteriorcingulate_volume   DS -1.98 4.95E-02 
LeftPutamen   DS -1.95 5.36E-02 
lhCorticalWhiteMatterVol   DS -1.95 5.39E-02 
LeftCaudate   DS -1.94 5.51E-02 
CorticalWhiteMatterVol   DS -1.93 5.54E-02 
rh_pericalcarine_volume   DS -1.92 5.67E-02 
rh_superiorparietal_volume   DS -1.92 5.68E-02 
CC_Anterior   DS -1.91 5.84E-02 
rhCorticalWhiteMatterVol   DS -1.91 5.85E-02 
rh_inferiortemporal_volume   DS -1.90 5.95E-02 
lh_inferiortemporal_volume   DS -1.89 6.16E-02 
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rh_supramarginal_volume   DS -1.84 6.76E-02 
RightPutamen   DS -1.82 7.07E-02 
rh_bankssts_volume   DS -1.81 7.22E-02 
lh_insula_volume   DS -1.81 7.24E-02 
SubCortGrayVol   DS -1.74 8.38E-02 
rh_caudalanteriorcingulate_volume   DS -1.74 8.48E-02 
rh_parsopercularis_volume   DS -1.70 9.22E-02 
RightCaudate   DS -1.69 9.26E-02 
LeftVentralDC   DS -1.68 9.64E-02 
rh_lingual_volume   DS -1.67 9.65E-02 
lh_cuneus_volume   DS -1.67 9.69E-02 
rh_parahippocampal_volume   DS -1.67 9.80E-02 
rh_transversetemporal_volume   DS -1.66 9.86E-02 
lh_rostralanteriorcingulate_volume   DS -1.66 9.97E-02 
LeftAccumbensarea   DS -1.64 1.03E-01 
RightVentralDC   DS -1.63 1.06E-01 
lh_caudalanteriorcingulate_volume   DS -1.59 1.14E-01 
lh_temporalpole_volume   DS -1.56 1.21E-01 
CC_Central   DS -1.55 1.23E-01 
lh_lingual_volume   DS -1.51 1.34E-01 
BrainStem   DS -1.49 1.39E-01 
Rightvessel   DS -1.48 1.43E-01 
rh_precentral_volume   DS -1.46 1.46E-01 
RightHippocampus   DS -1.42 1.59E-01 
lh_transversetemporal_volume   DS -1.38 1.69E-01 
Leftvessel   DS -1.36 1.76E-01 
CC_Posterior   DS -1.31 1.94E-01 
lh_pericalcarine_volume   DS -1.27 2.06E-01 
CC_Mid_Posterior   DS -1.22 2.24E-01 
RightCerebellumCortex   DS -1.13 2.59E-01 
lh_precentral_volume   DS -1.11 2.71E-01 
lh_supramarginal_volume   DS -1.10 2.73E-01 
lh_bankssts_volume   DS -1.08 2.84E-01 
rh_rostralanteriorcingulate_volume   DS -1.06 2.93E-01 
Leftchoroidplexus   DS -1.05 2.97E-01 
LeftCerebellumCortex   DS -0.93 3.54E-01 
lh_frontalpole_volume   DS -0.93 3.57E-01 
lh_entorhinal_volume   DS -0.91 3.62E-01 
lh_caudalmiddlefrontal_volume   DS -0.87 3.84E-01 
LeftCerebellumWhiteMatter   DS -0.83 4.08E-01 
WMhypointensities   DS 0.81 4.20E-01 
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rh_caudalmiddlefrontal_volume   DS -0.80 4.24E-01 
RightCerebellumWhiteMatter   DS -0.71 4.78E-01 
OpticChiasm   DS -0.45 6.50E-01 
Rightchoroidplexus   DS -0.05 9.59E-01 
CSF   DS -0.02 9.85E-01 
LeftnonWMhypointensities   DS NA NA 
LeftWMhypointensities   DS NA NA 
RightnonWMhypointensities   DS NA NA 
RightWMhypointensities   DS NA NA 
WMhypointensities   WS 3.27 1.39E-03 
rh_medialorbitofrontal_volume   WS -2.37 1.94E-02 
Leftvessel   WS -2.20 2.98E-02 
rh_entorhinal_volume   WS -1.93 5.63E-02 
lh_superiorparietal_volume   WS -1.91 5.84E-02 
lh_parstriangularis_volume   WS -1.85 6.72E-02 
Leftchoroidplexus   WS -1.84 6.74E-02 
OpticChiasm   WS -1.71 8.90E-02 
rh_superiorfrontal_volume   WS -1.60 1.11E-01 
RightVentralDC   WS -1.55 1.23E-01 
rh_temporalpole_volume   WS -1.54 1.26E-01 
rh_parstriangularis_volume   WS -1.53 1.29E-01 
rh_bankssts_volume   WS -1.51 1.34E-01 
rh_superiorparietal_volume   WS -1.48 1.41E-01 
lh_paracentral_volume   WS -1.47 1.44E-01 
Rightchoroidplexus   WS -1.45 1.49E-01 
rh_parsorbitalis_volume   WS -1.44 1.53E-01 
lh_entorhinal_volume   WS -1.42 1.57E-01 
LeftCerebellumWhiteMatter   WS 1.39 1.67E-01 
rh_fusiform_volume   WS -1.36 1.77E-01 
RightCerebellumWhiteMatter   WS 1.34 1.81E-01 
LeftCerebellumCortex   WS -1.30 1.95E-01 
lh_parsorbitalis_volume   WS -1.30 1.97E-01 
lh_precuneus_volume   WS -1.28 2.02E-01 
lh_caudalanteriorcingulate_volume   WS -1.27 2.06E-01 
RightCerebellumCortex   WS -1.24 2.19E-01 
rhCortexVol   WS -1.23 2.21E-01 
TotalGrayVol   WS -1.22 2.25E-01 
rh_paracentral_volume   WS -1.21 2.28E-01 
CortexVol   WS -1.20 2.33E-01 
lh_fusiform_volume   WS -1.19 2.35E-01 
lh_rostralanteriorcingulate_volume   WS -1.19 2.35E-01 
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lh_precentral_volume   WS -1.19 2.36E-01 
lh_superiorfrontal_volume   WS -1.17 2.46E-01 
RightInfLatVent   WS -1.16 2.47E-01 
lhCortexVol   WS -1.16 2.48E-01 
lh_inferiorparietal_volume   WS -1.09 2.77E-01 
lh_lateralorbitofrontal_volume   WS -1.09 2.78E-01 
lh_cuneus_volume   WS -1.08 2.81E-01 
nonWMhypointensities   WS -1.08 2.83E-01 
rh_postcentral_volume   WS -1.07 2.85E-01 
rh_inferiortemporal_volume   WS -1.07 2.87E-01 
CC_Mid_Anterior   WS 1.06 2.90E-01 
SubCortGrayVol   WS -1.05 2.98E-01 
rh_inferiorparietal_volume   WS -1.04 2.99E-01 
lh_supramarginal_volume   WS -1.04 2.99E-01 
lh_parsopercularis_volume   WS -1.03 3.03E-01 
rh_precuneus_volume   WS -1.01 3.13E-01 
rh_rostralmiddlefrontal_volume   WS -1.01 3.14E-01 
LeftVentralDC   WS -1.01 3.15E-01 
RightAccumbensarea   WS -0.99 3.22E-01 
rh_precentral_volume   WS -0.96 3.40E-01 
rh_frontalpole_volume   WS -0.94 3.50E-01 
lh_insula_volume   WS -0.92 3.59E-01 
rh_supramarginal_volume   WS -0.91 3.64E-01 
RightLateralVentricle   WS -0.90 3.70E-01 
rh_middletemporal_volume   WS -0.90 3.71E-01 
lh_middletemporal_volume   WS -0.85 3.94E-01 
LeftAccumbensarea   WS -0.85 3.97E-01 
rh_isthmuscingulate_volume   WS -0.84 4.00E-01 
rh_parahippocampal_volume   WS -0.84 4.01E-01 
SupraTentorialVol   WS -0.84 4.05E-01 
lh_rostralmiddlefrontal_volume   WS -0.82 4.14E-01 
LeftLateralVentricle   WS -0.79 4.33E-01 
lh_superiortemporal_volume   WS -0.75 4.57E-01 
rh_lateraloccipital_volume   WS -0.74 4.62E-01 
lh_posteriorcingulate_volume   WS -0.69 4.91E-01 
rh_lateralorbitofrontal_volume   WS -0.68 4.97E-01 
LeftCaudate   WS -0.68 4.98E-01 
CC_Central   WS 0.66 5.13E-01 
RightThalamusProper   WS -0.65 5.16E-01 
RightPallidum   WS 0.64 5.23E-01 
rh_cuneus_volume   WS -0.63 5.27E-01 
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lh_parahippocampal_volume   WS -0.62 5.33E-01 
lh_lateraloccipital_volume   WS -0.62 5.38E-01 
lh_lingual_volume   WS -0.62 5.38E-01 
LeftPutamen   WS -0.60 5.47E-01 
rh_superiortemporal_volume   WS -0.59 5.59E-01 
RightPutamen   WS -0.58 5.64E-01 
lh_medialorbitofrontal_volume   WS -0.58 5.64E-01 
lh_caudalmiddlefrontal_volume   WS -0.57 5.71E-01 
RightCaudate   WS -0.53 5.96E-01 
rh_insula_volume   WS -0.50 6.15E-01 
rh_lingual_volume   WS -0.47 6.37E-01 
rh_transversetemporal_volume   WS 0.47 6.39E-01 
rh_caudalanteriorcingulate_volume   WS -0.44 6.62E-01 
RightAmygdala   WS 0.44 6.62E-01 
rh_posteriorcingulate_volume   WS -0.41 6.82E-01 
lh_temporalpole_volume   WS -0.41 6.83E-01 
lhCorticalWhiteMatterVol   WS -0.34 7.37E-01 
CorticalWhiteMatterVol   WS -0.31 7.60E-01 
CC_Posterior   WS -0.29 7.76E-01 
LeftPallidum   WS -0.27 7.84E-01 
rhCorticalWhiteMatterVol   WS -0.27 7.85E-01 
BrainStem   WS -0.26 7.93E-01 
LeftInfLatVent   WS -0.26 7.96E-01 
lh_frontalpole_volume   WS -0.26 7.97E-01 
lh_bankssts_volume   WS -0.25 8.04E-01 
lh_isthmuscingulate_volume   WS -0.24 8.12E-01 
RightHippocampus   WS -0.24 8.14E-01 
CC_Mid_Posterior   WS 0.20 8.46E-01 
lh_pericalcarine_volume   WS -0.19 8.48E-01 
lh_postcentral_volume   WS -0.19 8.48E-01 
LeftThalamusProper   WS 0.16 8.70E-01 
lh_transversetemporal_volume   WS 0.15 8.79E-01 
rh_pericalcarine_volume   WS -0.14 8.85E-01 
LeftHippocampus   WS 0.13 8.95E-01 
rh_caudalmiddlefrontal_volume   WS 0.12 9.03E-01 
rh_rostralanteriorcingulate_volume   WS -0.07 9.45E-01 
CC_Anterior   WS 0.05 9.58E-01 
CSF   WS -0.04 9.70E-01 
lh_inferiortemporal_volume   WS -0.03 9.76E-01 
LeftAmygdala   WS 0.03 9.77E-01 
Rightvessel   WS -0.01 9.91E-01 
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rh_parsopercularis_volume   WS -0.01 9.92E-01 
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Table 21 Results from analysis comparing relationship with volume and age between 
participants with Down Syndrome and Williams Syndrome.  
ROI t p-value 
nonWMhypointensities 4.32 7.92E-05 
RightLateralVentricle 4.30 8.64E-05 
LeftLateralVentricle 4.16 1.35E-04 
RightInfLatVent 2.93 5.25E-03 
RightPallidum -2.63 1.14E-02 
WMhypointensities 2.57 1.34E-02 
LeftInfLatVent 2.55 1.42E-02 
lh_parstriangularis_volume -2.51 1.57E-02 
LeftThalamusProper -2.30 2.61E-02 
rh_parstriangularis_volume -2.13 3.83E-02 
CC_Mid_Anterior -2.11 4.05E-02 
LeftPallidum -2.10 4.15E-02 
rh_bankssts_volume -2.07 4.36E-02 
rh_medialorbitofrontal_volume -2.07 4.38E-02 
Leftvessel -2.07 4.41E-02 
lh_isthmuscingulate_volume -2.06 4.52E-02 
LeftHippocampus -2.04 4.67E-02 
RightThalamusProper -2.04 4.71E-02 
X.4thVentricle 2.01 5.05E-02 
RightAmygdala -1.96 5.57E-02 
lh_inferiorparietal_volume -1.85 7.08E-02 
lh_superiorparietal_volume -1.78 8.14E-02 
rh_superiorfrontal_volume -1.77 8.39E-02 
lh_medialorbitofrontal_volume -1.76 8.57E-02 
lh_postcentral_volume -1.75 8.65E-02 
rh_postcentral_volume -1.72 9.17E-02 
LeftAmygdala -1.70 9.49E-02 
rh_cuneus_volume -1.69 9.84E-02 
lh_superiorparietal_volume -1.63 1.09E-01 
lh_parsorbitalis_volume -1.63 1.10E-01 
WMhypointensities -1.59 1.18E-01 
lh_fusiform_volume -1.57 1.23E-01 
X.3rdVentricle 1.56 1.25E-01 
lh_precuneus_volume -1.56 1.26E-01 
lh_precuneus_volume -1.54 1.29E-01 
rh_lateralorbitofrontal_volume -1.53 1.33E-01 
lh_supramarginal_volume -1.53 1.33E-01 
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LeftCerebellumWhiteMatter 1.53 1.33E-01 
rh_rostralmiddlefrontal_volume -1.51 1.38E-01 
rh_lingual_volume -1.50 1.40E-01 
lh_rostralmiddlefrontal_volume -1.49 1.43E-01 
RightAccumbensarea -1.48 1.45E-01 
LeftPutamen -1.46 1.50E-01 
rh_fusiform_volume -1.45 1.53E-01 
rh_inferiorparietal_volume -1.45 1.55E-01 
LeftCerebellumCortex -1.44 1.55E-01 
rh_insula_volume -1.44 1.56E-01 
lh_superiorfrontal_volume -1.44 1.57E-01 
rh_rostralmiddlefrontal_volume -1.43 1.61E-01 
CC_Central -1.42 1.61E-01 
rhCortexVol -1.42 1.62E-01 
rh_precuneus_volume -1.42 1.62E-01 
LeftCerebellumWhiteMatter -1.42 1.63E-01 
rh_parsorbitalis_volume -1.41 1.67E-01 
TotalGrayVol -1.40 1.69E-01 
X.3rdVentricle 1.39 1.71E-01 
CortexVol -1.38 1.75E-01 
CC_Anterior -1.36 1.81E-01 
rh_transversetemporal_volume -1.35 1.83E-01 
rh_superiorparietal_volume -1.34 1.87E-01 
lhCortexVol -1.33 1.91E-01 
RightPutamen -1.32 1.95E-01 
rh_superiortemporal_volume -1.31 1.96E-01 
rh_middletemporal_volume -1.31 1.97E-01 
lh_parsorbitalis_volume -1.30 2.01E-01 
RightCerebellumWhiteMatter 1.30 2.01E-01 
RightVentralDC -1.29 2.03E-01 
lh_middletemporal_volume -1.29 2.04E-01 
RightAccumbensarea -1.28 2.05E-01 
rh_pericalcarine_volume -1.28 2.07E-01 
lh_lateralorbitofrontal_volume -1.28 2.08E-01 
lh_entorhinal_volume -1.27 2.09E-01 
rh_inferiortemporal_volume -1.26 2.13E-01 
rh_isthmuscingulate_volume -1.26 2.14E-01 
rhCorticalWhiteMatterVol -1.26 2.15E-01 
rh_parsopercularis_volume -1.25 2.16E-01 
lh_rostralanteriorcingulate_volume -1.25 2.17E-01 
CorticalWhiteMatterVol -1.25 2.18E-01 
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rh_precuneus_volume -1.24 2.21E-01 
CortexVol -1.24 2.21E-01 
lhCortexVol -1.24 2.22E-01 
rhCortexVol -1.24 2.23E-01 
lhCorticalWhiteMatterVol -1.23 2.25E-01 
lh_caudalanteriorcingulate_volume -1.22 2.29E-01 
lh_paracentral_volume -1.22 2.29E-01 
lh_parahippocampal_volume -1.22 2.29E-01 
lh_rostralmiddlefrontal_volume -1.21 2.31E-01 
CSF 1.21 2.34E-01 
RightCerebellumWhiteMatter -1.20 2.35E-01 
rh_paracentral_volume -1.19 2.40E-01 
LeftAccumbensarea -1.18 2.42E-01 
rh_posteriorcingulate_volume -1.18 2.44E-01 
rh_paracentral_volume -1.17 2.47E-01 
BrainStem -1.17 2.47E-01 
rh_frontalpole_volume -1.17 2.49E-01 
SupraTentorialVol -1.17 2.49E-01 
rh_supramarginal_volume -1.17 2.49E-01 
rh_entorhinal_volume -1.16 2.54E-01 
lh_inferiorparietal_volume -1.15 2.54E-01 
RightCerebellumCortex -1.15 2.54E-01 
lh_precentral_volume -1.15 2.58E-01 
lh_inferiortemporal_volume -1.14 2.59E-01 
lh_posteriorcingulate_volume -1.14 2.62E-01 
lh_lateraloccipital_volume -1.13 2.63E-01 
TotalGrayVol -1.13 2.64E-01 
rh_temporalpole_volume -1.13 2.65E-01 
lh_cuneus_volume -1.12 2.67E-01 
rh_superiorfrontal_volume -1.12 2.70E-01 
lh_middletemporal_volume -1.10 2.76E-01 
lh_insula_volume -1.08 2.85E-01 
SubCortGrayVol -1.08 2.86E-01 
rh_postcentral_volume -1.08 2.87E-01 
Rightvessel -1.08 2.88E-01 
lh_parstriangularis_volume -1.07 2.88E-01 
lh_parsopercularis_volume -1.07 2.90E-01 
lh_lateralorbitofrontal_volume -1.07 2.90E-01 
rh_inferiorparietal_volume -1.07 2.91E-01 
rh_precentral_volume -1.06 2.95E-01 
rh_parsorbitalis_volume -1.04 3.05E-01 
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rh_parstriangularis_volume -1.02 3.13E-01 
lh_transversetemporal_volume -1.02 3.15E-01 
rh_parahippocampal_volume -1.01 3.17E-01 
lh_lingual_volume -1.01 3.19E-01 
rh_superiortemporal_volume -1.00 3.23E-01 
OpticChiasm -0.99 3.27E-01 
LeftCaudate -0.98 3.34E-01 
lh_superiortemporal_volume -0.96 3.44E-01 
CC_Mid_Posterior -0.95 3.46E-01 
rh_lateraloccipital_volume -0.95 3.48E-01 
LeftPutamen -0.95 3.49E-01 
lh_parsopercularis_volume -0.94 3.52E-01 
lh_fusiform_volume -0.93 3.57E-01 
lh_superiortemporal_volume -0.93 3.58E-01 
lh_posteriorcingulate_volume -0.92 3.62E-01 
RightLateralVentricle 0.91 3.67E-01 
RightPutamen -0.90 3.73E-01 
lh_superiorfrontal_volume -0.89 3.78E-01 
rh_caudalanteriorcingulate_volume -0.89 3.79E-01 
lh_isthmuscingulate_volume -0.88 3.81E-01 
rh_lateralorbitofrontal_volume -0.87 3.87E-01 
LeftPallidum -0.87 3.91E-01 
RightCaudate -0.86 3.94E-01 
Rightchoroidplexus 0.86 3.95E-01 
lh_pericalcarine_volume -0.85 3.98E-01 
X.4thVentricle -0.85 3.99E-01 
LeftVentralDC -0.85 4.00E-01 
LeftLateralVentricle 0.84 4.05E-01 
rh_temporalpole_volume -0.82 4.14E-01 
lh_temporalpole_volume -0.81 4.23E-01 
OpticChiasm 0.80 4.26E-01 
rh_frontalpole_volume -0.79 4.35E-01 
lh_caudalmiddlefrontal_volume -0.77 4.43E-01 
rh_middletemporal_volume -0.77 4.45E-01 
rh_cuneus_volume -0.76 4.51E-01 
lh_paracentral_volume -0.76 4.53E-01 
lh_parahippocampal_volume -0.73 4.67E-01 
rh_isthmuscingulate_volume -0.73 4.69E-01 
RightHippocampus -0.73 4.70E-01 
rh_rostralanteriorcingulate_volume -0.72 4.76E-01 
rh_supramarginal_volume -0.71 4.80E-01 
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lh_bankssts_volume -0.71 4.81E-01 
rh_lateraloccipital_volume -0.68 5.03E-01 
rh_posteriorcingulate_volume -0.67 5.08E-01 
CC_Mid_Anterior 0.65 5.16E-01 
rh_caudalmiddlefrontal_volume -0.65 5.19E-01 
lh_insula_volume -0.65 5.22E-01 
CC_Posterior -0.63 5.32E-01 
SupraTentorialVol -0.62 5.39E-01 
rh_inferiortemporal_volume -0.61 5.43E-01 
rh_parahippocampal_volume -0.60 5.48E-01 
lh_lateraloccipital_volume -0.60 5.52E-01 
rh_insula_volume -0.59 5.57E-01 
rh_entorhinal_volume -0.59 5.61E-01 
rh_fusiform_volume -0.58 5.67E-01 
rh_caudalanteriorcingulate_volume -0.57 5.69E-01 
LeftAccumbensarea -0.57 5.72E-01 
rh_rostralanteriorcingulate_volume -0.57 5.73E-01 
LeftVentralDC -0.56 5.76E-01 
SubCortGrayVol -0.56 5.79E-01 
X.5thVentricle 0.54 5.89E-01 
lh_lingual_volume -0.54 5.91E-01 
lh_bankssts_volume -0.53 5.98E-01 
LeftThalamusProper 0.53 5.99E-01 
rh_pericalcarine_volume -0.52 6.06E-01 
lh_pericalcarine_volume -0.52 6.06E-01 
Rightvessel -0.50 6.19E-01 
lh_cuneus_volume -0.49 6.28E-01 
BrainStem 0.48 6.33E-01 
RightThalamusProper -0.47 6.37E-01 
LeftInfLatVent 0.47 6.37E-01 
Leftchoroidplexus 0.44 6.61E-01 
lh_medialorbitofrontal_volume -0.44 6.65E-01 
rh_lingual_volume -0.41 6.86E-01 
nonWMhypointensities 0.40 6.88E-01 
rh_precentral_volume -0.40 6.88E-01 
lh_frontalpole_volume -0.40 6.90E-01 
rh_superiorparietal_volume -0.37 7.11E-01 
lh_rostralanteriorcingulate_volume -0.36 7.21E-01 
rh_parsopercularis_volume -0.35 7.27E-01 
Leftvessel 0.35 7.28E-01 
RightHippocampus -0.33 7.39E-01 
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rh_medialorbitofrontal_volume -0.33 7.41E-01 
lh_inferiortemporal_volume -0.32 7.50E-01 
CC_Central 0.32 7.54E-01 
Leftchoroidplexus -0.31 7.56E-01 
rh_bankssts_volume -0.30 7.66E-01 
lh_caudalanteriorcingulate_volume -0.29 7.74E-01 
lh_postcentral_volume -0.27 7.87E-01 
RightInfLatVent -0.27 7.91E-01 
CC_Posterior 0.26 7.94E-01 
lh_caudalmiddlefrontal_volume -0.25 8.01E-01 
rhCorticalWhiteMatterVol 0.25 8.02E-01 
CorticalWhiteMatterVol 0.25 8.02E-01 
lhCorticalWhiteMatterVol 0.25 8.04E-01 
lh_entorhinal_volume 0.24 8.09E-01 
lh_temporalpole_volume -0.23 8.17E-01 
X.5thVentricle 0.20 8.43E-01 
RightAmygdala 0.19 8.47E-01 
rh_caudalmiddlefrontal_volume 0.16 8.72E-01 
lh_transversetemporal_volume -0.16 8.72E-01 
LeftCaudate -0.15 8.80E-01 
rh_transversetemporal_volume -0.14 8.88E-01 
RightVentralDC -0.14 8.90E-01 
LeftCerebellumCortex 0.12 9.09E-01 
DSxAge 0.11 9.10E-01 
RightPallidum 0.11 9.14E-01 
lh_frontalpole_volume -0.09 9.30E-01 
CC_Mid_Posterior -0.09 9.32E-01 
RightCaudate -0.07 9.42E-01 
lh_supramarginal_volume -0.06 9.49E-01 
RightCerebellumCortex -0.03 9.76E-01 
Rightchoroidplexus -0.03 9.77E-01 
LeftAmygdala 0.03 9.78E-01 
CC_Anterior 0.02 9.84E-01 
LeftHippocampus -0.02 9.85E-01 
CSF 0.01 9.95E-01 
lh_precentral_volume 0.00 9.99E-01 
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Appendix C  
SUPPORTING INFORMATION FOR CHAPTER 4 
Table 22 Post-hoc analysis of effect of significant interactions between SYNJ2-PI4KA, 
PARD3-MYH2, PDE3A- ABHD12B, and OR2L13-PRKG1 on the volume of RILV and 
LILV combined.  
 
Gene 1 Gene 2   
Gene SNP Gene SNP p-value 
LILV/RI
LV 
S
Y
N
J
2 
rs92
9528
9 
P
I
4
K
A 
rs17
805
1 1.52x10-
13 
PARD3 rs11596284 MYH2 rs3744566 
3.49x10-
8 
PDE3A rs11614805 ABHD12B rs7154732 
1.34x10-
10 
OR2L13 rs11590865 PRKG1 rs1922127 
1.85x10-
7 
 
Code for InterSNP program used in gene-gene interaction analysis 
Keyword Parameter Comment 
TPED
 /labs/twells/MEK/PWIA_Slope_Volume/ADNI_QC_FINAL_same_
keepsubjects.tped // path to the tped-File  
TFAM
 /labs/twells/MEK/PWIA_Slope_Volume/all_path_6cov/Pheno
_RILV_slopes_2/RILV_slopes.tfam 
ANNOTATIONFILE
 /labs/twells/MEK/InterSNP/annotationIlluSorted.txt  
COVARIATEFILE
 /labs/twells/MEK/PWIA_Slope_Volume/ADNI1_Volume_First_
covariates.txt 
PATHWAYFILE
 /labs/twells/MEK/InterSNP/KEGG_2_snp_b129.txt  
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STOREALL 1 "// 1=complete data will be read and 
stored, or 0=data will be read line by line for the current test 
and than deleted" 
QT  1  
SINGLE_MARKER 4  
SINGLETOP 100  
TWO_MARKER 1 "// Two-marker-analysis: 1=yes, 0=no""" 
TEST  5 "// 1=chi-square-test, 2= log-
linear model, " 6 = genotypic  
COVARIATES 1-6;  
PATHWAY  1  
SIMULATION 0  
MC_WITH_SM 0  
PRINTTOP 100 // Best n mulitmarker p-values are printed 
ANNOTATE 1  
GENECOL  5   
OUTPUTNAME
 /labs/twells/MEK/PWIA_Slope_Volume/all_path_6cov/Pheno
_RILV_slopes_3/output_RILV_slopes 
 
END   
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Appendix D  
SUPPORTING INFORMATION FOR CHAPTER 5 
Table 23 Mapping of Single Nucleotide Polymorphisms from significant interactions to 
gene and base pair location. 
SNP: reference SNP number of first SNP in SNP-SNP pair. Chr: Chromosome. BP: 
Base pair location. 
Gene RYR3 RYR3 CACNA1C CACNA1C 
SNP rs16972835 rs12901404 rs7132154 rs2302729 
Chr 15 15 12 12 
BP 33878846 34075300 2461223 2783972 
 
Code for InterSNP program used in gene-gene interaction analysis 
Keyword Parameter Comment 
TPED
 /labs/twells/MEK/AD_Pathway_InterSNP/AV45/dx_last_oppo
sitechip_followup/omni_follow.tped // path to the tped-
File  
TFAM
 /labs/twells/MEK/AD_Pathway_InterSNP/AV45/dx_last_oppo
sitechip_followup/omni/Pheno_Pheno_meanDVR/Pheno_meanDVR.tfam 
ANNOTATIONFILE
 /labs/twells/MEK/InterSNP/annotationIlluSorted.txt  
COVARIATEFILE
 /labs/twells/MEK/AD_Pathway_InterSNP/AV45/omni/AV45_SU
BJECTS_ADNI2omni_Cov6_dxlast.txt 
STOREALL 1 "// 1=complete data will be read and 
stored, or 0=data will be read line by line for the current test 
and than deleted" 
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QT  1  
SINGLE_MARKER 4  
SINGLETOP 10000  
TWO_MARKER 1 "// Two-marker-analysis: 1=yes, 0=no""" 
TEST  5 "// 1=chi-square-test, 2= log-
linear model, " 6 = genotypic  
COVARIATES 1-6;  
SIMULATION 0  
MC_WITH_SM 0  
PRINTTOP 1000 // Best n mulitmarker p-values are printed 
ANNOTATE 1  
GENECOL  5  
OUTPUTNAME
 /labs/twells/MEK/AD_Pathway_InterSNP/AV45/dx_last_oppo
sitechip_followup/omni/Pheno_Pheno_meanDVR/output_Pheno_meanDVR 
END   
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